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Abstract 
 
In the recent decades, there has been a shift in biological research towards data-driven 
analyses, where entire biological systems are investigated. System level analysis is applied 
in medical research with approaches such as personalized medicine and predictive 
medicine, where two of the goals are to predict diseases predispositions and the 
outcomes of medical treatments for each patient. In traditional medical and 
epidemiological research, medical conditions are investigated one at a time. This is done 
to eliminate predisposing effects of confounding factors such as other diseases and 
environmental components. In contrast, systems level research is often performed in a 
data-driven manner, where the aim is to analyze the impact of the full diseaseome instead 
of analyzing a disease as an isolated entity.  
 
This thesis presents four studies of health registry data, all with the aim to characterize 
how diseases correlate and develop throughout the entire population of Denmark. Three 
of the analyses have been carried out at a systems level, where groups of diagnoses have 
been examined to better understand disease relationships. It has been shown how disease 
progression over time can be analyzed with data-driven methods. This was done by 
identifying pairs of diagnoses that show strong temporal correlation and analyzing how 
patients progress in different trajectories of these diagnoses. Rather than focusing on a 
trajectory of a single disease, patterns of disease development across the full spectrum of 
pathology were identified. 
 
In another study included in this thesis, the hypothesis that gut bacteria plays a role in 
cardiovascular diseases is analyzed by comparing patients who have undergone full 
colectomy with patients who have their colon intact. Finally, a study shows how health 
registry data can be used to examine genetic diseases. The correlations between 
Mendelian and complex diseases have been analyzed to identify diseases that might share 
genetic etiology.  
 
The disease trajectories presented here is a step towards predicting outcome of medical 
treatment, by unraveling temporal disease correlations. While the correlations and 
trajectories are descriptive, the results represent ideal input to predictive models. 
Additional data concerning medical treatment and surgery, drug prescriptions and 
genotype can also be incorporated into such models. Thus, they can aid in the further 
development of personalized and predictive medicine. 
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Dansk resumé 
 
Der har i de seneste årtier været et skift indenfor forskning i biologi, hvor data-drevne 
metoder, der analyserer fulde biologiske systemer i stedet for isolerede delsystemer, er 
blevet taget i brug. Analyser foretaget på system niveau bliver brugt indenfor personalized 
and predictive medicine. Her er to af målene at kunne lave statistiske forudsigelser af  
virkningen af medicinsk behandling for den enkelte patient og forudsige hvilke 
fremtidige sygdomme, den enkelte patient er disponeret for. I traditionelle medicinske og 
epidemiologiske studier analyseres sygdomme én ad gangen. Dette gøres, så den 
prædisponerende effekt fra andre sygdomme og miljøets påvirkning af patienterne kan 
elimineres. I modsætning til dette analyserer undersøgelser på system niveau ofte det 
fulde sygdomsspektrum, i stedet for at analysere en sygdom som en isoleret enhed. 
 
Denne afhandling præsenterer fire register baserede studier, hvor målet er at karakterisere 
korrelationer mellem sygdomme og sygdomsudvikling for hele Danmarks befolkning. 
Tre af analyserne er blevet foretaget på system niveau, hvor grupper af sygdomme er 
blevet analyseret for at få bedre forståelse for sygdomssammenhængen. Det er blevet vist 
hvordan tidslig sygdomsudvikling kan analyseres med data drevne metoder. Dette er 
blevet gjort ved at identificere sygdomspar, som udviser stærk tidslig korrelation og 
analysere hvordan patienter følger forskellige baner af disse sygdomme. Der blevet 
fundet mønstre på tværs af det fulde spektrum af sygdomme, i stedet for at fokusere på 
en enkel sygdom. 
 
 
Ydermere indeholder afhandlingen et studie,  der analyserer en hypotese om tarm 
bakteriernes rolle i hjerte-karsygdomme. Studiet sammenligner patienter, der har fået 
foretaget fuld kolektomi med patienter, der stadigvæk har en intakt tyktarm. Slutligt 
præsenteres et studie, der viser hvordan registerdata kan bruges til at undersøge genetisk 
betingede sygdomme. Her vises hvordan korrelationer mellem Mendelske og komplekse 
sygdomme kan bruges til at identificere delt genetisk ophav mellem sygdomme.  
 
Analysen af sygdomsudvikling, der præsenteres her, er et skridt på vejen mod at 
forudsige effekten af medicinsk behandling. I deres nuværende form er analyserne af 
sygdomskorrelationer og sygdomsudvikling deskriptive, men kan bruges som input til 
forudsigende modeller. På denne måde kan de bruges i den fremtidige udvikling af 
personalied and predictive medicine. 
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Thesis overview 
 
This thesis presents retrospective data-driven analysis of disease correlations using the 
Danish National Patient Registry. Chapter 1 introduces the research field. The data used 
and other health related data sources are discussed in chapter 2. The disease correlations 
have been analyzed in a non-temporal manner described in work in progress I and 
discussed in chapter 3; and in a temporal manner that is extended to cover longer 
disease trajectories described in manuscript I and discussed in chapter 4. Work in 
progress II presents a thesis regarding the role of gut-bacteria in cardiovascular diseases, 
which is covered in chapter 5. Chapter 6 covers manuscript II that addresses how 
genetics knowledge can be inferred from disease correlations. Chapter 7 contains 
concluding remarks on the analyses. 
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Chapter 1: 
General introduction 
 
 
 
1.1 Background 
Humans have attempted to fight diseases for thousands of years - today using modern 
medicine based on scientific studies. Epidemiological studies are among the methods for 
inferring knowledge for new medical treatments. In the recent decades, genomics, 
proteomics and other fields of cellular biology have also become important contributors 
to knowledge that can lead to new medical treatments [1,2]. Systems Biology brought an 
important shift in paradigm within the biological sciences: Instead of examining a 
reduced and simplified part of a biological system, the whole system is now the target for 
examination [3]. This shift has now reached epidemiology with data-driven studies that 
analyze correlations for the entire system of diseases [4,5]. Such studies are an important 
part of the progress to characterize the complex interaction between diseases. It has 
already been shown that many genetic diseases are correlated through shared genes [6,7]. 
The effect of genes in diseases is not only limited to genetic (hereditary) diseases [7]. For 
example, genes that can limit the effect of AIDS have been identified [8]. It is also well 
known from epidemiological studies that diseases are also correlated through common 
predisposing factors such as the environment [9]. The effect of environmental factors 
can in some cases be explained by molecular mechanisms [7]. For example, a study 
shows it is possible that chronic stress affect cancer through a protein pathway [10].  
 
Since the sequencing and mapping of the human genome, there has been a large effort to 
create personalized medicine tailored to each patient's genome [9]. P4 medicine is the 
development of Personalized medicine that furthermore focuses on Prediction, 
Prevention, and Participatory [2,11]. One aim of P4 medicine is predicting the effects of 
treatments on individual patients [12]. Another aim is to predict future diseases from the 
current medical history of the patient in order to prevent them. The majority of genetic 
diseases are not caused by a single gene, but by a complex interaction between multiple 
genes, where each gene can contribute to many diseases [7,13]. Therefore, it important to 
study correlations between diseases to reach the goals of P4 medicine [14]. Correlation 
analysis can both uncover diseases that possibly share genetic etiology and diseases that 
correlate through a disease mechanism or common risk factor. This can assist in 
prognostics and clinical decision-making. Here temporality is an essential factor. 
Resolving the temporal directionality of disease correlations and analyzing longer disease 
progression patterns can serve as a basis for predicting future outcome.  
 
While there has been much focus on analyzing protein interaction networks and other 
molecular data, disease registries remain an underutilized source for uncovering 
correlations between diseases and investigating longer disease progression on a large 
scale [4]. The full population data available in these registries is useful to achieve the 
goals of P4 medicine, and methods from population statistics should be incorporated 
into all aspects of P4 medicine [15]. In recent years a few studies have started focusing 
on these registries as a source of large scale disease correlation analysis [4,16]. The work 
presented in this thesis is a continuation and extension of these initial steps.  
Chapter 1: 
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1.2 Epidemiological research 
Patterns of disease development in the population and the effects of demographics and 
risk factors on diseases are analyzed in epidemiology. This thesis presents 
epidemiological work on disease correlations, where one goal is to identify correlations 
and disease trajectories that can be explained by genetics. However, it is complicated to 
infer genetic knowledge from disease registry data as discussed in chapter 6. Therefore, 
this thesis focuses more on epidemiology than genetics.  
 
Epidemiological analyses that uses registry data to analyze correlations between pairs of 
diseases and between diseases and risk factors are very common [17]. For example, the 
Danish Cancer Registry has been integrated with the Registry of Induced Abortions to 
investigate risk of cancer after abortion [18] and with the Registry of Blood Donors to 
investigate risk of cancer after repetitive blood donation [19]. In both the studies, 
number of patients who were diagnosed with cancer after being subjected to the risk 
factor was counted and different groups of patients compared. No correlation between 
the two risk factor and cancer was found in these studies.  
 
These are examples of traditional epidemiological research, where a hypothesis is 
required before the study can be carried out. The abortion-cancer study [18] investigated 
a prior stated hypothesis [20]. A way of identifying new hypotheses is to focus on 
common severe diseases such as cancer and systematically study all the risk factors one 
by one. A risk in using this approach is the lack of correction for multiple testing (unless 
they are all studied simultaneously). Several different labs can study the same non-
significant risk factor until it is found to be significant by chance.  
 
It is an important aspect of epidemiology to control for confounding factors. In the 
study of blood donation and cancer, factors such as gender, age and number of blood 
donations were controlled for in the statistical analysis [19].  Ideally, studies should be 
designed so patients are compared to cases with same pre-disposing risks. For example, 
in cancer studies, smoking status should be part of the criteria for matching cases and 
controls. Age and gender are two other very important confounding factors. Elderly 
people are more prone to a variety of diseases as they are weakened by age. This can lead 
to an increased number of age-related diseases that co-occur in the same patient because 
the patient is old. Likewise, gender is important as diseases such as prostate cancer only 
occur in one gender. Other confounding factors include weight, lifestyle related factors 
(e.g. physical activity and alcohol consumption) and social status.  
 
 
1.3 Data driven research 
In the data driven approaches, the process is the inverse of hypothesis driven 
approaches: The data is collected and tested to form hypothesis a posteriori in an 
explorative manner. This approach is often used in studies that seek to illuminate entire 
systems rather than analyze specific subsets (such as a single disease). For data driven 
research, the objective is often to explore all possible correlations in a large data set (e.g. 
[4,5]. An important task here is to identify interesting hypotheses that can be translated 
into usage. For studies generating thousands or millions of hypotheses, this can be a big 
challenge requiring extensive amounts of manual work. However, because the full system 
(e.g. all diseases) is investigated when using data driven approaches, it is possible to 
identify surprising and novel results that would otherwise have gone unnoticed in 
Chapter 1: 
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hypothesis-driven research. In addition, because data driven research examines the whole 
system of disease correlations, it is possible to investigate groups of correlations instead 
of single correlations.  
 
The work on non-temporal co-morbidities and disease trajectories presented in this 
thesis contains examples of both benefits and challenges of data driven research. 
Diseases tended to correlate strongly in ways that can be expected from disease 
classifications, but less expected correlations were also identified. Identifying the new and 
unexpected correlations that were also interesting for further investigations was a 
challenge. It was also shown that analyzing correlations in a more stringent manner 
reduced the number of correlations, so the final set of correlation contains fewer trivial 
diagnoses. 
 
 
1.4 Hypotheses in data-driven research 
Even though data-driven analysis is often used as an antonym of hypothesis-driven 
analysis, there are always some fundamental hypotheses or assumptions in data-driven 
research that are not always tested explicitly. The main hypotheses for this thesis is that 
some biological processes cause diseases to occur in the same patients in a non-random 
fashion, and that this is reflected in medical registry data. There can be several 
explanations to why diseases co-occur non-randomly in the same patients. For example a 
common risk factor can predispose for multiple diseases, a disease mechanism can lead 
from one to another (such as cancer metastasizing or hepatitis C causing liver cancer 
which further can cause liver failure and related diseases) or a genetic mutation can drive 
both diseases. Irrespective of the cause, it is of interest to analyze disease correlations. 
From an epidemiological point of view, it is important in its own right to gain knowledge 
about the population prevalence of diseases and correlations with other diseases and risk 
factors. This can assist for prevention of diseases, by identifying risk groups who need to 
be monitored for a disease. From a molecular biological view, analysis of disease 
correlations is a source of understanding the underlying genetics.   
 
The hypothesis that the registry data can uncover biological processes is not tested 
directly in this thesis. However, we found many known and logical correlations among 
the results, which can serve as a sanity test for the hypothesis. It has also been observed 
in many epidemiological studies. However, we also found examples where the diseases 
appeared in the reverse order of the known causal relation. An example is the significant 
correlation from Manuscript I of hyperplasia of prostate leading to prostate cancer. Here 
the prostate cancer is the likely cause of the hyperplasia, and the direction observed in 
the registry is a consequence of how the diseases were diagnosed. Another such example 
from a different study of pneumonia patients where the patients who died quickly after 
arriving to the ER were found to be the healthiest [21]. This bias was caused by the 
routine that the patients who died quickly were not diagnosed as thorough as those 
surviving. There are many such examples and it is important to consider this when 
interpreting the results of registry analyses.  
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1.5 Disease progression and disease trajectories 
The study of disease progression over time is an important step towards being able to 
predict the disease outcome for a single patient.  When doing data-driven analysis of 
disease progressions on a large scale, the number of possibly trajectories that can be 
studied is a main issue. The number of combinations of diseases grows exponentially for 
each step added. It is therefore necessary to limit the number of possibly trajectories up 
front. Descriptive statistics (as the one presented in manuscript I) can be used to identify 
diseases that can predict severity of the future outcome. After identifying the diseases of 
interest, there are several ways of analyzing the disease progression. The progressions can 
be modeled as a state machine using methods such as Hidden Markov Models. This will 
help to characterize the progressions, but can also be used to predict further outcome. 
Alternatively, methods from machine learning can be used for prediction. This can 
involve methods such as neural networks that given the current history of the patient can 
predict future outcome. Many other options are available, and the most accurate results 
are likely to come from methods that combine features from different fields such as 
epidemiology, machine learning, network analysis etc.   
14 
Chapter 2: 
Data 
 
 
 
The data used in all studies of this thesis is from Danish National Patient Registry 
(NPR), which is a population wide disease registry. This chapter describes this registry 
along with other population registries. 
 
Recording of different population statistics has been performed for a long time. In 
Denmark the Bureau for Population Statistics (Statistics Denmark) was founded in 1850 
with the task of counting the population for taxation purposes. Nation-wide disease 
registries started already in 1942 with the Danish Cancer Registry. Since the introduction 
of the Central Person Registry (CPR) in 1968, all Danish citizens have been assigned a 
unique ID commonly known as the CPR-number. Individuals who have moved to 
Denmark to work or to stay permanently also get a CPR-number. The CPR system has 
been a contributing factor for the creation of a growing number of high quality registries, 
where the patients can be tracked across registries. While most of the registries were 
started for administration purposes, they have also been used for surveillance and 
research.  
 
Hospitals started reporting diagnoses and procedures to the NPR in 1977. It is one of 
the highest quality disease registries available for research in the world as it covers all 
encounters over a long period of time and allows researchers to obtain fully person-
identifiable data [22]. The data offers a great potential for doing large-scale studies. The 
other Nordic countries have disease registries as well. However, none of them cover as 
long a period of time as the Danish. Some cover fewer areas and others only recently 
have person-identifiable data available [22]. Other disease registries such as the US 
Medicare claim registry offer a larger population. However, it is a challenge to track 
patients without a centralized person identifier. In addition, the Medicare data has more 
biases since it only covers patients aged 65 and above who cannot afford private 
healthcare and some young disabled patients.  
 
 
2.1 Central Patient Registry 
CPR contains information on date of birth, date of death, names, addresses and civil 
status and other administrative data [23]. Many of the variables such as addresses have 
historical data as well. The parents of each person are listed making it possible to track 
kinship. Siblings can be identified through common parents, cousins through common 
grand parents and so on. This is limited to the generations alive in 1968. For older 
generations, it is possible to track them through church books, which are available online 
[24]. The date of death available through CPR are generally more accurate than the date 
supplied in death certificates, and are therefore used in the Causes of Death Registry.  
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2.2 National Patient Registry 
The National Patient Registry (NPR) contains data on diagnoses, surgical procedures, 
treatments and administrative information like waiting time for all hospital contacts in 
Denmark. Diagnoses are coded in ICD-10 (described in section 2.4.1). Initially the 
registry included only somatic inpatient encounters, but since 1987, outpatient and 
Emergency Room (ER) encounters have also been registered. There is also a registry for 
psychiatric hospitals, which has the same structure as NDR. Additional permissions are 
required to use this data. 
 
2.2.1 Reporting procedure 
The reporting to NPR has to follow guidelines for minimum registration, Fællesindhold for 
basis registrering af sygehuspatienter, published by Statens Seruminstitut. During a hospital 
encounter notes about the patient's state is made in the patient files. This includes 
physical examinations, confirmation and rejection of diagnoses, surgical procedures and 
treatment. When the patient is discharged, a doctor reads the patient files and reports 
diagnoses, procedures and treatment to the registry along with administrative 
information [22,25].  
 
2.2.2 Data quality 
The data from NPR has been used for many studies [17], however there have not been 
many reviews of the overall data quality. It has mainly been verified for special uses 
where discharge summaries and patient files have been obtained for a selection of 
diagnoses. Positive Prediction Value (PPV) and Negative Prediction Value (NPV) are 
common measurements of accuracy. The PPV is the percentage of rightfully assigned 
diagnoses (true positives) out of total number of reported diagnoses (sum of true and 
false positives), and NPV is the amount of true negatives for patients without the 
diagnosis. A study from 2011 shows that the data has high quality for calculating the 
Charlson comorbidity index [25]. Discharge Results showed an overall PPV of 98% and 
PPV between 82% and 100% for each of the 19 diagnoses covered by the Charlson 
index. A quality study of COPD diagnoses from 2011 reports a high PPV of 92%, but a 
lower NPV of 82% [26]. Other recent studies report a PPV of 75% for venous 
thromboembolism [27], 65.5% for acute coronary syndrome [28] and 59% for 
rheumatoid arthritis [29]. These studies demonstrate that quality of coding depends on 
the specialty and that conclusions should be drawn with care when relying solely on 
registry data. An older study from 1995 concludes that the less specific (3 digit ICD-8) 
codes have higher accuracy than the more specific (5 digit ICD-8) codes [30] which is 
still likely to be the case for the newer ICD-10. Using the less specific codes reduces 
errors where one specific code was wrongly chosen instead of another specific code.  
 
In [29] it is found that patients with only one rheumatoid arthritis encounter had a PPV 
of 42%, whereas patients with three or more have a PPV of 91%. Taking the number of 
encounters into consideration when analyzing the data could make the results more 
reliable. However, it is difficult to quantify how many encounters are needed, and it will 
be heavily dependent on the specialty. Studying the correlation between the quality and 
the number of repetitions for a wide variety of specialties would be very interesting and 
of use to many registry studies. An unpublished in-house study of heart defects shows a 
very small PPV for patients given an unspecified heart failure code, but a higher PPV for 
patients with specific diagnoses. This might be a general trend, and the PPV of 
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unspecific codes could be a focus when reviewing the accuracy of the registry. 
Temporality can also be an important factor in studying accuracy: Some diseases require 
an extensive follow-up period. If no such period is observed after a discharge with the 
disease, the patient might to not have the disease. 
 
A key issue for data quality is the fact that the data is used for billing purposes. The 
hospitals are reimbursed by the state according to Diagnosis Related Groups system for 
inpatients and Danish Ambulatory Grouping System for outpatients. These system takes 
diagnoses, age, the length of stay, and other factors into consideration when placing an 
encounter into a group with an associated reimbursement rate [31]. An important factor 
is which diagnosis is categorized as the main diagnosis and which is supplementary 
diagnosis. Changing which diagnosis is the main and which is the supplementary can 
change the reimbursement rate. Therefore, economic considerations also contribute in 
deciding the main diagnosis in addition to medical judgments. The reimbursement 
system also gives bias towards including additional diagnoses present in the patient, 
which are not relevant for the current encounter, and more severe diagnoses. As we have 
been ignoring the main and supplementary diagnosis categories, and have used codes at a 
less specific level where severity is not taken into account, the issues of main versus 
supplementary diagnosis and severity are not relevant to our studies. However, inclusion 
of diagnoses unrelated to the current encounter can influence our analysis.  
 
Given the issues with data quality, interpretation of results from registry studies should 
be done carefully. Special care must be taken for rare diseases where a large error rate has 
a big effect. For this reason the studies presented in this thesis are focusing on the strong 
signals from large patient groups.  
 
2.2.3 NPR dataset 
The data set we have analyzed data contains all records from 1996 to 2010. It covers 6.2 
million patients with 68 million hospital encounters and 54.9 million unique patient-
diagnosis associations. It is further described in Manuscript I. 
 
The NPR data set was cleaned by removing records with invalid personal identification 
numbers, records with only legacy ICD-8 diagnoses and records lacking primary 
diagnoses. Each record covers the time between admission to one ward until discharge 
from the hospital or to another ward. Records for inpatients were concatenated to cover 
an entire admission when there were discharges between wards. Readmissions of 
inpatients 1 day or less from a discharge were also concatenated to the first admission. 
1.5 million inpatient records were concatenated with other records giving 66.5 million 
concatenated admissions, outpatient visits and ER visits in total.  
 
 
2.3 Other registries 
2.3.1 Statistics Denmark 
Statistics Denmark releases yearly statistics reports on population census, income, 
employment, etc. These reports have been freely available online since 2001 through 
statistikbanken.dk. They also have data available for researchers in a person identifiable 
form. This includes data that can be used to describe the socioeconomic status of each 
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person, which is of interest as confounding factor in medical research. However, the data 
is only available through a closed data system. Researchers can only analyze the data with 
the programs made available by Statistics Denmark, making it tedious to use it. In 
addition, only small data sets can be exported from there to prevent users from exporting 
person-identifiable data. For medium and large-scale data analysis, this limits the 
usability.  
 
2.3.2 Diabetes Registry 
Diabetes is becoming an increasingly common disease [32]. Therefore, it is the target of 
many medical studies and of interest to epidemiologic studies. Many diabetes patients are 
treated by the general practitioner or at specialized clinics and only severe complications, 
such as diabetic foot ulcer, are treated at hospitals. Consequently, the prevalence of 
diabetes found in NPR is too low. In order to obtain an estimate of the diabetes 
prevalence in Denmark, the Danish Diabetes Registry, which integrates different data 
sources, was started. Unfortunately, the registry is based on uncertain indicators (for 
example repetitive blood samples), and there is no guarantee that people registered in it 
have diabetes [33,34]. As a result, it is not well suited for epidemiological studies. 
 
2.3.3 Drug prescription registry 
Statens Serum Institue maintains a registry of medicine prescriptions in Denmark. 
However, its aim is to survey the total medicine consumption and not all prescriptions 
are available on a person-identifiable level. Hospitals register medicine usage at 
department level. Since the data is on prescriptions and not sale or usage, it is not certain 
that patients used the medicine. Furthermore, the data is available through Statistics 
Denmark and is therefore prone to same difficulties as described in section 2.3.1. 
 
 
2.4 Disease classifications and resources 
2.4.1 ICD 
The International Classification of Disease, ICD, is a classification that covers the full 
spectrum of pathology. It is updated regularly; version 8 (ICD-8) was used in NPR from 
1977 to 1993, and version 10  (ICD-10) since 1994. The ICD-10 version used in NPR is 
a Danish adaptation with more codes. The US Medicare data still uses version 9, but will 
soon update to version 10. While the changes from version 8 to 9 are not large, there are 
many fundamental changes introduced in version 10. Therefore, there is no one to one 
mapping between them. This makes it almost impossible to compare correlations 
between the two versions if the mapping between versions is not carried out before 
calculating the correlations. 
 
ICD-10 is structured in 21 chapters that cover different areas of pathology. For example, 
there are chapters for different classes of diseases (e.g. chapter I ‘Infectious diseases’ and 
chapter II ‘Neoplasms’) and different anatomical structures. Each chapter is subdivided 
into more specific block such as ‘Intestinal infectious diseases’ in chapter I. Each of these 
blocks covers a range of codes. The codes are alphanumerical and start with one letter 
followed by two or three numbers. Codes with three characters are called level-3 codes, 
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and with four characters are called level-4 codes. The Danish ICD-10 adaption allows for 
more alphanumerical levels. 
 
The classification is hierarchical, so A000 ‘Cholera due to Vibrio cholerae 01, biovar 
cholerae’ is a sub-diagnosis of A00 ‘Cholera’. This fact can be used when counting the 
diagnoses. Patients having A000 can also be counted as having the more general A00 (the 
diagnosis can be “rounded”). The same applies for further sub-levels, e.g. G229A (only 
in the Danish ICD-10) where the patients having G229A, also can be counted for G229 
and G22.  
 
 
2.4.2 SNOMED-CT 
Systematized Nomenclature of Medicine and Clinical Terms, SNOMED-CT, is 
classification for diseases and healthcare with a strong focus on use in EHR systems. It is 
a combination of the two independent classifications SNOMED and CT. The terms are 
connected through relationships. The “is a” relationship is used to define the hierarchical 
structure where each term can have multiple parent terms. There are 17 base hierarchies 
(e.g. Clinical findings) and all terms can be traced back to one or more of these. Because 
of the possibility for multiple parents, the hierarchy cannot be used to “round” diagnoses 
to a more general diagnosis. Unlike ICD-10 the codes of SNOMED-CT are numeric 
identifiers that are used as a key in a database structure, and they make no sense by 
themselves.  
 
Advantages of using SNOMED-CT include that the similarity of terms can be calculated 
for all terms against all. In this way, the classification contains knowledge that for 
example could be used for analyzing disease correlations. In ICD-10, codes can only be 
in the same block or chapter or not related at all. Another advantage is the possibility of 
making for compound terms where two or more terms can be pre- or post-coordinated. 
This enables users to extend the classification for their needs and still maintain 
compatibility with other users of SNOMED-CT.  
 
 
2.4.3 UMLS 
Unified Medical Language System, UMLS, is a meta-classification that combines more 
than hundred classifications, among others ICD and SNOMED-CT. It can be used to 
perform cross mapping between different classifications. Like SNOMED-CT, it consists 
of terms connected by relationships. Because it consists of multiple classifications, it has 
issues such as redundant terms, and cyclic “is-a” relationships, where a term can be both 
an ancestor and predecessor of another term [35]. Some of these errors can be avoided 
by limiting which classifications are used.  
 
 
2.4.4 Mapping issues 
There is no objective truth of how diseases should be hierarchically structured and how 
many details to include in a classification. Therefore, there are large issues when mapping 
between different classifications and even between different versions of the same 
classification. Despite efforts to create cross mapping between classifications, no simple 
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solution to this problem exists. Sometimes the mapping is complex so that a 
combination of two diseases is mapped to one disease. Therefore, the full medical record 
of a patient can be necessary to map successfully. There is no publicly available full 
mapping between ICD-8 and ICD-10. ICD-9 has been mapped to ICD-10 as the 
registries in United States are switching to ICD-10.  
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Chapter 3: 
Disease correlations 
 
 
 
Correlation is a statistical term for measures of how much two variables are related to or 
depend on each other. Correlations between diseases commonly measure how much 
presence of one disease increases or decreases the risk of presence of another disease. 
Disease correlations are sometimes called (clinical) associations in epidemiology. This 
chapter mainly addresses non-temporal correlations while temporal correlations are 
discussed in chapter 4 and 5.  
 
Correlations between pairs of diseases have been quantified by counting the number of 
patients who have both the diseases in this thesis. A pair of diseases is said to be co-
morbid if they co-occur in the same patient. The strength of correlation for pairs of 
diseases is quantified using Relative Risk (RR). Together with statistical tests, this 
measure can be used to identify co-morbidities that are unlikely to occur together by 
chance and can be candidates for further investigations. 
 
Disease correlations can both be positive and negative. In the work in progress I on non-
temporal correlations 8% of the correlations were negative and in [4] a third were 
negative. A possible explanation for the high number of positive correlations is positive 
feedback: most diseases cause the patients to become weaker, and weakened patients get 
more diseases. It is interesting to analyze both positive and negative correlations. If the 
mechanism causing negative correlation can be identified and replicated, it can be used 
for treatment or prevention. While manuscript I and the work in progress I have only 
addressed positive correlations, the work in progress II have investigated negative 
correlation as well. 
 
 
3.1 Definitions of co-morbidity 
It is common to study one given index disease and name all diseases co-occurring with it 
co-morbidities [36]. The index diseases could also be replaced by a risk factor (e.g. being 
a blood donor [19]), a surgical procedure (like in the work in progress II) or other 
medical events. Presence of co-morbidities often gives rise to complications to treatment 
of diseases and generally affect the quality of life [37,38]. This is especially a problem for 
chronic diseases. For example, presence of COPD can cause complications among 
patients with myocardial infarction [39–41]. Therefore, some studies require that the co-
morbidities are chronic diseases. The Charlson index is used to assess the increased 
mortality for patients with chronic co-morbid diseases [42]. Given the presence of one or 
more of 19 primarily chronic diseases, the Charlson index is used to assess short-term 
mortality.  
 
Temporality is a key factor to consider in the definition of comorbidity. When the aim is 
to predict future disease, it is of obvious necessity to resolve the order of diseases. This is 
discussed in details in chapter 4 and 5. For some diseases, it takes several years for 
patients to develop complications, for example, retinopathy in diabetes [43]. In these 
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cases, a long time span is needed to detect the complications. In our study of colectomy 
described in the work in progress II, it was of interest to remove the initial co-
morbidities to be able to identify the long-term effects. Colectomy patients will be 
weakened by extensive surgery, and there is in an initial increased mortality risk caused by 
infections in addition to complications [44].  
 
 
3.2 Large-scale correlation analysis 
3.2.1 Previous large-scale studies 
Doing large-scale disease correlation analysis implies that all diseases are tested against all 
diseases for significant correlations. Only few large-scale studies that use registry data 
exist until now. The largest study so far is the study of Mendelian diseases in manuscript 
II, which covers more than 100 million patients from the US and Denmark. The second 
largest study uses 3 years of US Medicare data covering 13 million patients [4]. The study 
focuses on analyzing the correlations as a network, proving network properties (such as 
importance of “hub” diseases that have many significant correlations to others) and in 
general demonstrating that methods from network analysis are applicable for the analysis 
of disease correlations.  
 
3.2.2 Correction for multiple testing 
Data-driven analysis usually result in several thousands or hundreds of thousands 
significant pairs of diagnoses. Therefore, it is important to perform correction for 
multiple testing. If correction for multiple testing is not performed, the effective ! 
(probability of no false positives) decreases exponentially with the number of tests. For 
100 tests with an ! of 5%, the effective ! is above 99%, i.e. it is almost certain that false 
positives are among the hypotheses that are deemed significant. Two methods often used 
are Bonferroni correction and the Benjamini-Hochberg procedure. Bonferroni 
correction is the stricter of these two. While the Bonferroni corrections guarantees that 
each test has an effective probability for being falsely positive of less than !, the 
Benjamini-Hochberg procedure guarantees that the percentage of false positives in the 
significant set is maximum !.  
 
Both methods can be used, and it depends on the data which method is preferable.  A 
drawback of correcting for multiple testing is that only the strongest correlations, which 
are often the obvious, will remain significant. Since p-value is not a measure of 
“interestingness”, it is undesirable to only investigate correlations with very small p-
values. In cases where usage of Bonferroni correction would remove all significant pairs 
in the data or reduce the significant pairs to a few strong ones, the Benjamini-Hochberg 
method is preferable.  
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3.3 Work in progress I: Analysis of non-temporal co-morbidities 
This section presents the work in progress on analysis of non-temporal co-morbidities. 
The main part of the data analysis is finished, but the results still need to be interpreted. 
The aim of the study was to use the registry data to identify novel disease correlations 
that could be explained by either genetics or disease mechanisms. All pairs of diseases 
co-occurring in a patient were analyzed irrespective of the order in which they occurred 
or the time between their occurrences.  
 
 
3.3.1 Materials and methods  
!"#"$
We analyzed data from NPR, which is described in section 2.2 and manuscript I. We 
excluded codes related to pregnancy (ICD-10 chapters XV and XVI), general symptoms 
and signs not linked to a disease (chapter XVIII), external causes (chapters XIX and 
XX), and administration (chapter XXI). We subsequently rounded ICD-10 codes to 
level-3. This rounding reduces the dataset to 20.7 million unique patient–diagnosis 
associations covering 1,135 ICD-10 codes. This also limits the number of statistical tests, 
which need to be performed, from 1,022,534 to 460,657. 
 
To address biases from age and gender, the population was split into age and gender bins 
to stratify the correlation measure. The age bins were defined by birth decade (see 
supplementary figure S1 in Manuscript I). Most of the patients from the pre-1900 bins 
are deceased by 1996 and these bins were therefore removed. The bin for people born in 
2010 only cover one year and was also removed.  
 
%&''()"#*&+$,("-.'($
RR is a measure commonly used in medical and epidemiological research, and was used 
for this work as well as in manuscript I. RR is defined as the probability for some event 
in one group of subjects divided by the probability for this event in another group of 
subjects. The groups are often case group versus control group, or treated versus 
untreated. In this work, the case group was the observed patients with a pair of diseases, 
and the control group was what would be expected by random from the total population 
given no correlation between the diseases. Thus, the full population was used to calculate 
the frequency for both “groups”. 
 
Statistical tests are used to identify if a RR is large by random or not. This can be 
combined with a threshold on RR. For example, it can be required that the RR value is 2 
(corresponding to 100% increased risk) for the correlation to be subject to further 
studies. Any such threshold is of course arbitrary.  
 
An issue with RR is that it overestimates the correlation of rare diseases. If both diseases 
in a pair are rare, the expected value will be small which can result in high RR values 
based on few patients. For example, a pair of diseases where both occur in 200 out of 
one million patients will have a RR of 25 if they co-occur in one patient. An alternative 
to RR is Pearson's correlation, which correctly estimates pairs of rare or frequent 
diseases, but underestimates the correlation when one disease is frequent and the other 
rare. The two measures were used and compared against each other in [4], where they 
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resulted in different sets of significant pairs. However, it is hard to say if one is more 
correct than the other. We choose to use RR as it is widely used and accepted within the 
medical community.  
 
For a pair of disease A and B where there is N patients in the full population, NA patient 
have disease A, NB have B, CAB have both disease, RR is given by the ratio between the 
observed frequency of A and B together and the randomly expected frequency, 
 
 
 
 
 
It can be noted that when using the same population for both the observed and expected 
frequency, the definition becomes equal to ratio between the number of observed 
patients and the number of patients expected by random. Correction for age and gender 
was performed by changing calculating the number of patients expected by random for 
each age and gender bin and sum them, 
 
 
 
 
Bins were removed if one or both diseases were assigned to less than five patients.  
 
To address the issue that RR is overestimated for pairs of rare diseases, we added a 
pseudo count to the observed and expected value. For a pseudo-count of s, the formula 
for the pseudo count corrected relative risk (RRP) is, 
 
 
 
 
RRP has a maximum value of (CAB + s)/s. A pseudo count of s = 1 will limit to RRP is 
maximum CAB + 1. Thus, any pseudo count equal to or larger than 1 will limit the RRP 
of pairs with few co-occurrences. To select the pseudo count, we calculated the RR for 
integer pseudo-counts between 1 and 10. We evaluated average number number of 
patients with both diseases for the pairs with the 1000 largest RR values (figure 3.1) and 
found 3 to be an appropriate pseudo count.  
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Figure 3.1 Selection of pseudo count. The 1,000 pairs of diagnoses with the largest RR were identified for 
a range of pseudo count values. For each value, the average number of patients who have both the diseases 
from a pair was subsequently found. The plot shows the average number of patients plotted as a function 
of pseudo count. When not using pseudo count, the top 1,000 pairs have 1.9 patients on average, while for 
a pseudo count of 1 the top 1,000 have 518 patients. The slope of the function decreases for pseudo 
counts larger than 3. Therefore, we chose to use a pseudo count of 3. However, any value between 1 and 3 
would also have been acceptable. 
 
Fisher's exact test and the Mantel-Haenszel tests were used to calculate p-values for the 
estimates. Fisher's exact test was applied to cases with patients from only one bin, and 
Mantel-Haenszel was applied for cases with patients from more bins. We used a p > 0.05 
significance cutoff and applied Bonferroni correction to address the issue of multiple 
testing.  
 
%).-#('*+/$
We performed clustering on the statistical significant of pairs diagnoses (Bonferoni 
corrected p<0.05, RRP > 1) to obtain an overview of the comorbidities and identify 
groups of strongly correlated diagnoses. The MCL [45] clustering algorithm was used for 
this purpose. In order to focus on positive correlations and have a zero-point in the data, 
pairs with RR values less than 1 were removed, and 1 was subtracted from the remaining, 
 
 RRPcluster = RRP - 1 , for all pairs having RRP > 1 
 
MCL has one key parameter, the inflation factor, which influences the size and number 
of clusters. It can be chosen arbitrarily. As the aim of clustering was to find groups of 
strongly correlated diagnoses, we quantified the clustering result by the ratio of RR 
within the clusters to RR between the clusters. If there are NC diagnoses in the cluster 
and Ndiag - NC diagnoses outside the cluster then the ratio will be, 
 
! 
2
NC NC "1( )
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The inflation factor was selected by running the MCL algorithm for a range of different 
inflation factor values and calculating the ratio (figure 3.2).  
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Figure 3.1 Selection of inflation factor for diagnosis clustering. (A) The ratio of average RR within and 
average RR between clusters as a function of inflation factors. The highest ratio is obtained for the 
inflation factor of 4.3. (B) The number of clusters as a function of inflation factors. There are 121 clusters 
for the inflation factor of 4.3. 
 
A second round of clustering was performed, where the diagnoses from each cluster 
were concatenated into a meta-node, and the diagnoses of each patient in the original 
dataset were mapped to these meta-nodes. The patient-meta-node associations were used 
to calculate a RR between meta-nodes. Finally, MCL was used to cluster the meta-nodes. 
The inflation factor was selected in the same manner as with the initial clustering (figure 
3.3). 
 
  
!"" #"
Figure 3.3 Selection of inflation factor for meta-node clustering. (A) The ratio of average RR within and 
average RR between clusters as a function of inflation factors. The highest ratio is obtained for the 
inflation factor of 1.5. However, this results in only five clusters, and the high ratio can be explained by a 
low number of links between clusters. For inflation factors above 1.9, the highest ratio is obtained for 6.5-
7.3. (B) The number of meta-clusters as a function of inflation factors. There are 19 meta-clusters for the 
inflation factor in the interval 6.5-7.3.  
 
 
3.3.2 Results 
We identified 460,657 pairs of diagnoses that were co-occurring in five or more patients 
from at least one of the age and gender bins. Of those 148,081 were found to be 
significantly overrepresented (p<0.05, RRP>1).  
 
In order to comprehend and visualize the full set of population wide comorbidities and 
to reveal strongly inter-connected groups of diagnoses, we performed MCL clustering 
and found 121 clusters. To display higher-level structure in the comorbidities we 
performed a second round of clustering, where all diagnoses within clusters were 
concatenated into 19 meta-clusters (clusters of meta nodes), see figure 3.3 and 
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supplementary table 1 (p. 92). The clusters tend to contain diagnoses from the same 
ICD-10 chapter. For example, one cluster in meta-cluster 5 only contains psychiatric and 
behavioral diagnoses (green) and five out of ten clusters in meta-cluster 4 are mainly 
neoplasm diagnoses (brown). Other clusters contain diagnoses that correlate because 
they affect the same anatomy: In meta-cluster 6, the central cluster mainly consists of 
cancer of the lip and oral cavity together with diseases of oral cavity, salivary glands and 
jaws.  
 
We considered two approaches to infer knowledge using the clusters. One is to study the 
significant correlations within each cluster. It can be speculated that the diseases in the 
same clusters share etiology, which is especially interesting for diagnoses from different 
chapters. Another is to study the diseases that do not cluster together. For example, two 
clusters contain the majority of psychiatric and behavioral diagnoses (in meta-cluster 1 
and 5). They are likely to represent two patient groups, and it can be interesting to do 
further studies that explain why they are not clustered together. This can be examined by 
doing patient stratification based on the clusters: The patient can be clustered based on 
their associations to meta-nodes. Patient groups that share diagnoses from the same 
meta-nodes can be identified, and it can be seen if the meta-nodes correspond to 
different patient groups. These patient groups can be further characterized by age, 
gender and other shared diseases. This would be similar to an earlier study where patient 
stratification was based on diagnosis data from a psychiatric hospital [5].  
 
 
3.3.4 Further analyses 
It is important to assess the robustness of the clustering. Some clusters can be connected 
by few diagnoses that correlate strongly with many diseases. If they are removed from 
the dataset before clustering, it is possible that the clustering will look completely 
different. This effect can be tested by doing cross-validation: The set of diagnoses (or 
correlations) is randomly split into N parts, and the clustering is performed on the data 
set with one of the N parts left out. The stability of the clusters can be assessed across 
the N different clustering results. The pseudo count also has a significant effect on the 
clustering. We also applied the clustering on the full data (i.e. also non-significant 
correlations) without the pseudo count correction, where we found 141 clusters. These 
clusters consisted of a very heterogeneous combination of ICD-10 chapters, which is 
opposite to what we found in the pseudo count corrected data. To test the effect of the 
pseudo-count, the clustering algorithm can be applied to data sets with different pseudo-
counts. An important thing to keep in mind when doing these two analyses is to select 
the inflation factor in a stringent manner, so the difference is not due to difference in 
inflation factor. 
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Figure 3.3 Result of the diagnosis clustering and meta-node clusteringEach circle is one of the 121 
diagnosis clusters (or meta-node). The diagnosis codes are listed alphabetically within each cluster. The 
diagnosis codes and clusters are listed in supplementary table 1 (p. 92). The gray background fill around the 
clusters shows the meta-clustering. The numbers (1-19) refer to the meta-clusters. The layout of the 
clusters and meta-clusters is arbitrary.  
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3.3.4 Other results 
Initially, we attempted to do reduce the set of correlations for manual curration, by 
grouping the correlations based on chapter and other properties. For example, codes 
from several chapters, such as injuries, were assigned to one group. Another group was 
disease pairs from the same ICD-10 chapter, which are likely to be similar. The result 
was nine groups where one group contained the most interesting correlations. Given 
more time, the groups can be evaluated further by picking random pairs from each 
group, and manually rating if they are obvious or interesting. However, the results were 
abandoned in favor of using clustering to group the diagnoses. 
 
 
3.3.5 Discussion 
In this work, it is shown how data from millions of hospitalizations can be compacted 
into clusters of co-occurring diseases that may even be reclustered into forming an 
overview of comorbidities as a macro-pattern. At the same time, these clusters illustrate 
fine-grained correlations between individual diseases that may have different phenotypic 
manifestations and belong to different ICD-10 chapters. This view complements the 
traditional diseaseome visualizations. 
 
The major challenge in this work is the large amounts of significant co-morbidities 
identified. This is a challenge that applies to many fields that uses data-driven methods, 
and no general solution has been found for disease correlations yet. In [4], it is argued 
that methods from network analysis can be used to explore the correlations. However, it 
is not discussed how this will help to identify translational useful cases. The clustering 
approach presented here is one way of reducing the set of correlations to a smaller set of 
strong correlations. It is possible that even better results could be obtained by using 
clustering that allows one disease to be in more than one cluster, i.e. fuzzy clustering. 
This is likely to reflect the complex structure of diseases correlations.  
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Temporal correlations and 
disease trajectories 
 
 
 
The important aspect of temporality in disease correlations has been analyzed in 
manuscript I and the work in progress II (further described in chapter 5). The two 
studies use different methodology: In manuscript I, temporal correlations are analyzed in 
a data-driven manner. The correlation analysis is used to study disease progression over 
time. In the work in progress II, methods from survival analysis are used to assess the 
risk of cardiovascular diseases following a total colectomy procedure.  
 
 
4.1 Temporal correlations 
The temporal order in which diseases manifest themselves can be either random or 
determined by some known or unknown mechanism. In some cases, the temporality can 
be explained trivially by the age distributions of the diseases. Diagnoses given to 
newborns will obviously precede a wide range of diagnoses; cancer prevalence is higher 
among older people etc. HIV and AIDS is an example where there is a clear 
directionality. However, this does not imply that HIV is always diagnosed before AIDS. 
In some cases, the first HIV diagnosis can even be wrongly assigned to the patient after 
the outbreak of AIDS. Furthermore, the “symptom” diagnoses are in many cases 
diagnosed before the underlying disease causing it, for example, pneumonia in AIDS 
patients. Therefore, it is generally not possible to deduce causality based only on registry 
data. 
 
Two methods were used to infer the temporality of correlations. The results from the 
non-temporal analysis were disregarded for both methods. We examined pairs of 
diseases (1 and 2).  First, we calculated the RR of getting a disease 2 within a time frame 
given an occurrence of disease 1 (and the other way around). Then we used a binomial 
test to infer the temporal directionality of the significant pairs of diseases (i.e. testing if 
one disease occurs before the other). A correction for age was considered for the 
binomial direction test to correct for cases where the directionality was due to large 
difference in the age distributions of the diseases, as discussed above. However, this was 
found to be too conservative: the correction was punishing for the same temporal signal 
we were trying to identify. Given a maximum time frame of only 14.9 years, patients 
roughly belong to the same age group during the entire period. Therefore, this correction 
is not important. 
 
Initially, we estimated RR and tested the significance of different time frames to be able 
to study the temporal pattern of each disease pair. However, with the focus on disease 
trajectories, we needed only to know if one disease increased the risk of the other. 
Therefore, only one time frame was used. Instead of manually looking through lists of 
correlations, the trajectories were used to identify the interesting temporal correlations.  
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4.2 Disease trajectories 
The progression of a disease over time is also called a disease trajectory or illness 
trajectory. There is no formal definition of what constitutes a disease trajectory. Studies 
of trajectories focus on topics such as the age and gender's influence on the trajectory 
[46], conditions such as pain related to the disease [47] or how to give a patient the best 
nursing treatment [48,49]. An area that needs to be analyzed to realize the goals of P4 
medicine is how one disease progresses into other diseases. This knowledge is of key 
importance to be able to make early diagnostics and infer the effect that different 
genotypes have on disease progression.  
 
Ideally, a disease trajectory should be described using all confounding data that affect the 
outcome of diseases: Medical history, treatment, genetic data and environmental data. 
The NPR contains data that is crucial to make inference on disease trajectories: 
Diagnoses, treatment and surgery history along with age and gender, which are two of 
the most important confounding factors. Manuscript I uses the diagnosis history with the 
aim of describing the disease trajectories for a full nation in a data driven manner.  
 
 
4.3 Modeling disease trajectories 
Since there are no prior attempts at studying disease trajectories in a large scale for all 
diseases, there are no existing models for this purpose. The appropriate choice of model 
depends on the aim. Descriptive statistics of the trajectories require no model selection 
and can serve as a starting point for further analysis. If the aim is to study the effect of 
genotype or treatment on the disease progression, the models need to be able to handle 
stratifying factors. One possibility to address this need is to use state machine models, 
where a treatment switches to another state. Another possibility is usage of predictors 
such as neural networks that given the current medical and treatment history and 
genetics predicts future outcome.  
 
Hidden Markov Models (HMMs) are state machine models that can be used for pattern 
recognition in various kinds of data, for example DNA sequences and protein [50,51]. In 
a study of cancer progression HMMs were used to predict metastases [52]. The input for 
HMMs is a sequence of tokens, which for example could be diseases. The states for a 
given string is not known, but can be estimated using the HMM. Each state is associated 
with a set of output tokens it can emit with some probability and a set of probabilities for 
transition to other states or remaining in the same state. For modeling disease 
trajectories, the tokens can be diagnosis codes and states can correspond to different 
stages of the disease progression. Given a sequence of tokens and a HMM, the likelihood 
that the sequence is a result of this HMM can be calculated. By estimating HMMs for a 
variety of disease progression, a patient can be matched to a certain progression, and the 
HMMs can be used as a base for predicting future outcome. 
 
One concern with using HMMs for disease development is the Markov property of no 
memory: the next token in the sequence and its associated state only depends on the 
current token and state. This is not likely to be true for disease progression, where the 
full history for the patient is relevant for future states. Therefore, this issue has to be 
investigated further. Another main issue is to define the states and transition in a data 
driven setting where all diseases are considered. The questions of how many individual 
HMMs would be needed, which diseases each HMM should cover and which states and 
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transition patterns would be suitable are difficult to answer without further knowledge 
about disease trajectories. Thus, HMM did not fit our initial needs. 
 
In order to avoid a long and time-consuming analysis of an appropriate model, we 
decided to use a descriptive approach, where the number of patients with a given disease 
trajectory was simply counted. We defined a disease trajectory as a set of diseases (ICD-
10 codes) that must be observed in the patients in a given order. The first challenge with 
this approach is a combinatorial explosion: Given one thousand ICD-10 codes, there will 
be one million pairs to count and one billion triplets. To limit the number of trajectories 
to count, we restricted the trajectories to consist of pair-wise significant codes. Requiring 
the pairs to have a significant direction, so the first code is observed significantly more 
before the second code, restricted the diagnosis pairs to a set of 4,014, from which the 
trajectories were constructed.   
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4.4 Manuscript I: Patient-specific disease trajectories condensed 
from population-wide registry data 
 
Anders Boeck Jensen, Pope L. Moseley, Tudor I. Oprea, Sabrina Gade Ellesøe, Robert 
Eriksson, Henriette Schmock, Peter Bjødstrup Jensen, Lars Juhl Jensen, Søren Brunak. 
 
 
This manuscript presents the data driven work on identifying disease trajectories of 
disease development in the NPR data. 
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Anders Boeck Jensen1,2, Pope Moseley1,3, Tudor I. Oprea1,3, Sabrina Gade Ellesøe2,  
Robert Eriksson1,2, Henriette Schmock4, Peter Bjødstrup Jensen2, Lars Juhl Jensen2, 
Søren Brunak1,2* 
 
1Center for Sequence Analysis, Department of System Biology, Technical University of 
Denmark, Kgs. Lyngby, Denmark. 
2NNF Center for Protein Research, University of Copenhagen, Copenhagen, Denmark. 
3Department of Internal Medicine, University of New Mexico, Albuquerque, New 
Mexico, USA. 
4Institute of Biological Psychiatry, Mental Health Center Sct. Hans, Copenhagen 
University. Hospital, Roskilde, Denmark 
 
 
A key prerequisite for precision medicine is to estimate future disease progression 
from the history and current state of the patient. So far, disease correlations and 
disease trajectories have mainly been analyzed focusing on co-morbidities to a 
few index diseases or the progression of a single disease. Previous non-hypothesis 
driven analyses have been limited to time-unresolved diagnosis correlations, 
either without investigating the order in which diseases manifest themselves or 
analyzing data from a period of only a few years, which makes it difficult to 
resolve the order.  These studies demonstrated the potential of using patient 
registry data for exploring co-morbidity networks, but the focus was on the 
properties of the networks rather than on defining a comprehensive set of disease 
or diagnosis trajectories. Here we present a non-hypothesis driven analysis of 
temporal disease progression patterns based on an electronic health registry 
covering the whole population of Denmark. We make use of the entire spectrum 
of disease and convert a 6.2 million patient registry into 1,171 statistically 
significant disease trajectories obtained from data collected over 14.9 years. These 
trajectories can be grouped into patterns that centre on a smaller number of 
keystone diagnoses, such as Chronic Obstructive Pulmonary Disease (COPD) 
and gout, which are central to disease progression and hence important to 
diagnose early to prevent adverse outcome. Our analyses also highlight the 
importance of stratifying patients both by age and gender and into inpatients, 
outpatients and emergency department visits.  
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Introduction 
Population-wide analyses of disease correlations, co-morbidities and disease trajectories 
have so far mainly been carried out in a hypothesis driven manner with focus on a few 
diseases (Camilo and Goldstein, 2004; Finkelstein et al., 2009; Teno et al., 2001) or with 
focus on co-morbidities to index diseases (Petri et al., 2010). In contrast, this paper 
focuses on frequently observed temporal patterns over the entire spectrum of 
pathologies. Earlier data driven studies have used a network approach to analyze data 
covering three years of Medicare claims (mainly Americans 65 years or older) (Chen et 
al., 2009; Hidalgo et al., 2009). In this older population, investigators primarily identified 
diagnoses that were proximate to death (Hidalgo et al., 2009).  
 
We aim for defining a comprehensive set of disease trajectories observed across an entire 
population, rather than mainly understanding the mathematical properties of co-
morbidity networks as they have been constructed previously (Chen et al., 2009; Hidalgo 
et al., 2009). Both types of studies highlight the potential of using patient registry data for 
exploring co-morbidities and the temporal and non-temporal patterns they display.  
 
The data foundation for the analysis is the Danish National Patient Registry (NPR), 
which covers all hospital encounters (inpatient admissions, outpatient visits, and 
emergency room visits) of the entire Danish population from 1996 to 2010. Mandatory 
reporting from all Danish hospitals to the NPR limits population bias. This data set 
covers 6.2 million patients with a total of 66.5 million hospital encounters and 101 
million unique assignments of diagnoses coded in the International Classification of 
Diseases (ICD-10) terminology. The long time span and the size of the data set allowed 
us to analyze disease progression in the form of diagnosis trajectories. From the data we 
find 1,171 trajectories to have strong directional, statistical significance and thereby 
obtain a global picture of the most populated, directional co-morbidities observed in the 
clinic.   
 
 
Results  
As disease occurrences correlate strongly with age and gender, it is an obvious necessity 
to correct for these underlying baseline biases. Fig. 1 shows distributions of diseases 
across all 21 ICD-10 chapters in NPR stratified by age, gender and encounter type. 
Gender-specific differences in trends are clearly observable; most notably pregnancy-
related diagnoses assigned to women primarily in the age interval 15–45 (green). For 
males, injury codes standout among young men (red), but Fig. 1 clearly shows that these 
diagnoses segregate much stronger by encounter type than by gender or age. These 
examples stand out as some of the strongest correlations between diagnoses and 
encounter type, but our analysis demonstrated that this trend holds true for most ICD-10 
chapters. In this type of work we thus found that it is equally important to stratify 
diagnoses by the type of hospital encounter. An important consideration in the 
subsequent analyses was therefore to make use of this aspect to stratify diagnosis 
assignments into more precisely matched case–control groups. In this way we enable 
both the discovery of statistically significant correlations that would otherwise have been 
masked and the removal of statistically significant correlations that are trivially explained 
by encounter types. 
 
Chapter 4: 
Temporal correlations and disease trajectories 
 
  35 
 
Fig. 1. ICD-10 diagnoses from the National Danish Patient Registry covering the entire Danish population 
in the period 1996-2010. The data panels show females (left), males (right), inpatients (top), outpatients 
(middle), and emergency room patients (bottom). The color-coding corresponds to ICD-10 chapter 
structure starting from the bottom by "Certain infectious and parasitic diseases", (chapter I, hardly visible), 
"Neoplasms" (chapter II, brown), 21 chapters in all.   
 
To identify statistically significant, temporal correlations between diagnoses we used a 
case–control scheme where cases and controls were matched by age, gender and type of 
hospital encounter. The scheme consists of a pre-filtering step where initial p-values are 
estimated initially using a binomial test, and then confirmed using the full case-control 
matching.  
 
From the full data set, we identified 1,194,343 pairs (D1 " D2) of diagnoses where D2 
occurs within a five-year time frame of D1. From them we excluded in total 370,737 
codes related to pregnancy (chapters XV and XVI of ICD-10), general symptoms and 
signs not linked to a disease (chapter XVIII), external causes (chapters XIX and XX), 
and administration (chapter XXI). Among the 823,606 tested pairs, we identified 62,821 
that were observed in at least 10 encounters, had RR > 1 and were significant in the pre-
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filtering step with p < 0.001 (Bonferroni corrected for multiple testing). This number 
increases by ~10,000 if patients are stratified only by age and gender or only by type of 
hospital encounter, and by an additional ~8,000 when stratified by neither (see Table S1). 
Thus, stratification by type of hospital encounter is complimentary to and just as 
important as stratification by age and gender.  
 
In addition to identifying pairs with increased risk, we tested for significant directionality: 
Of the pairs D1 " D2 with significant RR > 1 we identified those where significantly 
higher number of patients had D1 occurring before D2 compared to the opposite 
direction or in the same admission. In all, 4,014 pairs were found to have a significant 
direction. All pairs were validated using the sampling model to be significant with p < 
0.01. Table S3 lists all the pairs and their corresponding RR and p-values. 
 
The 4,014 directional pairs were then combined into longer trajectories consisting of 
three, four or more diagnoses. We identified a set of 5,784 trajectories with three 
diagnoses that covers between 1 to 16,197 patients in the last step (2,939 of them cover 
more than 100 patients). These were extended to 1,171 trajectories of four diagnoses and 
further to 52 with five diagnoses all covered by at least 20 patients in the last step. The 
entire set of recurrent trajectories of four diagnoses each is shown in Table S4.  
 
To produce a more comprehensive overview we further clustered the trajectories based 
on which diagnoses they shared. As similarity measure between diagnosis pairs, we used 
the Jaccard Index. The clustering identified 15 clusters where the five largest respectively 
covered 46, 25, 12, 9 and 8 diagnoses. Below we focus on five of these trajectory clusters: 
diseases of the prostate, chronic obstructive pulmonary disease (COPD), cerebrovascular 
disease, cardiovascular disease, and diabetes mellitus. Below we describe their properties 
in detail.  
 
The prostate disease cluster is the simplest, progressing from prostate hypertrophy (ICD-
10 code: N40) through prostate cancer (C61) and obstructive uropathy (N13) to 
metastatic cancer (C79) and cancer-associated anemia (D63) (Fig. 2). Except for the 
expected prostate-specific complications, this nearly linear trajectory cluster is 
representative of general cancer progression to metastasis and anemia. 
 
The COPD cluster has a characteristic bowtie structure (Fig. 3). It starts by a variety of 
diagnoses from multiple ICD-10 chapters, including cardiovascular, skin, endocrine, and 
behavioral disorders. These all converge on COPD (J44) and proceed to respiratory 
failure (J96), pneumonia (J15), septicemia (A41) and other diagnoses. We tested that 
COPD was a central diagnosis in the cluster by calculating the RR of COPD occurring 
between all diagnoses preceding and succeeding COPD. We found that COPD had a RR 
of 5.1 (p<10-5).  
 
There is wide acceptance that cardiovascular disease-related morbidities are worsened in 
patients with COPD (Curkendall et al., 2006; Finkelstein et al., 2009; Salisbury et al., 
2007; Sidney et al., 2005). This association, however, generally considers the impact of 
cardiovascular events on pre-existing COPD or the co-existence of the two diagnoses. In 
contrast, our analysis demonstrates that a subsequent diagnosis of COPD has a profound 
impact on a number of cardiovascular diagnoses, whether angina pectoris (I20) or 
atherosclerosis (I70). In fact, all trajectories starting with atherosclerosis are followed by a 
subsequent COPD diagnosis, which supports the temporal pattern of diagnosis as well as 
pathophysiologic link. Once the diagnosis of COPD occurs, the disease trajectories tell a 
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story of rapid progression (typically 1.8–2.5 years) to a variety of subsequent diagnoses. 
However, the most common outcome after COPD appears to be death. Using a Kaplan-
Meyer estimate, we found that 49.7% of patients following a trajectory containing COPD 
die within 5 years compared to 21.3% in a matched control cohort. Over the full data 
period (14.9 years) 86.9% of COPD trajectory patients die while 36.2% of patients in the 
matched cohort die. The high-mortality rate is confirmed in another study (Suissa et al., 
2012): a 50% mortality at 3.6 years and 75% at 7.7 years from initial hospitalization.  
 
Similar to the COPD cluster, the cerebrovascular and diabetes clusters are characterized 
by convergence on keystone diagnoses, namely epilepsy (G40) and retinal disease (H36), 
respectively (Fig. 4 and Fig. 5). Epilepsy (with an RR of 6.6, p<10-5) is likely a marker of 
significant cerebrovascular compromise (Camilo and Goldstein, 2004) reflecting the 
severity of the underlying disease. Similarly, retinopathy (RR=20.1, p<10-5) is a marker of 
the degree of system-wide diabetic vasculopathy (Moss et al., 2003); population studies 
suggest that diabetic retinopathy is present in more than half of all diabetics (Kohner, 
1989). 
 
Gout (M10), like COPD and retinal disease, is a keystone diagnosis (RR=6.8, p<10-5) 
within the cardiovascular cluster and serves as central disease in a diabetes independent 
cardiovascular diseases cluster (Fig. 6). Associations between gout and cardiovascular 
disease have long been considered (Freedman et al., 1995), and allopurinol has recently 
been suggested for management of cardiovascular disease (Kelkar et al., 2011). In 
contrast, the recent CHARGE study failed to show a link between serum uric acid and 
cardiovascular risk (Yang et al., 2010). Our population-wide trajectory data support the 
epidemiologic relationship between gout and cardiovascular diseases. 
 
In addition to providing an important analysis of temporal disease associations across an 
entire population, the trajectories and their associated networks may be quite useful in 
refining study groups for comparative effectiveness research (CER). For example, the 4 
diagnosis trajectories beginning with angina (I20) ending with cardiac arrest (I46) include 
several combinations of disease diagnoses in the second and third positions. Chronic 
ischemic heart disease (I25) significantly increases the risk of a cardiac arrest to 1.13 (1.12 
to 1.42). Gout further increases the risk 1.99 (1.3-3.05). While numerous studies 
demonstrate the impact of ischemic heart disease in patients with renal failure (N18), 
renal failure as a subsequent diagnosis does not further increase the risk for cardiac arrest 
in the angina patient who develops chronic ischemic heart disease. Thus, one might use 
this data to design interventions based upon angina populations with and without gout, 
chronic ischemic heart disease, and so on.  
 
 
Discussion  
Systematically adding the temporal dimension to population-wide co-morbidity data has 
not been attempted previously using a non-hypothesis driven approach at this scale. We 
show for the first time that hospitalizations across an entire population of significant size 
can be used to extract and group trajectories as a novel way of describing biological 
disease progression and subsequently identifying keystone diagnoses.  
 
In this work we defined a diagnosis trajectory as an ordered series of diagnoses where the 
diagnoses were assigned to patients in the specific order. The order had to be followed 
strictly for a patient to be considered following it. Thus, for a trajectory starting with the 
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diagnoses D1 " D2 patients who had the diagnoses assigned in order D2 " D1 " D2 
again were not considered as following the trajectory. In cases where multiple diagnoses 
from the trajectory were assigned in the same discharge, they were considered to be in 
the correct order.  
 
This strict definition puts limits on how much variability each single trajectory is able to 
cover.  It means that bifurcating diagnoses which later converge on other diagnoses are 
not included in a single trajectory. Nonetheless, using our trajectory clustering approach 
we were able to cover this type of disease progression as well. Interestingly, using the 
clustering approach we were further able to reduce the patterns of disease progression 
from 1,171 individual trajectories down to less than ten major clusters covering most of 
the populated paths through the disease terminology space. As the underlying data 
foundation here is considerable and unbiased, this condensation is remarkable. However, 
it does also obviously reflect the numerical constraints set of the requirement for 
directionality in terms of relative risk.   
 
In terms of trajectory interpretation it is essential eventually to establish to what extent 
the directionality reflect underlying causal patterns or not. For example, it is interesting 
to speculate whether the disease state associated with the COPD diagnosis is the cause, 
or whether COPD is an ICD-10 surrogate for a variety of factors associated with 
increased morbidity, such as smoking, adverse effects of medications, or poor general 
health. The expected high degree of association between COPD and atherosclerosis 
supports the obvious smoking linkage. Hospitalization for pneumonia in the setting of 
underlying chronic disease is common, with odds ratios reported at 4.4 for COPD and 
3.24 for heart failure in one large study (Farr et al., 2000). Our model suggests an even 
more profound effect of these chronic conditions on pneumonia within a relatively short 
time span. COPD as a subsequent diagnosis of many trajectories may also demonstrate a 
medical systems issue, that of undiagnosed COPD, which becomes manifest only after 
another serious diagnosis is made. It is likely that COPD is coexistent with the initial 
diagnosis of most trajectories, yet it occurs as a second data point in multiple trajectories. 
 
Our findings demonstrate that the population-wide disease trajectory approach uncovers 
diagnosis linkages that have had unclear or conflicting relationships through 
epidemiologic or smaller sample case control approaches. We further demonstrate the 
importance of patient stratification and that stratification by type of hospital encounter is 
as important as stratification by age and gender.  
 
The trajectories have also a predictive potential where preceding steps can be used as a 
basis for predicting the most likely next step in the disease progression. A major 
additional perspective in using the catalog of disease trajectories established here is 
obviously to use them in the context of precision medicine and combine them with 
detailed molecular level characterization of each patient for better disease management of 
individual patients along the course each patient will take. 
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Fig. 2. Disease trajectories and trajectory-cluster for prostate cancer. The figure illustrates the transition 
from trajectories to a trajectory cluster. Each circle represents a diagnosis and is labeled with the 
corresponding ICD-10 code. The colors represent different ICD-10 chapters. The temporal diagnosis 
progression goes from left to right. A) All trajectories that contribute to the prostate-cancer cluster. The 
number of patients, who follow the trajectory until a given diagnosis, is given in the edges. B) The prostate 
cancer trajectory-cluster that represents all the trajectories. The width of the edges corresponds to the 
number of patients with the directed diagnosis pair from the full population. The cluster describes a 
normal progression from having hyperplesia of prostate diagnosed to having prostate cancer, cancer 
metastasis and anemia. 
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Fig. 3 COPD disease trajectory clusters.  A) The COPD cluster showing five preceding diagnoses leading 
to COPD and some of the possible outcomes.  
 
 
 
 
 
Fig. 4 Cerebrovascular Cerebrovascular cluster with epilepsy as key diagnosis.  
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Fig. 5 Diabetes disease trajectory clusters. Diabetes cluster showing progression from non-insulin 
dependent to insulin dependent diabetes. Retinal disorders are key diagnoses marking progression to worse 
conditions.   
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Fig 6 Cardiovascular disease trajectory clusters. A key finding is that gout is a central diagnosis in the 
cardiovascular cluster supporting evidence that gout is important to progression of cardiovascular diseases 
in a keystone manner. 
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Materials and Methods 
Study design 
The objective of this retrospective study was to identify and characterize disease 
trajectories using population-wide disease registry data using a data driven approach. The 
trajectories were derived using pairs of significant time-dependent diagnose correlations. 
A case-control scheme was used estimate the correlations' strength and p-value.  
The data used in the analysis is from the Danish National Patient Registry (NPR), which 
contains administrative information and primary and secondary diagnoses coded in the 
International Classification of diseases (ICD-10) covering every hospital contact in 
Denmark. It includes public and private hospital visits and covers all types of encounters: 
inpatient (admitted to the hospital with overnight stay), outpatient (visit without 
overnight stay) and emergency department contacts. 
 
The data set covers the period January 1996 to November 2010, and includes 68 million 
records for 6.2 million individuals. For inpatients the records cover the time between 
admission to a ward until discharge to either another ward or out of the hospital. 
Records covering two or more discharges between wards were combined into one 
covering the entire admission. In cases of re-admissions the same or the following day 
after a discharge the records were also combined. Doing this 1.5 million inpatient records 
were combined with other records giving 66.5 million encounters in total. Because 
private hospitals have only reported contacts from 2002, all of these, in total 1 million, 
were removed to maintain an unbiased data set. Private hospitals in Denmark 
approximately handle less than 1.6% of all admissions (routine treatment) and add less 
than 1% unique patient-diagnosis associations as 38.4% of the patient-diagnosis 
associations from private hospital are already covered by the public hospitals.  
 
The ICD-10 system has a hierarchical structure, where codes can be rounded to a less 
specific parent diagnosis code, block or chapter. We used this structure to round all 
codes to level 3. 
 
Diagnosis correlation measure 
We used relative risk (RR) to measure the strength of a correlation between a pair of 
diagnoses (D1 " D2). RR is defined as the ratio of observed number of D1 discharges 
(discharges with D1 assigned) followed by a D2 discharge within a 5-year time frame and 
the number expected at random with no correlation between the two diseases. The 
expected number was assessed using a case-control scheme sampling random control 
cohorts. P-values for RR were obtained using a binomial test that models the sampling 
procedure and corrected for multiple testing using Bonferroni correction. Due to 
correction for multiple testing for 823,606 pairs, we needed more than 82 million 
samples for each pair. The binomial model was used as a pre-filtering step in order to 
avoid a total running time of several thousands of computing years if performing the full 
procedure. Pairs included in the trajectories were validated using the full random 
sampling procedure.  
 
To account for confounding factors, control patients were matched to come from the 
same age and gender group as the case patient (as shown in Fig. S1). The type of 
encounter was matched for the D1 discharge. The season of the year and changes in 
diagnostic methods and focus over years are also confounding factors. We controlled for 
these by sampling the control discharge from the same week as the case D1 discharge. 
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Temporal correlation analysis 
Given a pair of diseases (D1 " D2) the case cohort was formed by identifying all 
discharges with D1 assigned. Control cohorts were formed by matching each case 
discharge with a random discharge that fulfills the matching criteria (same age and gender 
of the patients and same type of encounter and week of the discharge), resulting in a 
number (N) of control cohorts. D1 discharges that have one or more subsequent D2 
discharges within a five-year time frame were counted (Fig. S2). We denote the number 
for the case cohort as Ccases and as Ci, i = 1 .. N; for the control cohorts. RR is given by, 
 
 
 
The p-value was calculated as the percentage of the control cohort co-occurrence counts 
that are larger than the observed co-occurrence count, 
 
 
 
RR was estimated using 10,000 sampled control cohorts.  
 
In the binomial test modeling the sampling procedure, we considered each sampling of a 
single control discharge as a Bernoulli trial. Given the matching criteria there is a set of 
nmatch patients to select the random control from. A number, c, of these discharges will 
have D2 discharge within the time frame. This number can be pre-calculated without any 
sampling. The probability of sampling a control with a D2 discharge within the time 
frame is, 
 
 
 
The probability distribution for the total number of sampled D2 discharges is the sum of 
all single Bernoulli trials. We approximated the distribution by with the average of the 
probabilities for all D1 discharges, 
 
, 
 
where ndischarges is the number of discharges with D1. 
 
To make sure the binomial model is a valid substitution for the sampling giving p-values 
that are at least as conservative as the sampling procedure, we ran full sampling for 1,500 
pairs and compared with the simplification. We expect the simplification to perform 
worst where the variance of the probabilities contributing to the average probability is 
high. Therefore, we tested the 1,000 pairs with the largest variance, while 500 others were 
chosen at random. Fig. S3 shows the true p-values plotted against estimated p-values.  
The binomial model was found to be more conservative than the sampled p-values for 
small p-value. Thus the simplification is a valid substitute for the sampling procedure. To 
further guard against false positives due to the binomial model, the significance cutoff 
level was set to 0.001.  
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Testing for directionality 
The diagnosis pairs (D1, D2) that had RR > 1 and a significant p-value for one or both 
directions (D1 " D2 and/or D2 " D1) were tested for directionality. Binomial tests 
were used to identify pairs where significantly more patient had D1 assigned before D2 
or the other way around. For this, the first D1 and D2 discharges for patients with both 
diagnoses were identified and the order for each patient established. The number of 
patients with each order of the diagnoses was counted: ND1 with D1 assigned first, ND2 
with D2 assigned first and Nsame with D1 and D2 in the same discharge. Using two 
binomial tests we tested if ND1 or ND2 were significantly larger compared to a binomial 
distribution (ND1 + Nsame + ND2 samples with probability 50%). The p-values were 
Bonferroni corrected. If one of the tests showed a p-value less than 0.05 the pair was 
considered having a significant direction (only one of the tests can have significant p-
value).  
 
Diagnosis trajectories 
We counted the patients as following a disease trajectory only if the patient had the 
diagnoses assigned strictly in the order specified by the trajectory. Each step of the 
trajectory corresponded to a single diagnosis.  
 
We used the pairs of diagnoses from the temporal correlation analysis with significant 
direction to identify the trajectories to count. Trajectories with three diagnoses were 
obtained by combining pairs with overlapping diagnoses (D1 " D2 and D2 " D3 
combined to D1 " D2 " D3). They were subsequently extended with more 
overlapping pairs to obtain even longer trajectories. A greedy approach was used to find 
the three long trajectories covering the most patients. The pairs were sorted in 
descending order according to their discharge count. Pairs with an overlapping diagnosis 
were found starting from the top of the list and the number of patients following the full 
trajectory was counted. We stopped when the three long trajectories had no patients 
following them. All four and five long trajectories were then counted. Using this 
approach, all the trajectories covering the largest number of patients can be identified 
without counting every possible trajectory.  
 
Diagnosis trajectory clustering 
In the 1,171 four long diagnosis trajectories we identified groups of trajectories having 
large diagnosis overlap and representing variants of general patterns of disease 
progression. To identify these patterns systematically, we performed MCL clustering 
(Schaeffer, 2007) that assigned each of the 140 codes that make up the 1,171 trajectories 
to a cluster.  The Jaccard index was used as similarity measure (counting how many 
trajectories both diagnoses are part of and normalizing by the total number of 
trajectories either is part of). Trajectories with all diagnoses within the same cluster were 
combined into directed trajectory-clusters in which the patterns could be examined (Figs. 
2-6).  
 
Since the clustering was based on diagnoses, some trajectories had diagnoses from 
multiple clusters. Of the original 1,171 trajectories there were 378 that had all diagnoses 
within the same cluster. We increased this number to 608 by merging one smaller cluster 
into the largest and by including particular diagnoses to clusters if they contributed to 
complete trajectories with three diagnoses already within the cluster. In this way, some 
diagnoses appear in multiple clusters. Of the 608 trajectories 466 were within the largest 
cluster, 129 within the second largest cluster, 6 within the third largest, 5 within the 
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fourth largest and 2 in each their cluster. The second largest through the fourth largest 
cluster each revealed a distinct pattern of disease progression (the COPD, 
cerebrovascular and prostate cancer patterns) while the largest cluster had two major 
patterns in it: one focusing on diabetes mellitus and another focusing on cardio vascular 
diagnoses. 
 
To divide the largest cluster into the two patterns, the diagnoses within it were once 
again clustered using MCL. We used the same similarity measure as before, but using 
larger inflation factor. This resulted in four new sub clusters, where the largest covered 
diabetes mellitus diagnoses. We merged the second and third largest sub clusters which 
together covered cardio vascular diagnoses. Finally, the five clusters were visualized by 
representing diagnoses as nodes and making directed edges between consecutive 
diagnoses for all the trajectories within the same cluster.  
 
Verifying central diagnoses 
In most of the trajectory clusters we identified a keystone diagnosis.  In order to verify 
that they are important to the disease progression in the clusters, we for each key 
diagnosis counted how often it occurred between diagnoses preceding it and diagnoses 
succeeding it in the full population. We identified two sets of diagnoses: all diagnoses 
that could lead to the key diagnoses (the preceding set), and all diagnoses that could be 
reached from the key diagnoses (the succeeding set). Next we identified all patients who 
had one diagnosis from the preceding set follow by one from the succeeding set. Like 
when counting the trajectories, we discarded patients who have a diagnosis from the 
succeeding set before the first from the preceding set, and the diagnoses were allowed to 
occur in same admission. We then counted the patients having their first occurrences of 
the key diagnosis in the time from the first occurrence of a preceding diagnosis to the 
first occurrence of a succeeding diagnosis. 
 
In order to evaluate the count of the key diagnosis, we calculated RR and assigned p-
values by matching control patients using the same criteria as for the temporal 
correlation analysis. For each case patient we identified the number of days between the 
occurrence of the preceding diagnosis to the occurrence of the succeeding diagnosis. We 
counted the number of occurrences of the key diagnosis in the same period among the 
matched controls. The findings are summarized in Table S2. 
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Supplementary Materials 
 
 
Fig. S1. The NPR population distributed over gender and age (birth decade). The bins shown were used 
for stratification when matching control patients. For the temporal correlation analysis patients born 
before 1900 and in 2010 are removed from analyzes using the binning, as the subpopulations are too small 
to give adequate statistical results. However, the full population is used when counting the trajectories. 
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Fig. S2. Illustration of the random sampling procedure with N samplings of the co-morbidity of diagnose 
A followed by diagnose B within 1 year. A) Each discharge with diagnose A assigned are identified for all 
patients in order to make a cohort of case patients/discharges. Each case discharge is matched with a set of 
N randomly chosen control patients. The control patients are chosen among all patients with a discharge 
the same week as the case having the same gender and age group as the case patient. Each line in A) shows 
the case and its matched controls. B) The diagnose history of the cases and controls is examined to see if 
diagnose B occurred within 5 year of the matched week in which the case had diagnose A. X, Y and Z 
represents arbitrary other diagnoses. C) The number of these occurrences is counted for each cohort 
giving a number of overlaps. The count for the cases is the observed overlap while the control cohorts are 
used to estimate the p-values. 
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Fig. S3. Benchmarking of p-values estimated with binomial testing. Each point represents the sampled p-
value and the difference between estimated and sampled for a pair of diagnoses for some time limit. The 
estimated p-values are from the model with one population average. Red points are where the sampled 
model has smallest p-value, implying that the estimated model is more conservative. The fact that the 
estimated model is more conservative for small p-values reduced the likelihood that using the estimate will 
cause a false positive. As an extra precaution against false positives we used a p-value of 0.001 when using 
the estimated p-values. 
 
 
 
Stratifications Age and gender Not age and gender 
 Type of encounter 62,821 72,832 
Not type of encounter 72,937 81,058 
Table S1. Number of significant pairs in the temporal analysis given different combinations of patient 
stratification (for type of hospital encounter and for age and gender).  
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Key diagnose Have pattern Have key diagnosis Controls RR p-value 
G40 Epelepsy 41,681 2,902 (6.96%) 441.9 6.6 < 10-5 
H36 Retina disorder 66,758 5,255 (7.87%) 261.9 20.1 < 10-5 
J44 COPD 156,403 14,460 (9.25%) 2813.4 5.1 < 10-5 
M10 Gout 105,878 2,470 (2.33%) 363.5 6.8 < 10-5 
Table S2. Statistics on key diagnoses in trajectory clusters. The table shows counts of how many patients 
had the pattern (preceding diagnosis followed by succeeding diagnosis), how many of those had the key 
diagnosis in the period between the preceding and succeeding diagnosis, how many occurrences of the key 
diagnosis were found on average among the matched controls and RR and p-value for this. 10,000 sampled 
control cohorts were used to assess RR and p-values.  
 
 
Table S3 is 245 pages long and was left out. 
Table S3. Directional diagnosis pairs. All 4,014 pairs from the temporal analysis that were significant with 
RR > 1 and had significant directionality are given in the table. Diagnosis codes for the pair (D1 " D2) 
and statistics are given: Number of patients D1 assigned before D2, RR, associated p-value for the 
binomial model and the sampled p-value with the number of samples used to obtain it, and the p-value for 
directionality. The reported p-values are after Bonferroni correction. 
 
Table S4 is 37 pages long and was left out. 
Table S4. Trajectory counting. The table reports all 1171 length 4 trajectories along with patient counts, 
median age at onset of first diagnosis and median duration from onset of first diagnosis to each subsequent 
step. 
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4.5 Extending the trajectory model 
Our trajectory approach is quite rigid: The requirements for codes to participate are so 
conservative that only 4,014 out of more than 1 million co-occurring pairs or 62,821 
pairs with RR > 1 passed the cut-off. The approach can be made less conservative by 
using a more relaxed cut-off by using less strict correction for multiple testing or by 
skipping the testing for directionality. This will give a bigger base to construct more 
trajectories, but will also allow for more noise in form of disease pairs that have no true 
temporal correlation with each other. Some initial work with the trajectories indicated 
that the strict definition gave trajectories that were more interesting than without the 
requirement for directionality. However, because multiple changes were made in the 
same revision, the contrast between with and without this requirement was never fully 
made.  
 
The definition that each step is exactly one ICD-10 code puts a limit to how much the 
trajectory can cover. A consequence of this is that many trajectories are variants of each 
other with one code changed. Using clustering we were able to group these variants and 
illustrate their structure in one figure. However, patients can get diagnoses from different 
branches after a given step and there is no fixed starting point. Thus, patients can be in 
multiple diagnosis steps in the trajectory cluster at a given time. Without constraints on 
branching and a fixed starting point, it is impossible to unambiguously count how many 
patients followed a given transitions in the bundled trajectory. The HMM models 
discussed in section 4.3 can be used to resolve the counting issue. The information about 
selection of disease and transitions between diseases that are required to make HMMs 
are given in the descriptive trajectory counting. Each of the trajectory clusters can be the 
basis for modeling a HMM. The transitions between states can be limited to follow 
statistical significant paths like the trajectories. Figure 4.1 illustrates an example of how a 
HMM can be designed given the trajectory clusters. A method for obtaining more 
trajectories to base the HMMs on is to use the three-long trajectories rather than the 
four-long. Furthermore, patients can be clustered based on which three-long trajectories 
they share with other patients instead of clustering the trajectories based on diagnoses. In 
this way, a patient data point will be the set of trajectories he or she follows. A cluster in 
this space is a group of patient following similar trajectories. HMMs can be used to make 
consensus trajectory for each group of patients. 
 
4.5.1 Further modeling time 
Although time is modeled in the correlations and by the order of the diseases, time is not 
a direct variable in the trajectories. The time that passes between two diagnoses can 
contain crucial information about the outcome of the treatment. A short time can be 
indicative of fast progressions towards worse condition for the patient. Alternatively, it 
can be an indication of fast diagnosing and a fast treatment leading to better condition. 
Further development of the trajectories should model the time between diagnoses 
directly. 
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Figure 4.1 Illustration of one HMM for the cerebrovascular trajectory group (from manuscript I). (A) The 
trajectory cluster. (B) One way of converting the trajectory into a HMM. S is the starting state and the M1-
M4 are states reflecting different disease progression. The transition probabilities and output probabilities 
have to be estimated based on the data. The sketched model contains only diagnoses from the trajectory in 
the sequence for simplicity of the figure. An implementation of the model should contain probabilities of 
all diseases. The presence of other diseases is likely to assist in defining the states. 
 
 
With the current data, the effect of time can already be observed. The time of a trajectory 
can be reported in absolute time from first diagnosis or delta time between diagnoses. 
When using absolute times some trajectories reveal patients that discontinue the 
trajectory have longer time to their last diagnosis step than the patients who “finishes” 
the full trajectory. This might be an artifact of censoring: patients with long time to a 
diagnosis step have less time covered by the data to develop the next disease. However, it 
might also reveal important details about the trajectories. 
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The simplest method to model the time between the diseases in the descriptive model is 
to use a waiting state between disease steps, and to bin the time into large bins like within 
30 days, 1 year, more than one year. A problem with this is that this will increase the 
number of trajectories, and thus reduce the number of patients following each branch of 
a trajectory. Therefore, only cases where time has been shown to be important should be 
included in the current model. If HMMs are used to model the trajectories, the waiting 
time can be an output symbol. Each state can be associated with some waiting times or 
every second state could be waiting time to next disease occurrence. Alternatively, the 
time can be modeled using an exponential distributions for each step of the HMM. Since 
statistical inference on the HMMs is based on multiplying probabilities for a sequence to 
obtain a likelihood, it should be possible to integrate this with the waiting time 
probabilities. 
 
4.5.2 Including data on treatment and symptoms 
The current trajectories do not include treatment and surgical procedures. These data are 
available in NPR. While the current counting of disease trajectories is descriptive and 
only models outcome, adding the treatment adds a variable that doctors can actively 
affect. If the outcome of different kinds of treatment is successfully modeled, this can be 
of great importance to decision support. Treatments can be a step in the disease 
trajectories or an output symbol in a HMM.  
 
The classification of treatments and surgical procedures does not contain information on 
which treatments or procedures are used for a given disease. The association between 
treatment and diseases can be inferred from the data, possibly using a similar approach as 
the disease correlations. 
 
Codes from the symptom chapter of ICD-10 were left out from the correlation analysis. 
However, they can be used to describe the disease state. It is possible that some 
symptoms can be used to assess the severity of the current state and help predict future 
outcome. 
 
4.5.3 Including genetic information 
An aim of the trajectory analysis was also to investigate the effect of genetics on disease 
development. The genetic information would be input for a predictive model, so future 
outcome would be predicted based on the patient’s medical history and genome. As 
discussed in chapter 6, it is possible to infer some associations between diagnosis codes 
and genes. However, to properly test if this can be used to predict future outcome, we 
need the genetic data on patients.  
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It has long been known that the humane cells are outnumbered by 1 to 10 by microbial 
cells, which influence physiological processes in their host [53]. The bacteria residing in 
the gut tract are collectively called gut bacterium. The different gut bacteria can have a 
malignant, benign or beneficial effect on diseases depending on the personal gut genome. 
Among the hypothesized effects are influences on obesity [54], diabetes [55] and 
cardiovascular diseases [56].  
 
The direct way of assessing the effect of specific gut bacteria on diseases requires the gut 
bacteria genome to be sequenced. However, a simple way of determining the total effect 
is to study patients who undergo a total colectomy where their entire colon is removed. 
Since this operation removes all the colonic bacteria, neither the malignant nor the 
beneficial effects will be present in the patient after the surgery. Thus, analyzing the 
increased or decreased risk of diseases following colectomy is a way of gaining insight 
about the effect of the gut bacterium. In the work in progress II the hypothesis that 
removing the gut bacterium through total colectomy reduces the risk of cardiovascular 
diseases is tested.  
 
 
5.1 Survival analysis 
In manuscript I, temporal correlations were assessed using RR for a single time interval 
where occurrence of the disease was counted. Another approach for quantifying 
temporal correlations in a time dependent fashion is using methods from survival 
analysis. In survival analysis, the time it takes for some event to occur is analyzed. Any 
type of event can be studied, for example, occurrence of co-morbidities in patients. The 
main goal is to estimate the number of occurrences over time and to compare the 
outcome among different groups of subjects. The hazard function measures the 
percentage of survivors (subjects for whom the event has not occurred) at a given time 
point. It can be estimated with the non-parametric Kaplan-Meyer estimator and two or 
more groups can be compared with parametric estimators such as proportional hazards 
models. The latter results in odds-ratio that similarly to RR quantifies the difference 
between the groups.  
 
5.1.1 Kaplan-Meyer estimator and proportional hazards models 
Incomplete data due to censoring is a main issue that is addressed in survival analysis. A 
subject is censored if the event has not taken place by the end of the period covered by 
the data for the subject. The most common type of censoring is right-censoring, which 
applies to the colectomy study. This happens when patients are still alive at the end of 
the data period or are lost to follow-up (e.g. if the patient moves out of the country). In 
the case of the colectomy study, this happens as the data covers a fixed period of 14.9 
years. Patients having their colectomy in the start of the period have many years to 
Chapter 5: 
Colectomy & the gut bacteria 
 
  57 
develop co-morbidities, while patients in the end of the period have only few years or 
none at all.  
 
The issue was addressed in 1958 where Kaplan and Meier presented their estimator 
where the number of events among subjects at risk is counted [57]. Subjects contribute 
as positive survivors as long as the event has not occurred and they are covered by the 
data. Patient alive at the endpoint of their data are not counted as being at risk here after, 
and they no longer contribute to the percentage of survivors. 
 
Special statistical tests for comparing different groups are needed due to the censoring 
issue [58]. The proportional hazards models can be used for this purpose. They are 
parametric models that assume that the effect of some explanatory variables on the 
hazard function can be explained by a base hazard function multiplied with some 
parameter !. The base hazard function corresponds to the neutral hazard, and the 
parameter ! is a function of the explanatory variables, which can be different groups 
(such as case-control, man-woman). A partial log-likelihood method due to [59] can be 
used to estimate the constants for the ! function. The value of the ! function for a 
group can be interpreted as the log-odds for the group. 
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5.2 Work in progress II: Reduced risk of cardio-vascular disease 
following total colectomy 
This work has been done in collaboration with Teresa A. Ajslev, Thorkild I. A. Sørensen. 
The introduction, method and the main part of discussion are part of a manuscript draft 
that was written by Teresa (and corrected by Thorkild, Søren Brunak and me).  
 
 
5.2.1 Introduction 
The gut bacteria may play a role in atherosclerotic cardio-vascular disease (CVD) [60]. 
The host-microbial symbiosis has developed through primate evolution and may benefit 
both bacteria and the human host [61–64]. However, the intestinal bacterial symbiosis 
and the intestinal barrier function can be disrupted. Overgrowth of ’harmful’ bacterial 
strains may take place, which through nutritional fermentation may influence CVD risk 
[60,61,64,65]. In addition, a disrupted intestinal barrier, may lead to increased diffusion of 
lipopolysaccharide to the blood stream, which may induce systemic inflammation 
through endotoxemia, possibly contributing to the development of atherosclerotic 
diseases [61,66]. Lower gut bacterial richness has been associated with obesity as well as 
with an altered metabolic profile [67]. In view of the high frequency of CVD in the 
Western world, it may be that a disrupted gut microbiome is prevailing in this 
population. Based on these considerations, our hypothesis was that patients from a 
Western population, who have had a total colectomy, will have a reduced long-term risk 
of CVD. Using access to a nation-wide patient register in Denmark, we compared the 
long-term occurrence of CVD in patients who have had a total colectomy with all other 
patients as well as with four groups of patients who have undergone other types of 
surgery. 
 
 
5.2.2 Methods 
For this study, we used the nation-wide Danish National Patient Registry (NDR) 
covering all hospital contacts for patients from year 1996 through 2010 (14.9 years). 
Total colectomy is coded as JFH in the Scandinavian NOMESCO Classification of 
Surgical Procedures, and covers total removal of the large intestine with or without 
ileostomy as well as with or without ileo-rectal pouch. Patients who had undergone this 
procedure were compared with five groups of patients from the register. Group 1 
consists of inpatients discharges from the entire NDR population. The four other groups 
included patients who had undergone various types of surgery; Group 2 - appendectomy, 
Group 3 - any orthopedic surgery, Group 4 - any abdominal surgery leaving the colon 
intact, and Group 5 - major surgeries, unrelated to the gastrointestinal tract or the cardio-
vascular system (supplementary table 5.5). For each colectomy patient, five patients 
within each comparison group were matched by gender, year of birth (within same year), 
year and month of surgery (+/-24 months) and otherwise randomly selected (in a few 
cases for Group 2, the year of birth was we extended to +/- 1 year, because of too few 
matching patients). The cause for colectomy may influence the subsequent risk of CVD 
and therefore the investigation was supplemented by analyses stratified in two subgroups. 
One consisted of colectomy patients having either co-occurrence of a cancer diagnosis: 
any C-diagnoses in ICD-10; the other consisted colectomy patients with inflammatory 
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bowel diseases (IBD): Crohn’s Disease (K50), Ulcerative Colitis (K51), other non-
infective gastroenteritis and colitis (K52) and irritable bowel syndrome (K58) at the time 
of surgery.   
 
01($#*,($2('*&3$"#$'*-4$&5$%6!$
Since the focus of the study is the long-term CVD following colectomy, we restricted the 
analyses to occurrence of CVD from the age of 45 years. To avoid the possible influence 
of morbidity and mortality related to the surgery as such, the time period at risk began 
1,000 days after colectomy and the corresponding time points in the comparison groups. 
The matched patients in the comparison group were required to be alive 1000 days after 
their surgery or discharge, so that all included colectomy patients have five controls alive 
after 1000. The choice of 1,000 days was based on the cumulative hazard plots for the 
colectomy group and the five comparison groups; from that point in time, the slopes of 
the cumulative hazards were the same in all groups indicating comparable risks of fatal 
morbidity and mortality over time (Supplementary Figure S1).   
 
%6!$(7(+#-$$
Seven groups of diagnoses, likely encompassing CVD, were selected from the 
International Classification of Disease (ICD-10) covering hypertensive diseases (I10–13), 
acute ischemic heart diseases (I20, I21, I24, I46), chronic ischemic heart disease (I23, I25, 
I51), other heart diseases (I44–46, I48–51), cerebrovascular diseases (I61-I69), other 
arterial diseases (I35, I70-I74) and heart failure (I50). A composite end-point combining 
all the mentioned diseases was also included. The first occurrence of any of the diagnosis 
from a group or the composite endpoint was used as the occurrence date. Supplementary 
table 5.6 shows the names of ICD-10 diagnoses as well as the number of observed 
events in the colectomy patients and in the subgroups with co-occurring cancer and 
irritable or inflammatory bowel diseases.  
 
8#"#*-#*9")$"+"):-(-$
The risk of CVD in the colectomy patients were compared to the risk in the other 
groups of patients by hazard ratios with p-values estimated by analyses based on the Cox’ 
proportional hazard models. Gender and age were included as covariates in the model as 
well. Each of the five comparison groups was compared separately with the groups of 
colectomy patients, the total group and the subgroups with the defined co-occurring 
diagnoses at time of surgery. The underlying time variable of the models was the number 
of days from the 1,000 days after colectomy. All CVD diagnoses were individually 
analyzed, irrespective of the occurrence of the other CVD diagnoses. Patients were 
censored from the analyses either at time of death, but not at the occurrence of other 
CVD diagnoses. Level of significance set to 5% in all analyses adjusted according to 
Bonferoni correction (giving an effective level of 0.11%). 
 
5.2.3 Results 
Colectomy was performed in 4,057 patients age 45 and above from year 1996 to 2010 
with a median age of 67 years. A high post-surgical death rate was observed, with 18.6%  
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Figure 5.1 Kaplan-Meyer survival plot of the colectomy patients and all non-colectomy groups. The plot 
demonstrates the high mortality in the first 1,000 days following colectomy surgery. 
 
 
 
Figure 5.2 The hazard ratios and confidence intervals for the non-colectomy group 1 (all patients).  
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of colectomy patients deceased within the first 30 days and 41% (n=1,662) deceased 
within 1000 days. (figure 5.1). Thus, the group studied at risk of CVD included the 1,946 
colectomy patients alive 1000 days after surgery and five non-colectomy groups with 
9,730 individuals in each. Table 5.1 shows the number of CVD events in the colectomy 
and non-colectomy groups. The hazard ratio are shown with confidence intervals for the 
non-colectomy group 1 in figure 5.2, and for all groups and stratifications in figure 5.3. 
 
After correction for multiple testing, the risk of hypertensive disorders was significantly 
reduced in the colectomy patients compared to group 3, any orthopedic surgery, 
(p=0.0010, hazard ratio 0.74, 99.9% CI: 0.55-0.996), but not significant compared to the 
non-colectomy groups. We also saw a trend towards reduced risk for acute ischemic 
heart disease (0.53, CI: 0.77-1.12 for all patients) and chronic ischemic heart disease 
(0.47, CI: 0.71-1.06 for all patients) compared to the non-colectomy, but these results 
were not significant. We investigated the risk of developing heart failure, cerebrovascular 
disease and other arterial diseases and found no significant changes in hazard ratios (p = 
0.28, 0.31, 0.24 respectively compared to all patients). Furthermore, we grouped the  
 
 
 
Table 5.1 All patient diagnosis count. Number of non-censored colectomy and non-colectomy patients for 
each diagnosis group and the number out of these who was diagnosed with one disease from the group.  
All patients
Diagnosis group
Non-
censored 
pats.
Pats. w/ 
diagnosis 
group
Non-
censored 
pats.
Pats. w/ 
diagnosis 
group
Non-
censored 
pats.
Pats. w/ 
diagnosis 
group
Composite 1159 231 6408 1240 7352 1357
Hypertensive 
disorders 1464 133 8967 876 9199 905
Acute ischemic heart 
diseases 1621 89 9358 546 9627 569
Chronic ischemic 
heart disease 1643 74 9784 515 9896 449
Other arterial 
diseases 1666 70 10326 423 10245 348
Cardiac arrhymias 1614 89 9847 574 9932 510
Heart failure 1724 72 10455 419 10461 397
Cerebrovascular 
diseases 1680 92 10044 520 10180 439
All patients
Diagnosis group
Non-
censored 
pats.
Pats. w/ 
diagnosis 
group
Non-
censored 
pats.
Pats. w/ 
diagnosis 
group
Non-
censored 
pats.
Pats. w/ 
diagnosis 
group
Composite 7741 1493 7424 1458 7434 1378
Hypertensive 
disorders 9531 966 9255 921 9259 933
Acute ischemic heart 
diseases 10001 576 9883 591 9856 526
Chronic ischemic 
heart disease 10300 466 10155 451 10138 449
Other arterial 
diseases 10405 425 10427 394 10442 407
Cardiac arrhymias 10301 590 10138 553 10141 535
Heart failure 10715 403 10661 362 10647 375
Cerebrovascular 
diseases 10399 475 10438 472 10482 478
Colectomy Group 2
Group 3 Group 4 Group 5
Group 1
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 Cancer Non-cancer 
IBD 53 847 
Non-IBD 672 374 
Table 5.2 Number of colectomy patients stratified according to presence and non-presence of cancer and 
IBD.  
 
colectomy patients based on the likely cause of colectomy into a cancer and 
inflammatory bowel disease group (table 5.2). Table 5.3 and 5.4 shows the diagnosis 
counts for the two stratifications. We were not able to find any significant risk changes in 
any of the groups. 
 
5.2.4 Discussion 
This study investigated long term risk of CVD following total colectomy across a panel 
of diagnoses likely related to atherosclerosis. The postsurgical mortality rate after 
colectomy is high. By limiting the risk period to 1000 days following surgery and 
onwards the over-all mortality was similar in the colectomy group and the non-colectomy 
groups. We found patients with colectomy who survived 1000 days from the surgery had 
a significantly decreased risk of hypertensive disorders and a trend towards reduced risk 
of acute and chronic ischemic heart diseases.  
 
In the literature there is increasing evidence suggesting that the gut bacteria – whether 
through a “harmful” bacterial composition or by a disrupted intestinal barrier – is 
involved in CVD such as atherosclerosis. The direction of the causal relationship is 
however still unknown [66,68,69]. One theory is that bacterial fermentation in the gut 
leads to higher levels of trimethylamine-N-oxide (TMAO) which has been suggested to 
promote atherogenesis [60,62,65,70]. 
 
Another theory is that increased lipopolysaccharide (LPS) diffusion to the circulation 
through a disrupted intestinal barrier leads to metabolic endotoxemia [61,62,71]. For all 
of the investigated CVD diagnoses, a low-grade inflammatory origin of disease is 
possible, with previously observed elevated inflammatory markers among diseased 
individuals [66,69,72]. We encourage others to perform studies investigating the systemic 
metabolic and inflammatory states among the colectomy patients compared to relevant 
controls, before the pathway through the intestine can be confirmed. 
 
A potential limitation is the possibility of inaccuracy in CVD diagnosis and 
classifications, which may have introduced bias. However, since the specific diagnoses 
were grouped with similar diagnoses, we do not suspect that systematic or random 
misclassification should have influenced results. On the other hand, depending on 
severity of the underlying disease there may be differences in number of hospital 
contacts and thus in the possibility of obtaining a CVD diagnosis. To take care of such 
possible bias, five different comparison groups covering patients from different disease 
severity groups were generated. In addition, bias through confounding by indication - 
meaning that having surgery performed depends on disease severity and presence of co-
morbidities before surgery - should also have been revealed through the use of several 
comparison groups representing different severity of diseases.  
Chapter 5: 
Colectomy & the gut bacteria 
 
  63 
Patients were censored if they had prior history of the disease group. For the composite 
endpoint, 1,236 of 2,395 patients were censored. For the other groups between 671 and 
931 patients were censored. It is likely that having CVD from one group gives increased 
risk of getting a CVD from another group. This bias could be addressed by censoring the 
12,36 patients with prior history of the composite group. 
 
Another possible bias could be due to lifestyle changes following surgery, such as 
smoking cessation. The initiation to such changes may be higher in colectomy patients 
having inflammatory bowel disease than their comparison groups because smoking may 
relieve the symptoms in these patients. We cannot assess this properly by information 
from the registers.  
 
The stratification into cancer and IBD patients showed no significant results. A 
possibility to improve the stratification is to narrow the cancer diagnoses to colorectal 
cancer. Likewise, the IBD patients could be limited to Crohns' disease and ulcerative 
colitis. To compare the two groups, they also need to be matched for size and age and 
gender composition. 
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Table 5.3 Cancer patient diagnosis count. Number of non-censored colectomy and non-colectomy 
patients for each diagnosis group and the number out of these who was diagnosed with one disease from 
the group.  
 
Cancer patients Colectomy Group 1 Group 2
Diagnosis group
Non-
censored 
patients
Patients 
with 
diagnosis 
group
Non-
censored 
patients
Patients 
with 
diagnosis 
group
Non-
censored 
patients
Patients 
with 
diagnosis 
group
Composite 380 80 2189 435 2504 491
Hypertensive 
disorders 512 46 3255 313 3341 326
Acute ischemic heart 
diseases 576 25 3473 194 3565 200
Chronic ischemic 
heart disease 587 25 3626 204 3617 163
Other arterial 
diseases 597 23 3851 161 3787 154
Cardiac arrhymias 561 33 3635 232 3654 199
Heart failure 625 21 3896 158 3897 163
Cerebrovascular 
diseases 596 37 3717 193 3749 182
Cancer patients Group 3 Group 4 Group 5
Diagnosis group
Non-
censored 
patients
Patients 
with 
diagnosis 
group
Non-
censored 
patients
Patients 
with 
diagnosis 
group
Non-
censored 
patients
Patients 
with 
diagnosis 
group
Composite 2662 520 2569 543 2553 486
Hypertensive 
disorders 3453 352 3377 336 3360 338
Acute ischemic heart 
diseases 3733 225 3662 215 3629 181
Chronic ischemic 
heart disease 3814 174 3773 181 3739 165
Other arterial 
diseases 3856 162 3910 165 3874 146
Cardiac arrhymias 3811 224 3716 204 3767 229
Heart failure 4009 164 3987 157 4002 164
Cerebrovascular 
diseases 3882 189 3890 197 3918 192
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Table 5.4 Cancer patient diagnosis count. Number of non-censored colectomy and non-
colectomy patients for each diagnosis group and the number out of these who was 
diagnosed with one disease from the group.  
 
 
 
IBD patietnts Colectomy Group 1 Group 2
Diagnosis group
Non-
censored 
patients
Patients 
with 
diagnosis 
group
Non-
censored 
patients
Patients 
with 
diagnosis 
group
Non-
censored 
patients
Patients 
with 
diagnosis 
group
Composite 615 115 3154 614 3636 629
Hypertensive 
disorders 732 60 4229 434 4364 431
Acute ischemic heart 
diseases 785 44 4348 275 4472 284
Chronic ischemic 
heart disease 781 36 4539 238 4656 219
Other arterial 
diseases 810 33 4773 187 4774 149
Cardiac arrhymias 791 40 4593 267 4645 216
Heart failure 819 34 4831 200 4857 172
Cerebrovascular 
diseases 806 37 4663 232 4760 190
IBD patietnts Group 3 Group 4 Group 5
Diagnosis group
Non-
censored 
patients
Patients 
with 
diagnosis 
group
Non-
censored 
patients
Patients 
with 
diagnosis 
group
Non-
censored 
patients
Patients 
with 
diagnosis 
group
Composite 3802 714 3651 673 3621 671
Hypertensive 
disorders 4487 456 4353 415 4365 454
Acute ischemic heart 
diseases 4613 255 4567 278 4584 259
Chronic ischemic 
heart disease 4775 209 4705 201 4706 208
Other arterial 
diseases 4827 184 4809 173 4836 198
Cardiac arrhymias 4802 257 4740 264 4702 231
Heart failure 4947 171 4924 143 4889 160
Cerebrovascular 
diseases 4820 211 4831 200 4830 203
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Figure 5.3 The hazard ratios for all non-colectomy groups shown as a heatmap for the full group of 
patients and the cancer and IBD stratifications. Blue colors correspond to a reduced risk, while red colors 
correspond to an increased risk. The significance is not illustrated.  
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5.2.5 Supplementary material 
 
 
Suplementary table 5.5 Specification of non-colectomy patient groups.  
 
1 All hospital in-patients Hospital admission, not necessarily surgery
2 Appendectomy JEA (combined with ICD-10 K35.3)
3 Orthopaedic surgery N Musculoskeletal system
JFA Local operation intestine
JK Biliary tract
JA Abdominal wall, mesentery peritoneum, and greater omentum
JB Diaphragm and gastro-oesophageal reflux
JC Oesophagus
JD Stomach and duodenum
JF Intestine
JG Rectum
JH Anus and perianal tissue
JFB0 Small bowel resection
JFB1 Reversal of small bowel segment
JFB20 Ileocaecal resection
JFB21 Laparoscopic ileocaecal resection
BA Thyroid glands
BB Parathyroid glands
BC Adrenal glands
G Chest wall, pleura, mediastinum, diaphragm, trachea, bronchus and lung
JM Spleen
K Urinary system, male genital organs and retroperitoneal space
L Female genital organs
NCSP codesNon-colectomy groups
Large surgeries not in the 
gastrointestinal-tract5
Surgeries in the 
gastrointestinal tract 
leaving the intestine intact
4
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Suplementary table 5.5 Specification diagnosis groups.  
 
 
Diagnose group
I10 Essential (primary) hypertension
I11 Hypertensive heart disease
I12 Hypertensive renal disease
I13 Hypertensive heart and renal disease
I20 Angina pectoris
I21 Acute myocardial infarction
I24 Other acute ischaemic heart diseases
I46 Cardiac arrest
I23 Certain current complications following acute myocardial infarction
I25 Chronic ischaemic heart disease
I51 Complications and ill-defined descriptions of heart disease
I44 Atrioventricular and left bundle-branch block
I45 Other conduction disorders
I47 Paroxysmal tachycardia
I48 Atrial fibrillation and flutter
I49 Other cardiac arrhythmias
Heart failure I50 Heart failure
I61 Intracerebral haemorrhage
I62 Other nontraumatic intracranial haemorrhage
I63 Cerebral infarction
I64 Stroke, not specified as haemorrhage or infarction
I65 Occlusion and stenosis of precerebral arteries, not resulting in cerebral infarction
I66 Occlusion and stenosis of cerebral arteries, not resulting in cerebral infarction
I67 Other cerebrovascular diseases
I68 Cerebrovascular disorders in diseases classified elsewhere
I69 Sequelae of cerebrovascular disease
I35 Nonrheumatic aortic valve disorders
I70 Atherosclerosis
I71 Aortic aneurysm and dissection
I72 Other aneurysm
I73 Other peripheral vascular diseases
I74 Arterial embolism and thrombosis
ICD code
Hypertensive disorders
Acute ischemic heart 
diseases
Chronic ischemic heart 
disease
Cardiac arrhymias
Cerebrovascular diseases
Other arterial diseases
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Interactions between proteins and links between diseases and proteins have extensively 
been characterized the last decades [4]. Protein-protein interactions (PPI) can be used to 
identify links between diseases at the level of functional protein modules, networks or 
pathways [13,73], and there are various papers and databases that gather these 
interactions such as STRING [74], “INWEB” [13,75] and BioGRID [76]. This can be 
supplemented with data from disease registries and medical patient records, which 
constitutes a valuable piece of information for identifying diseases that correlate through 
molecular pathways [4,5,7,77]. To elucidate if there is a molecular link between the 
diseases that correlate, we need to know what genes have been related to the diseases. 
We can among others use the information gathered in databases such as OMIM [78] or 
Uniprot [79] for this purpose. Given a curated set of disease-gene links and a reliable 
protein network, the genetic etiology of diseases, as well as the molecular link between 
correlated diseases can be studied. 
 
 
6.1 Linking genes and diseases 
The Online Mendelian Inheritance in Man, OMIM, is a resource for linking Mendelian 
and complex diseases to genes [78]. Each genetic disease and gene listed in it has a 
structured text that describes the gene or disease with references to the literature. Text 
mining can be applied to obtain structured data out of the text records [13]. OMIM can 
be used to obtain curated link between diseases and disease genes [5]. Given a pair of 
highly correlated diseases, we can study the shared disease proteins and the protein 
networks that connect these proteins to uncover the molecular link between diseases.  
 
The ICD-10 diagnosis codes in the registry data have to be mapped to OMIM disease 
identifiers. In doing this, one has to take into account that the diseases in OMIM become 
highly subdivided and that the database has no hierarchical structure, which complicates 
the mapping. It should be considered that ICD-10 is disease centric while OMIM is gene 
centric. There is no direct mapping between ICD-10 and OMIM publicly available 
currently, but other disease centric classifications like Disease Ontology are easier to map 
to OMIM. Other resources such as UniProt, which is a protein database that provides 
curated information that can be used to obtain disease-gene links. Unlike OMIM, 
Uniprot is more disease oriented, which would make the mapping between ICD10 and 
Uniprot disease-protein links much easier, faster and reliable. 
 
The main challenge in using registry data and health records is the lack of genetic data of 
the patients. Without this, it is unknown which kind of genetic disposition the patient has 
for the diseases. The Mendelian diseases are mainly associated to a specific gene 
mutation. On the contrary, the complex diseases caused by mutations in multiple genes 
and other factors, and even summing the effects of all these mutations and factors, we 
often can explain very little of that disease. Another challenge is to remove the effect of 
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other confounding factors. With correction for only age and gender, many important 
factors like drugs and lifestyle are contributing to the correlation signal. It is naïve to 
think that the correlations identified in the registry data are mainly due to genetics.  
 
 
6.2 Mendelian code 
An approach to uncover the underlying genetic etiology of complex diseases is presented 
in manuscript II. Some rare Mendelian diseases can predispose for common complex 
diseases. In the manuscript the example of Huntington's disease predisposing for type II 
diabetes is cited. A possible explanation is that type 2 diabetes and Huntington's disease 
in part share genetic causes. The same phenomenon may be seen for other pairs of 
Mendelian and complex diseases. If this is the case, such pairs can be identified by strong 
correlation between the two diseases. The study presented in the manuscript II tests this 
hypothesis using registry data. 
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6.3 Manuscript II: A Non-Degenerate Code of Deleterious Variants in 
Mendelian Loci Contributes to Complex Disease Risk 
 
 
David R. Blair, Christopher S. Lyttle, Jonathan M. Mortensen, Charles F. Bearden, 
Anders Boeck Jensen, Hossein Khiabanian, Rachel Melamed, Raul Rabadan, Elmer V. 
Bernstam, Søren Brunak, Lars Juhl Jensen, Dan Nicolae, Nigam H. Shah, Robert L. 
Grossman, Nancy J. Cox, Kevin P. White, and Andrey Rzhetsky 
 
Published in Cell 2013, 155:1 p. 70-80 
 
This is a large-scale cross-nation study, where my contribution to the work was to run 
the method on the NPR data and provide the results.  
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SUMMARY
Although countless highly penetrant variants have
been associated with Mendelian disorders, the ge-
netic etiologies underlying complex diseases remain
largely unresolved. By mining the medical records of
over 110 million patients, we examine the extent to
which Mendelian variation contributes to complex
disease risk. We detect thousands of associations
betweenMendelian and complex diseases, revealing
a nondegenerate, phenotypic code that links each
complex disorder to a unique collection of Mendelian
loci. Using genome-wide association results, we
demonstrate that common variants associated with
complex diseases are enriched in the genes indi-
cated by this ‘‘Mendelian code.’’ Finally, we detect
hundreds of comorbidity associations among Men-
delian disorders, and we use probabilistic genetic
modeling to demonstrate that Mendelian variants
likely contribute nonadditively to the risk for a subset
of complex diseases. Overall, this study illustrates a
complementary approach for mapping complex dis-
ease loci and provides unique predictions concern-
ing the etiologies of specific diseases.
INTRODUCTION
Clinicians and geneticists have previously observed that rare,
Mendelian disorders, such as thalassemia and cystic fibrosis,
certain chromosomal abnormalities (such as Down and Kleinfel-
ter syndromes), and severely deleterious copy-number variants
(CNV) often predispose patients to more common, apparently
nonMendelian diseases. For example, patients with beta-thalas-
semia, Huntington disease and Friederichs ataxia often develop
type 2 diabetes mellitus (De Sanctis et al., 1988; Podolsky et al.,
1972; Ristow, 2004), and carriers of the genetic variants associ-
ated with Lujan-Fryns and DiGeorge (velo-cardio-facial) syn-
dromes display an increased risk for schizophrenia (De Hert
et al., 1996; Sinibaldi et al., 2004). Additionally, bearers of the
16p11.2 microdeletions and microduplications often develop
autism (Kumar et al., 2008; Tabet et al., 2012). In such cases,
the simple and complex diseases have been long suspected of
sharing genetic architecture; whether there is a broader pattern
of such associations, however, remains unclear.
A large and growing number of Mendelian and chromosomal
diseases have been precisely assigned to particular causal
genetic events. Although Mendelian disorders often manifest
many of the same complexities that are associated with multi-
genic diseases, such as incomplete penetrance and genetic
modification (Badano et al., 2006), they remain the best under-
stood in terms of their underlying genetic etiologies. This is
because the variants underlying Mendelian diseases are gener-
ally highly penetrant and nearly unaffected by the environment.
Furthermore, their physiologic effects are often severe, allowing
for very early diagnosis, sometimes even prenatally. Therefore, in
contrast to more complex human disorders, the clinical diag-
nosis of a Mendelian disease reveals unique insight into the
genotype of the affected patient. Consequently, we hypothesize
that statistically significant comorbidities between complex and
Mendelian illnesses represent a type of genetic association, in
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which a non-Mendelian phenotype is mapped to the genetic loci
that cause the Mendelian disease.
By analyzing millions of electronic clinical records obtained
from distinct regions of the United States and Denmark, we
demonstrate that such ‘‘transitive’’ genetic associations are
consistent and ubiquitous, yielding insight into the etiology of
complex diseases. Furthermore, we observe that each complex
disease possesses a unique Mendelian disease allelic architec-
ture, creating a nondegenerate code that identifies each illness
by its associated Mendelian loci. In support of our transitive
association hypothesis, we demonstrate that complex disease
genome-wide association signals are specifically enriched
within the genetic loci indicated by this code. Finally, we use
mathematical modeling to demonstrate that the variants under-
lying Mendelian disorders likely interact with one another to
contribute to complex disease risk, highlighting the potential of
clinical data for uncovering complicated genetic architectures.
RESULTS
Clinical Record Analysis
We mined the administrative data associated with millions of
clinical records for evidence of comorbidity among Mendelian
and complex diseases. As a rule, such records are maintained
in order to facilitate patient billing rather than academic research,
and therefore, they may be incomplete and variably biased (van
Walraven and Austin, 2012). However, this does not diminish
their overall utility for making accurate inferences about clinical
phenotypes in large populations. The key to such analyses is
to carefully consider how missing data and biases may affect
the conclusions of the intended research and, if required, intro-
duce appropriate corrections. Becausewe conditioned our infer-
ences on the observed disease incidence counts, our comorbid-
ity estimates did not depend on the accurate estimation of
marginal disease prevalence. Therefore, we assumed a ‘‘missing
at random’’ model for undocumented records that is common
practice for epidemiological studies with uninformatively missing
data (Lyles and Allen, 2002). Finally, we took great care to focus
our data analysis on clearly identifiable phenotypes (see Exper-
imental Procedures), and we detected disease comorbidity
using a sophisticated statistical pipeline that accounted for a
large set of potentially confounding demographic, socioeco-
nomic, and environmental factors (for details, see Extended
Experimental Procedures and Figure S1 available online).
We judged the quality of our statistical inferences by com-
paring the results generated from multiple, distinct clinical data
sets. In the present study, we examined eight data sets, with
the smallest and largest describing approximately 150,000 and
100million unique patients, respectively (see Table 1; Figure 1A).
We found that our estimates of the comorbidity risks for the
complex-Mendelian disease pairs were remarkably consistent
(see Figures 1F and 1G, all correlation p values < 5 3 10!8),
which is reassuring considering that the data sets represent pop-
ulations in different geographic regions with variable ethnic
structure and disease prevalence (Figures 1B and 1C). Although
the US data set may possibly partially overlap with the smaller,
North American ones (CU, NYPH, SU, TX, and UC), the smaller
data sets should be nearly completely disjoint from one another
and from DK, indicating that duplicate records do not drive this
result (see Extended Experimental Procedures for a more
detailed treatment of potentially confounding factors). Although
other groups havemined clinical record data sets for disease co-
morbidities in the past (Hidalgo et al., 2009; Lee et al., 2008), the
vast majority of the relationships detected in this study are likely
to be novel, as associations among complex and Mendelian dis-
eases have never been analyzed at this scale (over 100 million
unique patients) (see Figures 1D and 1E for a comparison to pre-
viously published results).
A Nondegenerate Mendelian Phenotypic Code for
Complex Diseases
Figure 2 summarizes all of the significant comorbidities that were
detected among the complex and Mendelian disorders within
our compendium of clinical records (see Table S4 for detailed re-
sults). Each colored cell in the matrix indicates the logarithm of
the relative risk associated with a significant clinical signal, and
the complex diseases are grouped according to our current un-
derstanding of their pathophysiology. Reassuringly, many of the
known comorbidities are replicated within our data set. For
example, we detected significant comorbidity between lipopro-
tein deficiencies and myocardial infarction (Strong and Rader,
2012) and ataxia telangiectasia and breast cancer (Sellers,
1997). However, the majority of the 2,909 associations shown
in Figure 2 have not been previously reported. For example,
our analysis uncovered significant clinical comorbidities
between Marfan syndrome and several neuropsychiatric dis-
eases (autism, bipolar disorder, and depression), and it deter-
mined that fragile X is significantly associated with asthma,
psoriasis, and viral infection, highlighting a potential immune
system dysfunction in these patients (Ashwood et al., 2010).
In Figure 3A, the rows and columns of the comorbidity
matrix have been rearranged such that disorders with similar
Table 1. The Clinical Record Data Sets Utilized in This Study
Data Set Description
Encoding
Type
Number of
Unique Patients
CU Columbia University, 1985–
2003
ICD9 1,505,822
DK Denmark; database covering
most of the country’s
population
ICD10 6,214,312
NYPH New York Presbyterian
Hospital and Columbia
University; 2004–present
ICD9 767,978
SU Stanford University ICD9 806,369
TX University of Texas at
Houston
ICD9 1,599,528
UC University of Chicago ICD9 146,989
USA MarketScan insurance
claims data set
ICD9 99,143,849
MED Medicare database ICD9 13,039,018
Total: 123,223,865
This table provides a brief description, the ICD encoding type, and the
size of each data set. The MED data set was used for comparison and
was not included in the full meta-analysis.
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comorbidity structure are placed adjacent to one another.
Importantly, this rearrangement demonstrates that each com-
plex disease was comorbid with a diverse and unique combina-
tion of Mendelian phenotypes. Despite extensive variation within
this ‘‘Mendelian code,’’ much of our current understanding of the
pathophysiology of complex diseases is nonetheless recapitu-
lated (see Figure S2). To illustrate, we computed the Euclidean
distance between every pair of shared risk profiles and produced
the neighbor-joining tree (Saitou andNei, 1987) that best approx-
imates this set of statistics (Figure 3B). Not surprisingly, the re-
sulting tree contained many groupings that are highly consistent
with our current knowledge of disease etiology. For example,
autism, intellectual disability, and epilepsy form a tight cluster
in the tree (replicated in 96% of bootstrap pseudosamples),
consistent with previous genetic studies that have uncovered
variants underlying the risk for all three neuropsychiatric traits
(Shinawi et al., 2010).
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Figure 1. A Systematic Comparison of the
Eight Clinical Record Data Sets Analyzed
in This Study
(A) The total number of records in each data set,
broken down by gender.
(B and C) The average prevalence for the complex
and Mendelian diseases across the eight data
sets.
(D and E) Using the superset of the discovered
associations (based on the original seven data
sets; see Extended Experimental Procedures for
details), we compared the number of association
signals that were detected in each data set inde-
pendently, depicted as the percentage of all
associations discovered in the union of the seven
data sets (excluding MED): (D) Mendelian-com-
plex and (E) Mendelian-Mendelian associations.
(F) The rank correlation among relative risk esti-
mates (lower diagonal) and disease prevalence
(upper diagonal) for each significantly comorbid
complex-Mendelian disease pair across the eight
distinct data sets.
(G) Scatter plots depicting the relative risk corre-
lations for three pairs of data sets, indicated using
the colored boxes in (F).
See also Tables S2 and S3.
Complex Disease GWA Signals Are
Enriched within the Genetic Loci
Implicated by the Mendelian Code
We conjectured that the significant com-
plex-Mendelian comorbidities displayed
in Figure 2 indicate that the genes and
pathways perturbed in the Mendelian dis-
orders also play a role in the etiology of
the corresponding complex diseases.
Thus, we hypothesized that the ‘‘Mende-
lian code’’ could be used to pinpoint loci
that harbor complex disease-predispos-
ing genetic variants. To test this predic-
tion, we probed legacy genome-wide
association (GWA) results (NIH, 2012)
and asked whether common variants associated with the com-
plex diseases were enriched within the loci implicated by the
Mendelian comorbidities. Overall, we observed that complex
disease GWA signals were globally enriched in Mendelian loci
(106 observed, 55.3 expected, 1.92-fold enrichment, p = 4.0 3
10!10), an observation that has been previously highlighted by
others (Lupski et al., 2011). Furthermore, when we restricted
our analysis to unique signals only (i.e., removed duplicate sig-
nals that were replicated in subsequent studies), the enrichment
fell to 1.6-fold but remained highly significant (63 observed, 40.4
expected, p = 4.6 3 10!5). Importantly, complex disease-spe-
cific GWA signals were specifically enriched in the precise loci
indicated by the Mendelian phenotypic code (1.97-fold enrich-
ment, 40 observed, 20.1 expected, p = 5.7 3 10!5, see Table
S1 for detailed results), suggesting that the comorbidities high-
lighted in Figure 2 reflect a shared complex-Mendelian genetic
architecture. Moreover, the GWA signals enriched in comorbid
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Mendelian loci weremore likely to be detected inmultiple studies
than those in other genic SNPs, including those that lie within
noncomorbid Mendelian loci (replication rates: 0.8 versus 0.36,
p = 0.026, Mann-Whitney-U test). Overall, these results suggest
that the loci implicated by the Mendelian code are likely to
contain a spectrum of complex disease predisposing variants,
providing testable hypotheses for future gene resequencing
and exome analyses (see Discussion for details).
Mendelian Disorders Share Significant Clinical
Comorbidity
Our analysis generated a surprisingly large number of statisti-
cally significant clinical associations between pairs of Mendelian
disorders (462 after conservative statistical filtering; see
Extended Experimental Procedures; Figure 4, Figures S3 and
S4; Table S5). We propose that these associations represent
interactions among genetic variants in distinct Mendelian loci,
and we found that it was possible to map individual interactions
to specific biological hypotheses. As an example, we observed
significant shared risk between fragile X and glycogenosis
(odds ratio = 859.09), and this effect remained highly significant
after controlling for a wide variety of potentially confounding fac-
tors, including disease similarity, age, gender, ethnicity, and
environment (see Extended Experimental Procedures). A link
between fragile X and glycogenosis has been previously pro-
posed in the molecular genetics literature (De Boulle et al.,
1993; Zang et al., 2009), and glycogen metabolism has been
suggested to play an important role in fragile X pathophysiology
and treatment (Min et al., 2009). A few anecdotal cases aside,
however, most of the relationships in Figure 4 represent totally
undocumented interactions among rare and highly deleterious
genetic variants.
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Figure 2. The Significant Comorbidity Relationships among the Complex and Mendelian Disease Pairs
Entries in the matrix indicate the log10-transformed relative risk associated with each significantly comorbid complex-Mendelian disease pair. The complex
phenotypes are grouped by our current understanding of their pathophysiology. The symbols _ and \ indicate male- and female-specific diseases, respectively.
The numerical values underlying each association are provided in Table S4. The statistical procedure for generating these values is outlined in Figure S1.
See also Tables S1, S2, and S3.
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We do acknowledge that some of the apparently significant
comorbidities could be due to confounding factors. First, mis-
coding errors during medical billing could create false signals
of comorbidity. This could happen, for example, if two distinct
physicians examined the same patient but erroneously entered
different billing codes because of the clinical ambiguity of the
Mendelian disease. Second, the co-occurrence of Mendelian
phenotypes could be an artifact of a cryptic population structure.
As a result of assortative mating, some subpopulations could be
enriched with multiple Mendelian diseases, increasing the
apparent rate of rare disease co-occurrence. Although these
biases seem plausible, we do not believe that they contribute
significantly to the comorbidities depicted in Figure 4 for the
following reasons. First, although medical billing errors were
likely present in the data sets, we went great lengths to estimate
and remove their effects (see Extended Experimental Proce-
dures). Second, our statistical analysis procedure included a
variety of demographic and environmental covariates, and we
found that these potential confounders contributed only margin-
ally to the shared risk amongMendelian disorders, casting doubt
on the cryptic population structure hypothesis.
Perhaps more importantly, there are additional, orthogonal
pieces of evidence that indicate that the previous two con-
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Figure 3. Complex-Mendelian Comorbid-
ities Provide Unique Insight into the Etiology
of Complex Diseases
(A) The data matrix from Figure 2 is reordered such
that similar rows and columns are adjacent to one
another (accomplished using greedy clustering).
(B) The neighbor-joining tree for the complex
phenotypes was constructed from the Euclidean
distances among the relative risks displayed in
Figure 2 and (A). The bootstrap numbers (10,000
replicates) over tree arcs indicate the reliability of
the corresponding partitions, with 100 being the
most reliable and zero the least. The color of the
tree labels is preserved with regard to the group-
ings of the phenotypes depicted in Figure 2.
(C) Heatmap comparing the qualities of fit for the
two multilocus genetic models discussed in the
main text over a range of loci numbers. The value
of the log10-Bayes factor indicates the support for
the combinatorial model in comparison to the
additive model. A log10-Bayes factor of one in-
dicates that, given the data, the combinatorial
model is ten times more likely than is the additive
model. See Figure S5 for a graphical comparison
of the model fits to the complex disease risk data.
See also Tables S1, S2, and S3 and Figure S2.
founders are unlikely to contribute perva-
sively toMendelian-Mendelian comorbid-
ity. For example, we found that comorbid
Mendelian disorders, even after removing
all clinically similar disease pairs, tended
to map to genetic loci that are signifi-
cantly more functionally alike than is ex-
pected by chance, as measured by their
distances within a large human gene
network (Lee et al., 2011) (see Extended Experimental Proce-
dures, p value < 0.00001). This result fits naturally with the theory
of widespread epistasis amongMendelian variants, but it cannot
be easily explained using either of the other two hypotheses.
Additionally, cryptic population structure, billing code errors,
and genetic interactions make very different predictions with
respect to complex disease risk in patients diagnosed with
multiple comorbid Mendelian disorders (see Experimental Pro-
cedures). In the next section, we use probabilistic modeling to
provide direct statistical evidence that the risk for several com-
plex diseases is highly consistent with the genetic modifier
hypothesis described above.
Mendelian Loci Contribute to Complex Disease Risk in a
Nonadditive Manner
Examining the complex disease risk in patients with compound
Mendelian phenotypes offered an additional avenue for assess-
ing the likelihood of the three mechanisms proposed in the
previous section. As a simple example, assume that the relation-
ships in Figure 4 were dominated by miscoding errors. If this
were true, then an individual diagnosed with one comorbid Men-
delian disorder should have the same average risk for the com-
plex disease as an individual diagnosed with two. Instead, we
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observed that individuals diagnosed with two comorbid Mende-
lian phenotypes had a higher average risk for the complex dis-
ease in 62 out of the 65 of the illnesses considered in this study
(p value = 6.2 3 10!12, Wilcoxon signed-rank test). Such ana-
lyses provide only indirect evidence for the genetic modifier
hypothesis. To provide direct statistical evidence, we formulated
two probabilistic genetic models for complex disease risk in
patients diagnosed with compound Mendelian phenotypes.
The first, termed the additive model (Risch, 1990), is consis-
tent with cryptic population structure and assumes that the
4.00.0
Absolute Comorbidity Log10-Odds Ratio
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Community 2
Community 4
Community 3
Community 5
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Community 7
Community 8
Figure 4. The Significant Comorbidity Relationships Detected among All Pairs of Mendelian Diseases
The upper diagonal of the matrix displays the log10-transformed odds ratios for the significant associations, with grayscale intensity indicating the effect size of
the association. The lower diagonal displays the community structure determined using a network-clustering algorithm (Blondel et al., 2008), with each com-
munity corresponding to a unique color and associations between diseases within the same community colored accordingly. The numerical values underlying
each association are provided in Table S5. The statistical procedure for generating these values is depicted in Figure S3. An unfiltered version of the matrix is
displayed in Figure S4.
See also Tables S2, S3, and S5.
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Mendelian variants contribute independently to complex disease
risk. The second, called the combinatorial model, invokes a sim-
ple mechanism for genetic epistasis among the Mendelian vari-
ants. By fitting each model to the clinical data sets, we formally
tested whether the genetic modifier hypothesis was supported
by the observed risk profiles of the complex diseases.
The two genetic models that we considered share several
assumptions in common. First, both assume that each complex
disease is associated with a set of genetic loci, some of which
are linked to Mendelian phenotypes as well. This assumption
ensures that eachmodel is capable of accounting for the comor-
bidity structure that was observed within the clinical data.
Second, the models assume that the genetic loci under consid-
eration possess only dominant, recessive, or X-linked (haploid)
variants, although the frequency and penetrance of such variants
can vary freely. Third, they assume that the penetrance values
for the complex diseases, at both Mendelian and other loci,
are sampled from some population-level distribution. Similarly,
both models assume that the frequencies of the deleterious
genotypes are sampled from a population-level distribution as
well. Finally, the models assume that the total number of loci
associated with any complex disease is finite and fixed.
The twomodels differed in one important assumption only: the
additive genetic model assumes that the effects of the delete-
rious genotypes contributed independently (additively) to com-
plex disease risk (Risch, 1990), whereas our nonadditive model
breaks this assumption by introducing ‘‘communities’’ of loci.
Essentially, such communities represented loci that normally
function in a coordinated manner, and our nonadditive model
assumes that at least one adverse genetic event must be present
within multiple communities in order to generate significant com-
plex disease risk. Thus, this community-based genetic model re-
quires combinations of particular deleterious genotypes, so we
refer to it as the combinatorial model to differentiate it from other
nonadditive genetic mechanisms. In the present study, the
combinatorial model was constructed to be as simple as
possible and included only two communities of loci.
Although the assumptions outlined above are simple, they
generate two models that make distinctly different predictions
in terms of the average complex disease risk in patients withmul-
tiple comorbid Mendelian phenotypes (see the Extended Exper-
imental Procedures for details). Specifically, the additive model
predicts that the average complex disease risk should increase
linearly as function of the number of comorbidMendelian pheno-
types, whereas the combinatorial model predicts a superlinear
(polynomial) increase. Furthermore, if billing record miscoding
errors were included into the additive model, the increase in
complex disease risk would become sublinear. All three
signatures were visually apparent in the risk profiles for the com-
plex diseases (see Figure S5), although sublinear increases were
rare (approximately 5 out of 65 illnesses). To formally quantify the
evidence in favor of each model, we took a Bayesian approach
and computed their posterior probabilities conditioned on the
clinical data (see Extended Experimental Procedures).
Because of the computational burden associated with fitting
genetic models to over 100 million patients, we selected a repre-
sentative sample of 20 complex diseases for analysis. In prac-
tice, the population-level mean of the genotype frequencies
and the total number of complex disease predisposing loci
were not jointly identifiable, so we repeated the model selection
procedure for a range of potential loci numbers (see Experi-
mental Procedures). Eachmodel was clearly favored for a subset
of diseases, but the combinatorial model had stronger overall
support across the entire set (see Figure 3C). For diseases that
displayed a sublinear increase in risk (consistent with possible
miscoding errors), the additive model was supported over the
combinatorial by a wide margin (see diabetes mellitus type II in
Figure S5). Overall, this result provides additional and orthogonal
support for the hypothesis that Mendelian-Mendelian comorbid-
ities were driven by genetic interactions. It also suggests that
certain complex diseases (such as Addisons disease, acute
glomerulonephritis, and malignant brain neoplasms, but not
the two forms of diabetes or bipolar disorder) have a nonadditive
(epistatic) genetic architecture with respect to Mendelian dis-
ease variants.
DISCUSSION
Highly penetrant mutations have not been found for most com-
mon, complex diseases, despite intensive search. Although
rare single-nucleotide and copy-number variants have been
implicated in some complex disorders, including intellectual
disability (Vissers et al., 2010), schizophrenia (Bassett et al.,
2008) and autism (Iossifov et al., 2012), these results appear to
be the exception rather than the norm. The fact that we observed
widespread comorbidity among Mendelian and complex dis-
eases suggests that rare, highly penetrant variants do in fact
play a significant role in complex disease risk, but their delete-
rious effects do not result in single, isolated diseases. Instead,
highly deleterious genetic variants likely induce a variety of path-
ological consequences, consistent with the Mendelian code
displayed in Figures 2 and 3A. Such analysis resonates with
the results of recent genetic dissections of oligogenic traits,
such as Bardet-Biedl syndrome, which appears to harbor a
diverse genetic architecture that produces a variety of clinical
phenotypes (Katsanis et al., 2001; Zaghloul et al., 2010).
In addition to these direct associations, we also observed that
common risk variants associated with complex diseases were
specifically enriched in comorbid Mendelian loci. The most
obvious explanation for this is that some of the patients included
in GWA studies carried genetic variation that predisposed them
to both the Mendelian and complex diseases. However, there
are several reasons to be skeptical of this hypothesis. First, sub-
jects with Mendelian disorders are typically, by design, excluded
from GWAS (Zhao et al., 2010). Second, Mendelian diseases are
rare and have overt clinical presentations, so the unintentional in-
clusion of such carriers in the studies is highly improbable.
Finally, even if the rate of accidental sampling of Mendelian phe-
notypes were aberrantly high, we do not believe that ‘‘synthetic’’
genome-wide associations, in which the detected common var-
iants are in linkage disequilibriumwithMendelian disease alleles,
drive our results (Dickson et al., 2010). As discussed at length by
others (Visscher et al., 2012), numerous empirical and theoretical
analyses are simply not consistent with this interpretation.
As an alternative explanation, we and others (Lupski et al.,
2011) propose that Mendelian genes carry both rare and
76 Cell 155, 70–80, September 26, 2013 ª2013 Elsevier Inc.
common deleterious variants, such that alleles from both ends of
the frequency spectrum contribute to disease risk. Rare, highly
penetrant variants cause Mendelian disorders, whereas com-
mon variants with milder effects contribute to the complex phe-
notypes. By design, GWAS detect only the latter end of the
frequency spectrum, and the former is typically uncovered
through linkage analysis and sequencing. When the Mendelian
and complex phenotypes are similar, we can think of the two dis-
orders as different ends of the same genetic and phenotypic
spectrum, known as the allelic series hypothesis. In fact, there
are several well-documented examples of this phenomenon,
such as the familial and common forms of Parkinsonism and
blood lipid disorders (Manolio et al., 2009).
However, aside from a few special cases, this straightforward
definition of allelic series is not very helpful when explainingMen-
delian and complex phenotypes that are comorbid and share
genetic loci but are biologically dissimilar. For example, asthma
and systemic primary carnitine deficiency share clinical risk and
are both associated with variants in the SLC22A5 locus, but
there is no obvious relationship between the biology underlying
these two diseases. Instead, we suggest a modification to the
allelic series hypothesis that considers the multifactorial nature
of gene function. On one end of the spectrum, we hypothesize
that very rare, Mendelian disease variants completely or nearly
completely abolish all of a gene’s physiological functions. There-
fore, their effects are highly penetrant and pleiotropic, resulting in
overt pathologies (like Mendelian disease), while increasing a
carrier’s risk for a variety of other disorders. On the other end,
less deleteriousmutationsmay perturb the same genes, but their
effects are more limited, perhaps modifying only a subset of a
gene’s functions. In such instances, the resulting deleterious
effects may be quite subtle, allowing the variants to reach rela-
tively high population frequencies. Moreover, their ultimate path-
ological manifestations may be very different than those that are
observed in patients harboring Mendelian variants, reflecting the
different subsets of physiological functions perturbed by each
mutation type.
With this in mind, we hypothesize that the loci underlying
comorbid Mendelian disorders represent strong candidates for
harboring complex disease-predisposing genetic variants with
moderate and weak effects, as the Mendelian associations
have already suggested that the underlying gene is involved in
the pathophysiology of the complex disorder. This theory is sup-
ported by our GWAS enrichment results, but we believe that it
extends to rare variants with larger effects as well. Because
they have already been shown to contain a variety of complex
disease predisposing variants, we propose that the best candi-
dates for testing this hypothesis are perhaps those loci that
were found to contain both common risk and Mendelian
disease-causing variants (see Table S1). Consistent with this
hypothesis, we note that 4 out of the 7 neoplasms for which
GWAS results were available were found to associate with
both common and rare Mendelian genetic variants in the TERT
locus, which encodes the human telomerase reverse transcrip-
tase. Mendelian variants within this locus completely abolish
reverse-transcriptase enzymatic activity, resulting in several
overt, pathological symptoms (combined into a syndrome called
dyskeratosis congenita) (Kirwan and Dokal, 2009). Recently, a
rare germline variant in the promoter region of TERT was linked
to a familial form of melanoma, although carriers of the allele
may have increased risk for other neoplasms as well (Horn
et al., 2013). In support, somatic variants within the promoter re-
gion of TERT were also found in a variety of human cancer cell
lines (Huang et al., 2013) and solid tumors (Killela et al., 2013).
Such results raise the intriguing possibility that a spectrum of
TERT-associated variants, both rare and common, somatic
and germline, increase one’s risk for neoplastic disease.
Furthermore, our complex-Mendelian comorbidity analysis
predicted that schizophrenia, bipolar disorder, autism, and
depression are all associated with the following four Mendelian
loci: SYNE1, PRPF3, CACNA1C, and PPP2R2B. Consistent
with their hypothesized shared genetic architecture (Cross-
Disorder Group of the Psychiatric Genomics Consortium et al.,
2013), these four loci were also found to harbor common genetic
variants that influence risk for this same set of diseases. Interest-
ingly, exome sequencing in autism patients has uncovered both
de novo and inherited potentially deleterious variants in SYNE1
(O’Roak et al., 2011; Yu et al., 2013). We find this result particu-
larly interesting, as it suggests that these four genes may also
harbor rare variants that predispose carriers to multiple neuro-
psychiatric disorders. If this is correct, then pooling strategies
that combine sequence data from patients with these different,
but related, complex phenotypes could offer a simple approach
for increasing the power to identify rare variants with modest
effects.
In the second part of our study, we discovered approximately
450 comorbidity associations among pairs of Mendelian disor-
ders, suggesting that genetic interactions amongMendelian var-
iants are quite common. Consistent with this hypothesis, we
used genetic modeling to demonstrate that epistatic effects
could be detected in the complex disease risk profiles of patients
diagnosed with multiple, comorbid Mendelian disorders. At the
very least, our results suggest that strongly deleterious variants
have a high propensity for modifying the effects of other delete-
rious alleles in functionally similar genes. However, the existence
of nonadditive effects among rare genetic variants could have
practical consequences as well. For example, undocumented
epistasis among rare variants in distinct loci could negatively
impact the power of targeted resequencing studies.
Although our inference of widespread, nonadditive genetic
effects is novel, the fact that highly penetrant genetic variants
are subject to modification by other alleles that exist in trans is
well known. For example, at first glance, the Mendelian disorder
retinitis pigmentosa appears to follow the ‘‘independent effects’’
assumption of genetic additivity quite well (Parmeggiani, 2011),
as several, highly penetrant mutations in distinct genes have
been associated with the phenotype. However, this disease
was also one of the first Mendelian phenotypes with clearly
demonstrated digenic inheritance (Kajiwara et al., 1994), and
epistatic interactions among multiple loci have been reported
for other Mendelian phenotypes as well, such as Bardet-Biedl
syndrome (Badano et al., 2006). There are also known examples
in which trans genetic variants modify the specific symptoms of
Mendelian disorders. More specifically, several suspected ge-
netic modifiers have been previously identified for cystic fibrosis
(CF) (Cutting, 2010), a recessive disease caused by mutations in
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the CFTR gene. CF patients display a variety of symptoms,
including mucus congestion in the lungs, intestinal obstruction,
diabetes, abnormal gut microflora, and liver disease, and nearly
a dozen loci have been identified that appear to modulate the
strength of these clinical symptoms (Cutting, 2010). For
example, variation in EDNRA appears to affect the pulmonary
function of CF patients, whereasMSRA alleles modulate intesti-
nal obstruction.
In summary, we detected thousands of instances of comor-
bidity between complex-Mendelian and Mendelian-Mendelian
disease pairs. The existence of such associations was not unex-
pected; however, their widespread nature was surprising.
Furthermore, although there is a growing body of evidence that
genetic interactions are common across both Mendelian and
complex traits, such as Alzheimer’s disease (Badano and Katsa-
nis, 2002), facioscapulohumeral dystrophy type 2 (Lemmers
et al., 2012), and Hirschsprungs disease (Wallace and Anderson,
2011), we believe that this is the first instance in which such re-
lationships have been uncovered systematically across multiple
complex diseases. Ultimately, we demonstrate that digital
phenotypic data can be utilized to infer genetic and genomic
architectures, potentially allowing for extensive, novel analyses
in the field of human disease genetics. Moreover, this work
highlights the importance of documenting a wider spectrum of
Mendelian and other disease traits in a very large population of
humans, perhaps the entire United States or even multiple coun-
tries, in order to uncover the pathophysiology associated with
very rare genetic events.
EXPERIMENTAL PROCEDURES
Phenotype Curation and Billing Code Assignments
To identify the clinical phenotypes of interest, we used the disease codes pro-
vided by the International Disease Classification (ICD) system (WHO, 2010)
(see Table 1). The mappings between billing codes (both ICD9 and ICD10)
and diseases were obtained from Rzhetsky et al. (2007) and by manual cura-
tion, first by a PhD-level contractor trained in a biomedical field and second by
two of the authors, iteratively. All billing code mappings for the complex and
Mendelian diseases are provided in Tables S2 and S3, respectively. The billing
codes enabled the identification of 65 specific complex disorders and 95Men-
delian disease groups (representing 213 disorders) (see Tables S2 and S3,
respectively). Note, this reduction of 213-to-95 was not a choice of experi-
mental design but was necessitated by the ICD9 code taxonomy. See
Extended Experimental Procedures for additional details.
Clinical Record Analysis
Each clinical record database was first parsed (see Table 1), removing dupli-
cate records and identifying patients that harbored the diseases of interest.
In theory, a small fraction of these records could be shared between US and
the other, smaller US data sets (CU, NYPH, SU, TX, UC) because some
patients could have been documented in multiple databases. Because dupli-
cate records would strongly bias the results for rare diseases, we decided
against simply combining the information from different data sets into a single
meta-analysis. Instead, we performed an independent statistical analysis for
each data set and then combined the results according to a conservative pro-
cedure (see Extended Experimental Procedures for details). For the complex-
Mendelian comorbidity analysis, any disease pair containing a complex or
Mendelian disease that was specific to males or females (indicated by _ and
\, respectively, in Figure 2) was analyzed after conditioning on the appropriate
gender; gender-specific diseases were not included in the Mendelian-Mende-
lian analysis. The MED data set (Hidalgo et al., 2009; Lee et al., 2008) was
excluded from the meta-analysis, as we were unable to consistently identify
our phenotypes of interest. Specifically, the MED data set provides individual
ICD9 code counts only, but many of the disorders used in our analysis map to
multiple such codes. Additional details concerning our statistical procedures
for the analysis of complex-Mendelian and Mendelian-Mendelian disease
pairs are provided in the Extended Experimental Procedures.
Neighbor-Joining Tree Inference
The complex disease tree was constructed from the Mendelian comorbidity
relationships using the neighbor-joining method (Saitou and Nei, 1987). See
Extended Experimental Procedures for additional details.
GWAS Enrichment Analysis
To test for an enrichment of common, complex disease risk variants inMende-
lian loci, we aligned legacy genome-wide association results (NIH, 2012) with
the SNP-to-gene annotations provided by SCAN (Gamazon et al., 2010). Bino-
mial tests that specifically controlled for gene length and SNP annotation
biases were used to assess enrichment (see Extended Experimental Proce-
dures for details).
The Additive and Nonadditive Genetic Models for Complex Disease
Risk
In the main text, we briefly described two competing genetic models that
specify distinct mechanisms for how multiple Mendelian disease variants
combine to affect complex disease risk. Ultimately, the additive and combina-
torial models make very different predictions with respect to the increase in
complex disease risk as a function of the number of comorbid Mendelian phe-
notypes, allowing them to be differentiated within our massive clinical data
sets. The mathematical details concerning this prediction are somewhat
involved, and the interested reader should consult the Extended Experimental
Procedures. In the following section, we simply introduce our competing
genetic models using standard notation.
Consistent with common practice (Risch, 1990), each of our genetic models
treats the genotype (g) and phenotype (f) of an individual as random variables.
Their joint probability is equivalent to the expected population frequency of in-
dividuals that possess both a particular genotype (G) and disease of interest
(D). It is computed by taking the product of the genotype frequency and its
corresponding penetrance:
Pðf=D;g=GjQÞ=Pðg=GjQÞPðf=Djg=G;QÞ=FðGÞ3WDðGÞ;
where F(G) is the probability of observing genotypeG andWD(G) is the genetic
penetrance ofGwith respect to phenotype D (i.e., the probability of D givenG)
(Risch, 1990). The overall expected prevalence of the disease within the
population is computed by summing the previous probability over all possible
genotypes:
Pðf=DjQÞ=
X
G
FðGÞ3WDðGÞ:
Although not included for the sake of simplicity, environmental factors can be
easily incorporated into this framework through the inclusion of additional
random variables.
Our additive genetic model is specified within the previous framework by
defining the following simple penetrance function (Risch, 1990):
WDðGÞ= 1#
Yn
i = 1
½1#WDðGiÞ%;
where n is the number of independent loci affecting phenotypeD, andWD(Gi) is
the marginal penetrance function of the genotype at the ith locus (Risch, 1990)
that may take a variety of forms (dominant, recessive, additive, etc.). Techni-
cally, the model assumes that each locus contributes independently to com-
plex disease risk, and this assumption generally underlies most ‘‘additive’’
models in human genetics. That said, it also approximates a stricter definition
of ‘‘additivity,’’ in which the probability of the complex disease is simply the
linear combination of the penetrance probabilities of the individual loci (Risch,
1990).
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Our nonadditive genetic model assumes that the deleterious genotypes
belong to a different ‘‘communities’’ of loci that act coordinately, and at least
one adverse genetic event must be present within multiple communities in
order to generate significant complex disease risk. Because this model re-
quires combinations of deleterious alleles, we call it the ‘‘combinatorial’’
model. To illustrate, imagine two disjoint groups of loci, or ‘‘communities,’’
each harboring a set of genotypes that predispose an individual to the disease
of interest. We denote the two communities using circle and square sub-
scripts, such that fgB;1;gB;2; :::; gB;nBg and fg,;1;g,;2; :::; g,;n,g denote
the genetic loci that belong to each community and nB and n, denote com-
munity sizes. To simplify notation, wewill indicate either the square or the circle
community, depending on context, using the C symbol ðC = fB;,gÞ.
Assuming an additive model within each community, the penetrance function
for the two-community combinatorial model is
WDðGÞ=
Y
C˛fB;,g
 
1#
YnC
i = 1
½1#WDðGiÞ%
!
:
Note that more general formulations of the model could allow for more than
two communities and a variety of different community- and loci-specific pene-
trance functions.
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Chapter 7: 
Concluding remarks 
 
 
 
7.1 A systems approach to epidemiology 
During the data-driven work with disease correlations, I found that lists of correlations 
that are candidates for further studies are of very little interest themselves. There must be 
some plan for the further studies of the candidate lists. They could be used to identify 
hypotheses for further examinations in a traditional epidemiological study. However, it is 
a time consuming task to identify interesting candidates among the thousands of 
significant correlations. Ultimately, it is questionable if this process is better or faster than 
the processes used to identify hypotheses in hypothesis driven research. The temporal 
analysis presented in manuscript I is an example of how a list of comorbidities can be 
converted into trajectories and used for discovering patterns across not only pairs of 
diseases, but groups of diseases. This is a better strategy to utilize the results of data-
driven analyses. The clustering method presented in the work in progress with non-
temporal correlations is also an approach to investigate the full system of correlations 
rather than just pairs of diseases.  
 
Traditional epidemiology seeks to investigate the relation between one disease and a risk 
factor and eliminate the signal from all other diseases and risk factors. Regardless of the 
corrections made, this is a very difficult task. Diseases have a complex nature, and often 
there is no simple causal explanation to their development. The data-driven studies 
presented in this thesis are a part of a move towards doing epidemiological studies of the 
full system of correlations rather than attempting to reduce the outcome to a single risk 
factor.  
 
7.1.1 Improvements of the correlation measures 
Although the data-driven studies were epidemiological, they lack the stringency that is 
expected from a traditional epidemiological study. Future work on disease correlation 
needs to incorporate basic techniques from epidemiology [15]. 
 
In the work on both non-temporal correlations and the temporal correlations, the 
majority of correlations were positive. As discussed in chapter 3, this can be because of 
positive feedback: Sick and weak people get sicker. In manuscript I and the work in 
progress I, the frequency expected by random given no correlation between a pair of 
diseases was used to calculate RR. Thus, the null hypothesis is that diseases co-occur 
randomly when the age and gender signal is controlled for. This is a weak null-
hypothesis, when diseases correlate positively even when there is no direct causality. This 
is especially a problem, if trying to make statistical inference on disease trajectories. A 
patient who has a history of four different diseases is likely to be weaker than a patient 
who is picked randomly out of the full population. To improve the null-model, patients 
need to be matched with control patients who have similar medical history. The control 
for inpatient, outpatient and ER encounters indirectly does this to some degree. Severe 
diseases are mainly treated in inpatient care and injuries. Other diseases of less severity 
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are treated in ERs, and in case of severe incidents, an ER or outpatient would be 
admitted to the hospital. The matching was done more stringent in the colectomy study, 
where colectomy patients were matched with patients having undergone other kind of 
surgical procedures.  
 
Another issue is in the ICD-10 classification. A diagnosis such as I10 Essential 
hypertension is similar to I11 Hypertensive heart disease and I13 Hypertensive heart and 
renal disease in that all the diagnoses refer to the same condition: hypertension. It would 
be beneficial for both the statistics and the medical interpretation to combine these. 
While it is feasible to combine the diagnoses in a study of few diseases, it is a large and 
tedious task in a study of all diseases. The main problem is that there is no objective true 
set of basic diseases and conditions. The differences between classifications demonstrate 
this very well. Any attempt to reduce the full set of ICD-10 diagnoses to a smaller set of 
basic diseases will depend on personal judgment.  
 
 
7.2 Opportunities and limitations 
Several other interesting data sources can be used for analyzing correlations and disease 
progression. Patient health records are a source of medical knowledge that can be used in 
a similar fashion to the registries. With the transition from paper journals to electronic 
health records (EHR), performing large-scale studies on health records is becoming more 
widespread [77]. In addition to the information that is reported to disease registries, the 
EHRs provide access to structured data such as drug prescriptions and clinical text. This 
allows for much more detailed diagnostic description of patients. It is likely that data on 
more confounding factors can be found in this data.  
 
Using the CPR data it is possible to link family members together, which would give the 
opportunity to investigate heritable diseases in a large scale. This could be used to assess 
which patients have a genetic variant of a disease. It is also important to have the link 
between mother and child when studying diagnoses related to pregnancy. Some codes 
that are relevant to the child are registered in the mother's records. Due to this, we did 
not analyze diagnoses regarding births in the data-driven correlation analyses.  
 
It is well known that income and other socioeconomic factors are confounding factors 
for diseases (e.g. diabetes and obesity [80], and cancer [81]). Data on socioeconomic 
factors is available from Statistics Denmark and can contribute in further studies. The 
main challenge here is to do the large-scale analysis within the systems of Statistic 
Denmark.  
 
Another interesting data source is drug prescriptions. Correlations can be a result of 
adverse drug effects if a drug is used to treat one disease, but cause another disease (or 
medical condition) as adverse effect. Removing the drug bias would be beneficial. Having 
these data for a large population would also give opportunity to do Comparative 
Effectiveness Research (CER). Different combinations of drugs and other medical 
treatment could be analyzed in order to assess the efficacy. Drugs have an obvious effect 
on disease progression, and prescription data could be a key variable in modeling disease 
trajectories. Other use of this data includes drug surveillance [82,83] and identification of 
adverse effects from drugs [84].  
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Even though NPR offers the full hospitalization history of patients, we lack data from 
the private practitioner. This is an important part of the medical history, as many 
contacts will never lead to hospitalization. Unfortunately, the Danish public health 
insurance registry does not contain diagnoses. It is used solely for reimbursement of the 
private practitioners, who are generally paid per contact regardless of the diagnosis. 
Therefore only very few codes in the registry point to a specific disease.   
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Supplementary table 1: List of ICD-10 diagnoses and clusters (work in progress 1). The 
listing shows the result of the clustering and meta-clustering of ICD-10 diagnoses. 
Clusters are listed under the meta-clusters they are part of. The meta-cluster numbers 
refers to the numbers shown in figure 3.3. The clusters are numbered from the largest 
cluster to the smallest. 
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Meta Cluster 1 
 
Cluster 1 
A00 Cholera 
A08 Viral and other specified 
intestinal infections 
A37 Whooping cough 
B01 Varicella [chickenpox] 
B05 Measles 
B34 Viral infection of unspecified 
site 
B43 Chromomycosis and 
phaeomycotic abscess 
E40 Kwashiorkor 
E71 Disorders of branched-chain 
amino-acid metabolism and fatty-
acid metabolism 
E74 Other disorders of 
carbohydrate metabolism 
E75 Disorders of sphingolipid 
metabolism and other lipid 
storage disorders 
E77 Disorders of glycoprotein 
metabolism 
E86 Volume depletion 
F44 Dissociative [conversion] 
disorders 
F51 Nonorganic sleep disorders 
F72 Severe mental retardation 
F73 Profound mental retardation 
G08 Intracranial and intraspinal 
phlebitis and thrombophlebitis 
G11 Hereditary ataxia 
G13 Systemic atrophies primarily 
affecting central nervous system 
in diseases classified elsewhere 
G24 Dystonia 
G31 Other degenerative 
diseases of nervous system, not 
elsewhere classified 
G40 Epilepsy 
G41 Status epilepticus 
G47 Sleep disorders 
G54 Nerve root and plexus 
disorders 
G55 Nerve root and plexus 
compressions in diseases 
classified elsewhere 
G80 Cerebral palsy 
G81 Hemiplegia 
G82 Paraplegia and tetraplegia 
G83 Other paralytic syndromes 
G90 Disorders of autonomic 
nervous system 
G92 Toxic encephalopathy 
G95 Other diseases of spinal 
cord 
G96 Other disorders of central 
nervous system 
G98 Other disorders of nervous 
system, not elsewhere classified 
G99 Other disorders of nervous 
system in diseases classified 
elsewhere 
H47 Other disorders of optic 
[2nd] nerve and visual pathways 
H48 Disorders of optic [2nd] 
nerve and visual pathways in 
diseases classified elsewhere 
I63 Cerebral infarction 
J00 Acute nasopharyngitis 
[common cold] 
J02 Acute pharyngitis 
J03 Acute tonsillitis 
J06 Acute upper respiratory 
infections of multiple and 
unspecified sites 
J10 Influenza due to other 
identified influenza virus 
J12 Viral pneumonia, not 
elsewhere classified 
J15 Bacterial pneumonia, not 
elsewhere classified 
J17 Pneumonia in diseases 
classified elsewhere 
J18 Pneumonia, organism 
unspecified 
J22 Unspecified acute lower 
respiratory infection 
J36 Peritonsillar abscess 
J39 Other diseases of upper 
respiratory tract 
J40 Bronchitis, not specified as 
acute or chronic 
J69 Pneumonitis due to solids 
and liquids 
J96 Respiratory failure, not 
elsewhere classified 
J99 Respiratory disorders in 
diseases classified elsewhere 
K59 Other functional intestinal 
disorders 
L60 Nail disorders 
L62 Nail disorders in diseases 
classified elsewhere 
L84 Corns and callosities 
L89 Decubitus ulcer 
M21 Other acquired deformities 
of limbs 
M40 Kyphosis and lordosis 
M41 Scoliosis 
M42 Spinal osteochondrosis 
M47 Spondylosis 
M48 Other spondylopathies 
M50 Cervical disc disorders 
M51 Other intervertebral disc 
disorders 
M53 Other dorsopathies, not 
elsewhere classified 
M54 Dorsalgia 
M62 Other disorders of muscle 
M84 Disorders of continuity of 
bone 
M89 Other disorders of bone 
M96 Postprocedural 
musculoskeletal disorders, not 
elsewhere classified 
M99 Biomechanical lesions, not 
elsewhere classified 
Q02 Microcephaly 
Q04 Other congenital 
malformations of brain 
Q07 Other congenital 
malformations of nervous system 
Q40 Other congenital 
malformations of upper 
alimentary tract 
Q65 Congenital deformities of 
hip 
Q66 Congenital deformities of 
feet 
Q80 Congenital ichthyosis 
Q81 Epidermolysis bullosa 
 
Cluster 4 
A07 Other protozoal intestinal 
diseases 
A09 Diarrhoea and 
gastroenteritis of presumed 
infectious origin 
A51 Early syphilis 
A52 Late syphilis 
A53 Other and unspecified 
syphilis 
A55 Chlamydial 
lymphogranuloma (venereum) 
A60 Anogenital herpesviral 
[herpes simplex] infection 
A63 Other predominantly 
sexually transmitted diseases, 
not elsewhere classified 
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A64 Unspecified sexually 
transmitted disease 
A81 Atypical virus infections of 
central nervous system 
B00 Herpesviral [herpes simplex] 
infections 
B02 Zoster [herpes zoster] 
B07 Viral warts 
B08 Other viral infections 
characterized by skin and 
mucous membrane lesions, not 
elsewhere classified 
B09 Unspecified viral infection 
characterized by skin and 
mucous membrane lesions 
B20 Human immunodeficiency 
virus [HIV] disease resulting in 
infectious and parasitic diseases 
B21 Human immunodeficiency 
virus [HIV] disease resulting in 
malignant neoplasms 
B22 Human immunodeficiency 
virus [HIV] disease resulting in 
other specified diseases 
B23 Human immunodeficiency 
virus [HIV] disease resulting in 
other conditions 
B24 Unspecified human 
immunodeficiency virus [HIV] 
disease 
B33 Other viral diseases, not 
elsewhere classified 
B35 Dermatophytosis 
B36 Other superficial mycoses 
B37 Candidiasis 
B39 Histoplasmosis 
B45 Cryptococcosis 
B55 Leishmaniasis 
B64 Unspecified protozoal 
disease 
B68 Taeniasis 
B71 Other cestode infections 
B77 Ascariasis 
B81 Other intestinal 
helminthiases, not elsewhere 
classified 
B86 Scabies 
C46 Kaposi's sarcoma 
D64 Other anaemias 
J13 Pneumonia due to 
Streptococcus pneumoniae 
J14 Pneumonia due to 
Haemophilus influenzae 
J16 Pneumonia due to other 
infectious organisms, not 
elsewhere classified 
J20 Acute bronchitis 
L21 Seborrhoeic dermatitis 
L72 Follicular cysts of skin and 
subcutaneous tissue 
L73 Other follicular disorders 
L75 Apocrine sweat disorders 
 
Cluster 5 
A44 Bartonellosis 
A46 Erysipelas 
A49 Bacterial infection of 
unspecified site 
A82 Rabies 
B99 Other and unspecified 
infectious diseases 
E54 Ascorbic acid deficiency 
E87 Other disorders of fluid, 
electrolyte and acid-base 
balance 
F05 Delirium, not induced by 
alcohol and other psychoactive 
substances 
F10 Mental and behavioural 
disorders due to use of alcohol 
F11 Mental and behavioural 
disorders due to use of opioids 
F12 Mental and behavioural 
disorders due to use of 
cannabinoids 
F13 Mental and behavioural 
disorders due to use of sedatives 
or hypnotics 
F14 Mental and behavioural 
disorders due to use of cocaine 
F15 Mental and behavioural 
disorders due to use of other 
stimulants, including caffeine 
F16 Mental and behavioural 
disorders due to use of 
hallucinogens 
F17 Mental and behavioural 
disorders due to use of tobacco 
F18 Mental and behavioural 
disorders due to use of volatile 
solvents 
F19 Mental and behavioural 
disorders due to multiple drug 
use and use of other 
psychoactive substances 
F40 Phobic anxiety disorders 
F55 Abuse of non-dependence-
producing substances 
F62 Enduring personality 
changes, not attributable to brain 
damage and disease 
F63 Habit and impulse disorders 
F65 Disorders of sexual 
preference 
I72 Other aneurysm 
I80 Phlebitis and 
thrombophlebitis 
I82 Other venous embolism and 
thrombosis 
I87 Other disorders of veins 
J86 Pyothorax 
K29 Gastritis and duodenitis 
K30 Dyspepsia 
L02 Cutaneous abscess, 
furuncle and carbuncle 
L03 Cellulitis 
L08 Other local infections of skin 
and subcutaneous tissue 
M80 Osteoporosis with 
pathological fracture 
M86 Osteomyelitis 
 
Cluster 8 
A23 Brucellosis 
B67 Echinococcosis 
D50 Iron deficiency anaemia 
D53 Other nutritional anaemias 
D62 Acute posthaemorrhagic 
anaemia 
E42 Marasmic kwashiorkor 
E43 Unspecified severe protein-
energy malnutrition 
E46 Unspecified protein-energy 
malnutrition 
E51 Thiamine deficiency 
E60 Dietary zinc deficiency 
E85 Amyloidosis 
I43 Cardiomyopathy in diseases 
classified elsewhere 
I81 Portal vein thrombosis 
I85 Oesophageal varices 
I86 Varicose veins of other sites 
I98 Other disorders of circulatory 
system in diseases classified 
elsewhere 
K20 Oesophagitis 
K25 Gastric ulcer 
K26 Duodenal ulcer 
K27 Peptic ulcer, site unspecified 
K28 Gastrojejunal ulcer 
K70 Alcoholic liver disease 
K71 Toxic liver disease 
K72 Hepatic failure, not 
elsewhere classified 
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K74 Fibrosis and cirrhosis of liver 
K75 Other inflammatory liver 
diseases 
K76 Other diseases of liver 
K77 Liver disorders in diseases 
classified elsewhere 
K92 Other diseases of digestive 
system 
Q44 Congenital malformations of 
gallbladder, bile ducts and liver 
 
Cluster 18 
B66 Other fluke infections 
E10 Insulin-dependent diabetes 
mellitus 
E11 Non-insulin-dependent 
diabetes mellitus 
E12 Malnutrition-related diabetes 
mellitus 
E13 Other specified diabetes 
mellitus 
E14 Unspecified diabetes 
mellitus 
E15 Nondiabetic hypoglycaemic 
coma 
E16 Other disorders of 
pancreatic internal secretion 
E66 Obesity 
E90 Nutritional and metabolic 
disorders in diseases classified 
elsewhere 
G59 Mononeuropathy in 
diseases classified elsewhere 
G63 Polyneuropathy in diseases 
classified elsewhere 
H28 Cataract and other disorders 
of lens in diseases classified 
elsewhere 
H36 Retinal disorders in 
diseases classified elsewhere 
L14 Bullous disorders in 
diseases classified elsewhere 
L97 Ulcer of lower limb, not 
elsewhere classified 
M14 Arthropathies in other 
diseases classified elsewhere 
 
Cluster 29 
B80 Enterobiasis 
B82 Unspecified intestinal 
parasitism 
K50 Crohn's disease [regional 
enteritis] 
K51 Ulcerative colitis 
K56 Paralytic ileus and intestinal 
obstruction without hernia 
K57 Diverticular disease of 
intestine 
K62 Other diseases of anus and 
rectum 
K63 Other diseases of intestine 
K66 Other disorders of 
peritoneum 
K91 Postprocedural disorders of 
digestive system, not elsewhere 
classified 
 
Cluster 32 
G12 Spinal muscular atrophy 
and related syndromes 
G70 Myasthenia gravis and other 
myoneural disorders 
G71 Primary disorders of 
muscles 
G72 Other myopathies 
G73 Disorders of myoneural 
junction and muscle in diseases 
classified elsewhere 
M33 Dermatopolymyositis 
M36 Systemic disorders of 
connective tissue in diseases 
classified elsewhere 
M60 Myositis 
M63 Disorders of muscle in 
diseases classified elsewhere 
 
Cluster 35 
B15 Acute hepatitis A 
B16 Acute hepatitis B 
B17 Other acute viral hepatitis 
B18 Chronic viral hepatitis 
B19 Unspecified viral hepatitis 
B27 Infectious mononucleosis 
E80 Disorders of porphyrin and 
bilirubin metabolism 
K73 Chronic hepatitis, not 
elsewhere classified 
 
Cluster 43 
J61 Pneumoconiosis due to 
asbestos and other mineral fibres 
J62 Pneumoconiosis due to dust 
containing silica 
J64 Unspecified pneumoconiosis 
J68 Respiratory conditions due 
to inhalation of chemicals, gases, 
fumes and vapours 
J70 Respiratory conditions due 
to other external agents 
J92 Pleural plaque 
 
Cluster 49 
D74 Methaemoglobinaemia 
K42 Umbilical hernia 
K43 Ventral hernia 
K45 Other abdominal hernia 
K46 Unspecified abdominal 
hernia 
K67 Disorders of peritoneum in 
infectious diseases classified 
elsewhere 
 
Cluster 60 
I30 Acute pericarditis 
I31 Other diseases of 
pericardium 
I32 Pericarditis in diseases 
classified elsewhere 
I40 Acute myocarditis 
 
Cluster 64 
D80 Immunodeficiency with 
predominantly antibody defects 
D81 Combined 
immunodeficiencies 
D83 Common variable 
immunodeficiency 
D84 Other immunodeficiencies 
 
Cluster 68 
D55 Anaemia due to enzyme 
disorders 
D56 Thalassaemia 
D57 Sickle-cell disorders 
D58 Other hereditary haemolytic 
anaemias 
 
Cluster 70 
I84 Haemorrhoids 
K60 Fissure and fistula of anal 
and rectal regions 
K61 Abscess of anal and rectal 
regions 
L05 Pilonidal cyst 
 
Cluster 85 
L10 Pemphigus 
L12 Pemphigoid 
L13 Other bullous disorders 
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Cluster 86 
C17 Malignant neoplasm of small 
intestine 
E34 Other endocrine disorders 
Q97 Other sex chromosome 
abnormalities, female phenotype, 
not elsewhere classified 
 
Cluster 109 
D68 Other coagulation defects 
E72 Other disorders of amino-
acid metabolism 
 
Cluster 111 
D66 Hereditary factor VIII 
deficiency 
D67 Hereditary factor IX 
deficiency 
 
Cluster 116 
A80 Acute poliomyelitis 
B91 Sequelae of poliomyelitis 
 
Meta Cluster 2 
 
Cluster 22 
C51 Malignant neoplasm of vulva 
C52 Malignant neoplasm of 
vagina 
C60 Malignant neoplasm of 
penis 
D01 Carcinoma in situ of other 
and unspecified digestive organs 
D07 Carcinoma in situ of other 
and unspecified genital organs 
D25 Leiomyoma of uterus 
D26 Other benign neoplasms of 
uterus 
D28 Benign neoplasm of other 
and unspecified female genital 
organs 
M88 Paget's disease of bone 
[osteitis deformans] 
N75 Diseases of Bartholin's 
gland 
N77 Vulvovaginal ulceration and 
inflammation in diseases 
classified elsewhere 
N84 Polyp of female genital tract 
N85 Other noninflammatory 
disorders of uterus, except cervix 
N90 Other noninflammatory 
disorders of vulva and perineum 
N92 Excessive, frequent and 
irregular menstruation 
 
Cluster 37 
B88 Other infestations 
D24 Benign neoplasm of breast 
N60 Benign mammary dysplasia 
N61 Inflammatory disorders of 
breast 
N62 Hypertrophy of breast 
N63 Unspecified lump in breast 
N64 Other disorders of breast 
Q83 Congenital malformations of 
breast 
 
Cluster 39 
N81 Female genital prolapse 
N89 Other noninflammatory 
disorders of vagina 
N94 Pain and other conditions 
associated with female genital 
organs and menstrual cycle 
N96 Habitual aborter 
N97 Female infertility 
Q51 Congenital malformations of 
uterus and cervix 
Q52 Other congenital 
malformations of female genitalia 
 
Cluster 41 
B87 Myiasis 
C53 Malignant neoplasm of 
cervix uteri 
C57 Malignant neoplasm of other 
and unspecified female genital 
organs 
D06 Carcinoma in situ of cervix 
uteri 
N82 Fistulae involving female 
genital tract 
N87 Dysplasia of cervix uteri 
N88 Other noninflammatory 
disorders of cervix uteri 
 
Cluster 42 
M22 Disorders of patella 
M23 Internal derangement of 
knee 
M76 Enthesopathies of lower 
limb, excluding foot 
M77 Other enthesopathies 
M92 Other juvenile 
osteochondrosis 
M93 Other osteochondropathies 
M94 Other disorders of cartilage 
 
Cluster 69 
F64 Gender identity disorders 
L67 Hair colour and hair shaft 
abnormalities 
L68 Hypertrichosis 
Q84 Other congenital 
malformations of integument 
 
Cluster 72 
N70 Salpingitis and oophoritis 
N71 Inflammatory disease of 
uterus, except cervix 
N73 Other female pelvic 
inflammatory diseases 
N74 Female pelvic inflammatory 
disorders in diseases classified 
elsewhere 
 
Cluster 73 
K35 Acute appendicitis 
K36 Other appendicitis 
K37 Unspecified appendicitis 
K38 Other diseases of appendix 
 
Cluster 87 
C54 Malignant neoplasm of 
corpus uteri 
C55 Malignant neoplasm of 
uterus, part unspecified 
N95 Menopausal and other 
perimenopausal disorders 
 
Cluster 93 
E28 Ovarian dysfunction 
L83 Acanthosis nigricans 
N98 Complications associated 
with artificial fertilization 
 
Cluster 94 
A54 Gonococcal infection 
A56 Other sexually transmitted 
chlamydial diseases 
A74 Other diseases caused by 
chlamydiae 
 
Cluster 95 
N72 Inflammatory disease of 
cervix uteri 
N86 Erosion and ectropion of 
cervix uteri 
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N93 Other abnormal uterine and 
vaginal bleeding 
 
Cluster 113 
F52 Sexual dysfunction, not 
caused by organic disorder or 
disease 
F66 Psychological and 
behavioural disorders associated 
with sexual development and 
orientation 
 
Cluster 114 
A59 Trichomoniasis 
N76 Other inflammation of 
vagina and vulva 
 
Meta Cluster 3 
 
Cluster 6 
A78 Q fever 
B85 Pediculosis and phthiriasis 
I83 Varicose veins of lower 
extremities 
L00 Staphylococcal scalded skin 
syndrome 
L01 Impetigo 
L20 Atopic dermatitis 
L22 Diaper [napkin] dermatitis 
L23 Allergic contact dermatitis 
L24 Irritant contact dermatitis 
L25 Unspecified contact 
dermatitis 
L26 Exfoliative dermatitis 
L27 Dermatitis due to 
substances taken internally 
L28 Lichen simplex chronicus 
and prurigo 
L29 Pruritus 
L30 Other dermatitis 
L42 Pityriasis rosea 
L44 Other papulosquamous 
disorders 
L45 Papulosquamous disorders 
in diseases classified elsewhere 
L50 Urticaria 
L51 Erythema multiforme 
L53 Other erythematous 
conditions 
L54 Erythema in diseases 
classified elsewhere 
L55 Sunburn 
L56 Other acute skin changes 
due to ultraviolet radiation 
L74 Eccrine sweat disorders 
L80 Vitiligo 
L85 Other epidermal thickening 
L86 Keratoderma in diseases 
classified elsewhere 
L88 Pyoderma gangrenosum 
L92 Granulomatous disorders of 
skin and subcutaneous tissue 
L98 Other disorders of skin and 
subcutaneous tissue, not 
elsewhere classified 
L99 Other disorders of skin and 
subcutaneous tissue in diseases 
classified elsewhere 
 
Cluster 10 
A03 Shigellosis 
C74 Malignant neoplasm of 
adrenal gland 
C75 Malignant neoplasm of other 
endocrine glands and related 
structures 
D35 Benign neoplasm of other 
and unspecified endocrine 
glands 
D44 Neoplasm of uncertain or 
unknown behaviour of endocrine 
glands 
E20 Hypoparathyroidism 
E21 Hyperparathyroidism and 
other disorders of parathyroid 
gland 
E22 Hyperfunction of pituitary 
gland 
E23 Hypofunction and other 
disorders of pituitary gland 
E24 Cushing's syndrome 
E25 Adrenogenital disorders 
E26 Hyperaldosteronism 
E27 Other disorders of adrenal 
gland 
E29 Testicular dysfunction 
E30 Disorders of puberty, not 
elsewhere classified 
E31 Polyglandular dysfunction 
E35 Disorders of endocrine 
glands in diseases classified 
elsewhere 
E44 Protein-energy malnutrition 
of moderate and mild degree 
E83 Disorders of mineral 
metabolism 
E88 Other metabolic disorders 
E89 Postprocedural endocrine 
and metabolic disorders, not 
elsewhere classified 
M81 Osteoporosis without 
pathological fracture 
M82 Osteoporosis in diseases 
classified elsewhere 
M85 Other disorders of bone 
density and structure 
N46 Male infertility 
N91 Absent, scanty and rare 
menstruation 
Q98 Other sex chromosome 
abnormalities, male phenotype, 
not elsewhere classified 
 
Cluster 11 
I00 Rheumatic fever without 
mention of heart involvement 
M00 Pyogenic arthritis 
M01 Direct infections of joint in 
infectious and parasitic diseases 
classified elsewhere 
M02 Reactive arthropathies 
M03 Postinfective and reactive 
arthropathies in diseases 
classified elsewhere 
M05 Seropositive rheumatoid 
arthritis 
M06 Other rheumatoid arthritis 
M08 Juvenile arthritis 
M09 Juvenile arthritis in diseases 
classified elsewhere 
M11 Other crystal arthropathies 
M12 Other specific arthropathies 
M13 Other arthritis 
M15 Polyarthrosis 
M17 Gonarthrosis [arthrosis of 
knee] 
M18 Arthrosis of first 
carpometacarpal joint 
M19 Other arthrosis 
M24 Other specific joint 
derangements 
M25 Other joint disorders, not 
elsewhere classified 
M61 Calcification and ossification 
of muscle 
M65 Synovitis and tenosynovitis 
M66 Spontaneous rupture of 
synovium and tendon 
M67 Other disorders of synovium 
and tendon 
M68 Disorders of synovium and 
tendon in diseases classified 
elsewhere 
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M70 Soft tissue disorders related 
to use, overuse and pressure 
M71 Other bursopathies 
M75 Shoulder lesions 
M79 Other soft tissue disorders, 
not elsewhere classified 
 
Cluster 40 
G56 Mononeuropathies of upper 
limb 
G57 Mononeuropathies of lower 
limb 
G58 Other mononeuropathies 
G60 Hereditary and idiopathic 
neuropathy 
G61 Inflammatory 
polyneuropathy 
G62 Other polyneuropathies 
G64 Other disorders of 
peripheral nervous system 
 
Cluster 47 
A50 Congenital syphilis 
K21 Gastro-oesophageal reflux 
disease 
K22 Other diseases of 
oesophagus 
K23 Disorders of oesophagus in 
diseases classified elsewhere 
K44 Diaphragmatic hernia 
Q39 Congenital malformations of 
oesophagus 
 
Cluster 48 
B30 Viral conjunctivitis 
H13 Disorders of conjunctiva in 
diseases classified elsewhere 
H16 Keratitis 
H17 Corneal scars and opacities 
H18 Other disorders of cornea 
H19 Disorders of sclera and 
cornea in diseases classified 
elsewhere 
 
Cluster 53 
B26 Mumps 
C07 Malignant neoplasm of 
parotid gland 
D11 Benign neoplasm of major 
salivary glands 
K11 Diseases of salivary glands 
L11 Other acantholytic disorders 
 
Cluster 58 
L93 Lupus erythematosus 
L95 Vasculitis limited to skin, not 
elsewhere classified 
M32 Systemic lupus 
erythematosus 
M35 Other systemic involvement 
of connective tissue 
 
Cluster 77 
L40 Psoriasis 
M07 Psoriatic and enteropathic 
arthropathies 
M73 Soft tissue disorders in 
diseases classified elsewhere 
 
Cluster 88 
M20 Acquired deformities of 
fingers and toes 
Q69 Polydactyly 
Q70 Syndactyly 
 
Cluster 90 
E73 Lactose intolerance 
K58 Irritable bowel syndrome 
K90 Intestinal malabsorption 
 
 
Cluster 97 
L94 Other localized connective 
tissue disorders 
M34 Systemic sclerosis 
 
Meta Cluster 4 
 
Cluster 13 
B06 Rubella [German measles] 
B40 Blastomycosis 
N10 Acute tubulo-interstitial 
nephritis 
N11 Chronic tubulo-interstitial 
nephritis 
N12 Tubulo-interstitial nephritis, 
not specified as acute or chronic 
N13 Obstructive and reflux 
uropathy 
N20 Calculus of kidney and 
ureter 
N21 Calculus of lower urinary 
tract 
N22 Calculus of urinary tract in 
diseases classified elsewhere 
N23 Unspecified renal colic 
N28 Other disorders of kidney 
and ureter, not elsewhere 
classified 
N29 Other disorders of kidney 
and ureter in diseases classified 
elsewhere 
N30 Cystitis 
N32 Other disorders of bladder 
N33 Bladder disorders in 
diseases classified elsewhere 
N35 Urethral stricture 
N39 Other disorders of urinary 
system 
N40 Hyperplasia of prostate 
N42 Other disorders of prostate 
N99 Postprocedural disorders of 
genitourinary system, not 
elsewhere classified 
Q42 Congenital absence, atresia 
and stenosis of large intestine 
Q60 Renal agenesis and other 
reduction defects of kidney 
Q61 Cystic kidney disease 
Q62 Congenital obstructive 
defects of renal pelvis and 
congenital malformations of 
ureter 
Q63 Other congenital 
malformations of kidney 
Q64 Other congenital 
malformations of urinary system 
 
Cluster 14 
C40 Malignant neoplasm of bone 
and articular cartilage of limbs 
C41 Malignant neoplasm of bone 
and articular cartilage of other 
and unspecified sites 
C47 Malignant neoplasm of 
peripheral nerves and autonomic 
nervous system 
C48 Malignant neoplasm of 
retroperitoneum and peritoneum 
C49 Malignant neoplasm of other 
connective and soft tissue 
C56 Malignant neoplasm of 
ovary 
C58 Malignant neoplasm of 
placenta 
C76 Malignant neoplasm of other 
and ill-defined sites 
C78 Secondary malignant 
neoplasm of respiratory and 
digestive organs 
C79 Secondary malignant 
neoplasm of other sites 
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C80 Malignant neoplasm without 
specification of site 
C97 Malignant neoplasms of 
independent (primary) multiple 
sites 
D17 Benign lipomatous 
neoplasm 
D20 Benign neoplasm of soft 
tissue of retroperitoneum and 
peritoneum 
D21 Other benign neoplasms of 
connective and other soft tissue 
D27 Benign neoplasm of ovary 
D36 Benign neoplasm of other 
and unspecified sites 
D39 Neoplasm of uncertain or 
unknown behaviour of female 
genital organs 
D48 Neoplasm of uncertain or 
unknown behaviour of other and 
unspecified sites 
D63 Anaemia in chronic 
diseases classified elsewhere 
D71 Functional disorders of 
polymorphonuclear neutrophils 
M90 Osteopathies in diseases 
classified elsewhere 
N80 Endometriosis 
N83 Noninflammatory disorders 
of ovary, fallopian tube and 
broad ligament 
Q50 Congenital malformations of 
ovaries, fallopian tubes and 
broad ligaments 
 
Cluster 25 
C34 Malignant neoplasm of 
bronchus and lung 
C37 Malignant neoplasm of 
thymus 
C38 Malignant neoplasm of 
heart, mediastinum and pleura 
C39 Malignant neoplasm of other 
and ill-defined sites in the 
respiratory system and 
intrathoracic organs 
C45 Mesothelioma 
D15 Benign neoplasm of other 
and unspecified intrathoracic 
organs 
D19 Benign neoplasm of 
mesothelial tissue 
D38 Neoplasm of uncertain or 
unknown behaviour of middle ear 
and respiratory and intrathoracic 
organs 
E32 Diseases of thymus 
J90 Pleural effusion, not 
elsewhere classified 
J91 Pleural effusion in conditions 
classified elsewhere 
J93 Pneumothorax 
J94 Other pleural conditions 
 
Cluster 44 
C64 Malignant neoplasm of 
kidney, except renal pelvis 
C65 Malignant neoplasm of renal 
pelvis 
C66 Malignant neoplasm of 
ureter 
C68 Malignant neoplasm of other 
and unspecified urinary organs 
D30 Benign neoplasm of urinary 
organs 
D41 Neoplasm of uncertain or 
unknown behaviour of urinary 
organs 
 
Cluster 50 
C61 Malignant neoplasm of 
prostate 
C62 Malignant neoplasm of testis 
C63 Malignant neoplasm of other 
and unspecified male genital 
organs 
D29 Benign neoplasm of male 
genital organs 
D40 Neoplasm of uncertain or 
unknown behaviour of male 
genital organs 
N43 Hydrocele and 
spermatocele 
 
Cluster 51 
C18 Malignant neoplasm of 
colon 
C19 Malignant neoplasm of 
rectosigmoid junction 
C20 Malignant neoplasm of 
rectum 
C21 Malignant neoplasm of anus 
and anal canal 
D12 Benign neoplasm of colon, 
rectum, anus and anal canal 
D37 Neoplasm of uncertain or 
unknown behaviour of oral cavity 
and digestive organs 
 
Cluster 65 
N34 Urethritis and urethral 
syndrome 
N36 Other disorders of urethra 
N37 Urethral disorders in 
diseases classified elsewhere 
N41 Inflammatory diseases of 
prostate 
 
Cluster 96 
A58 Granuloma inguinale 
K40 Inguinal hernia 
K41 Femoral hernia 
 
Cluster 101 
C15 Malignant neoplasm of 
oesophagus 
C16 Malignant neoplasm of 
stomach 
 
Cluster 105 
C67 Malignant neoplasm of 
bladder 
D09 Carcinoma in situ of other 
and unspecified sites 
 
Meta Cluster 5 
 
Cluster 9 
F06 Other mental disorders due 
to brain damage and dysfunction 
and to physical disease 
F09 Unspecified organic or 
symptomatic mental disorder 
F20 Schizophrenia 
F21 Schizotypal disorder 
F22 Persistent delusional 
disorders 
F23 Acute and transient 
psychotic disorders 
F24 Induced delusional disorder 
F25 Schizoaffective disorders 
F28 Other nonorganic psychotic 
disorders 
F29 Unspecified nonorganic 
psychosis 
F30 Manic episode 
F31 Bipolar affective disorder 
F32 Depressive episode 
F33 Recurrent depressive 
disorder 
F34 Persistent mood [affective] 
disorders 
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F38 Other mood [affective] 
disorders 
F39 Unspecified mood [affective] 
disorder 
F41 Other anxiety disorders 
F43 Reaction to severe stress, 
and adjustment disorders 
F45 Somatoform disorders 
F48 Other neurotic disorders 
F50 Eating disorders 
F53 Mental and behavioural 
disorders associated with the 
puerperium, not elsewhere 
classified 
F59 Unspecified behavioural 
syndromes associated with 
physiological disturbances and 
physical factors 
F60 Specific personality 
disorders 
F61 Mixed and other personality 
disorders 
F68 Other disorders of adult 
personality and behaviour 
F69 Unspecified disorder of adult 
personality and behaviour 
F92 Mixed disorders of conduct 
and emotions 
F99 Mental disorder, not 
otherwise specified 
 
Cluster 12 
E67 Other hyperalimentation 
F01 Vascular dementia 
F07 Personality and behavioural 
disorders due to brain disease, 
damage and dysfunction 
F54 Psychological and 
behavioural factors associated 
with disorders or diseases 
classified elsewhere 
G43 Migraine 
G44 Other headache syndromes 
G45 Transient cerebral 
ischaemic attacks and related 
syndromes 
G46 Vascular syndromes of 
brain in cerebrovascular 
diseases 
G91 Hydrocephalus 
G93 Other disorders of brain 
G94 Other disorders of brain in 
diseases classified elsewhere 
G97 Postprocedural disorders of 
nervous system, not elsewhere 
classified 
H82 Vertiginous syndromes in 
diseases classified elsewhere 
I60 Subarachnoid haemorrhage 
I61 Intracerebral haemorrhage 
I62 Other nontraumatic 
intracranial haemorrhage 
I64 Stroke, not specified as 
haemorrhage or infarction 
I65 Occlusion and stenosis of 
precerebral arteries, not resulting 
in cerebral infarction 
I66 Occlusion and stenosis of 
cerebral arteries, not resulting in 
cerebral infarction 
I67 Other cerebrovascular 
diseases 
I68 Cerebrovascular disorders in 
diseases classified elsewhere 
I69 Sequelae of cerebrovascular 
disease 
Q00 Anencephaly and similar 
malformations 
Q01 Encephalocele 
Q03 Congenital hydrocephalus 
Q75 Other congenital 
malformations of skull and face 
bones 
 
Cluster 27 
A15 Respiratory tuberculosis, 
bacteriologically and 
histologically confirmed 
A16 Respiratory tuberculosis, not 
confirmed bacteriologically or 
histologically 
A17 Tuberculosis of nervous 
system 
A18 Tuberculosis of other organs 
A19 Miliary tuberculosis 
A31 Infection due to other 
mycobacteria 
B69 Cysticercosis 
B79 Trichuriasis 
B90 Sequelae of tuberculosis 
J85 Abscess of lung and 
mediastinum 
K93 Disorders of other digestive 
organs in diseases classified 
elsewhere 
M83 Adult osteomalacia 
 
Cluster 34 
F02 Dementia in other diseases 
classified elsewhere 
G10 Huntington's disease 
G20 Parkinson's disease 
G21 Secondary parkinsonism 
G22 Parkinsonism in diseases 
classified elsewhere 
G23 Other degenerative 
diseases of basal ganglia 
G25 Other extrapyramidal and 
movement disorders 
G26 Extrapyramidal and 
movement disorders in diseases 
classified elsewhere 
I02 Rheumatic chorea 
 
Cluster 56 
E53 Deficiency of other B group 
vitamins 
E55 Vitamin D deficiency 
E56 Other vitamin deficiencies 
E58 Dietary calcium deficiency 
E61 Deficiency of other nutrient 
elements 
 
Cluster 71 
F00 Dementia in Alzheimer's 
disease 
F03 Unspecified dementia 
F04 Organic amnesic syndrome, 
not induced by alcohol and other 
psychoactive substances 
G30 Alzheimer's disease 
 
Cluster 108 
D51 Vitamin B12 deficiency 
anaemia 
D52 Folate deficiency anaemia 
 
Cluster 112 
M16 Coxarthrosis [arthrosis of 
hip] 
M91 Juvenile osteochondrosis of 
hip and pelvis 
 
Cluster 115 
A88 Other viral infections of 
central nervous system, not 
elsewhere classified 
H81 Disorders of vestibular 
function 
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Meta Cluster 6 
 
Cluster 2 
A42 Actinomycosis 
C00 Malignant neoplasm of lip 
C01 Malignant neoplasm of base 
of tongue 
C02 Malignant neoplasm of other 
and unspecified parts of tongue 
C03 Malignant neoplasm of gum 
C04 Malignant neoplasm of floor 
of mouth 
C05 Malignant neoplasm of 
palate 
C06 Malignant neoplasm of other 
and unspecified parts of mouth 
C08 Malignant neoplasm of other 
and unspecified major salivary 
glands 
C09 Malignant neoplasm of tonsil 
C10 Malignant neoplasm of 
oropharynx 
C11 Malignant neoplasm of 
nasopharynx 
C12 Malignant neoplasm of 
piriform sinus 
C13 Malignant neoplasm of 
hypopharynx 
C14 Malignant neoplasm of other 
and ill-defined sites in the lip, oral 
cavity and pharynx 
C32 Malignant neoplasm of 
larynx 
C33 Malignant neoplasm of 
trachea 
C50 Malignant neoplasm of 
breast 
C77 Secondary and unspecified 
malignant neoplasm of lymph 
nodes 
D00 Carcinoma in situ of oral 
cavity, oesophagus and stomach 
D02 Carcinoma in situ of middle 
ear and respiratory system 
D05 Carcinoma in situ of breast 
D10 Benign neoplasm of mouth 
and pharynx 
D14 Benign neoplasm of middle 
ear and respiratory system 
E41 Nutritional marasmus 
E47  
E63 Other nutritional deficiencies 
E64 Sequelae of malnutrition and 
other nutritional deficiencies 
G50 Disorders of trigeminal 
nerve 
I89 Other noninfective disorders 
of lymphatic vessels and lymph 
nodes 
J04 Acute laryngitis and 
tracheitis 
J05 Acute obstructive laryngitis 
[croup] and epiglottitis 
J35 Chronic diseases of tonsils 
and adenoids 
J37 Chronic laryngitis and 
laryngotracheitis 
J38 Diseases of vocal cords and 
larynx, not elsewhere classified 
J95 Postprocedural respiratory 
disorders, not elsewhere 
classified 
K00 Disorders of tooth 
development and eruption 
K01 Embedded and impacted 
teeth 
K02 Dental caries 
K03 Other diseases of hard 
tissues of teeth 
K04 Diseases of pulp and 
periapical tissues 
K05 Gingivitis and periodontal 
diseases 
K06 Other disorders of gingiva 
and edentulous alveolar ridge 
K07 Dentofacial anomalies 
[including malocclusion] 
K08 Other disorders of teeth and 
supporting structures 
K09 Cysts of oral region, not 
elsewhere classified 
K10 Other diseases of jaws 
K12 Stomatitis and related 
lesions 
K13 Other diseases of lip and 
oral mucosa 
K14 Diseases of tongue 
L43 Lichen planus 
L58 Radiodermatitis 
L59 Other disorders of skin and 
subcutaneous tissue related to 
radiation 
L66 Cicatricial alopecia [scarring 
hair loss] 
M87 Osteonecrosis 
Q18 Other congenital 
malformations of face and neck 
Q31 Congenital malformations of 
larynx 
Q32 Congenital malformations of 
trachea and bronchus 
 
Cluster 16 
H60 Otitis externa 
H62 Disorders of external ear in 
diseases classified elsewhere 
H65 Nonsuppurative otitis media 
H66 Suppurative and unspecified 
otitis media 
H67 Otitis media in diseases 
classified elsewhere 
H68 Eustachian salpingitis and 
obstruction 
H69 Other disorders of 
Eustachian tube 
H70 Mastoiditis and related 
conditions 
H71 Cholesteatoma of middle 
ear 
H72 Perforation of tympanic 
membrane 
H73 Other disorders of tympanic 
membrane 
H74 Other disorders of middle 
ear and mastoid 
H80 Otosclerosis 
H83 Other diseases of inner ear 
H90 Conductive and 
sensorineural hearing loss 
H91 Other hearing loss 
H92 Otalgia and effusion of ear 
H93 Other disorders of ear, not 
elsewhere classified 
H94 Other disorders of ear in 
diseases classified elsewhere 
H95 Postprocedural disorders of 
ear and mastoid process, not 
elsewhere classified 
J65 Pneumoconiosis associated 
with tuberculosis 
 
Cluster 45 
E84 Cystic fibrosis 
J01 Acute sinusitis 
J30 Vasomotor and allergic 
rhinitis 
J31 Chronic rhinitis, 
nasopharyngitis and pharyngitis 
J32 Chronic sinusitis 
J33 Nasal polyp 
 
Cluster 61 
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C69 Malignant neoplasm of eye 
and adnexa 
D31 Benign neoplasm of eye and 
adnexa 
H11 Other disorders of 
conjunctiva 
H31 Other disorders of choroid 
 
Cluster 75 
H02 Other disorders of eyelid 
H04 Disorders of lacrimal system 
Q10 Congenital malformations of 
eyelid, lacrimal apparatus and 
orbit 
 
Cluster 89 
C44 Other malignant neoplasms 
of skin 
D04 Carcinoma in situ of skin 
L57 Skin changes due to chronic 
exposure to nonionizing radiation 
 
Cluster 98 
C30 Malignant neoplasm of 
nasal cavity and middle ear 
C31 Malignant neoplasm of 
accessory sinuses 
 
Cluster 104 
C43 Malignant melanoma of skin 
D03 Melanoma in situ 
 
Meta Cluster 7 
 
Cluster 3 
A04 Other bacterial intestinal 
infections 
A05 Other bacterial foodborne 
intoxications, not elsewhere 
classified 
A27 Leptospirosis 
A41 Other septicaemia 
A48 Other bacterial diseases, not 
elsewhere classified 
A98 Other viral haemorrhagic 
fevers, not elsewhere classified 
B48 Other mycoses, not 
elsewhere classified 
D65 Disseminated intravascular 
coagulation [defibrination 
syndrome] 
E70 Disorders of aromatic 
amino-acid metabolism 
E78 Disorders of lipoprotein 
metabolism and other 
lipidaemias 
E79 Disorders of purine and 
pyrimidine metabolism 
I10 Essential (primary) 
hypertension 
I11 Hypertensive heart disease 
I12 Hypertensive renal disease 
I13 Hypertensive heart and renal 
disease 
I15 Secondary hypertension 
I22 Subsequent myocardial 
infarction 
I70 Atherosclerosis 
I73 Other peripheral vascular 
diseases 
I74 Arterial embolism and 
thrombosis 
I77 Other disorders of arteries 
and arterioles 
I95 Hypotension 
J09 Influenza due to identified 
avian influenza virus 
J11 Influenza, virus not identified 
J80 Adult respiratory distress 
syndrome 
J81 Pulmonary oedema 
K52 Other noninfective 
gastroenteritis and colitis 
K55 Vascular disorders of 
intestine 
K65 Peritonitis 
L87 Transepidermal elimination 
disorders 
M10 Gout 
M30 Polyarteritis nodosa and 
related conditions 
M31 Other necrotizing 
vasculopathies 
N00 Acute nephritic syndrome 
N01 Rapidly progressive 
nephritic syndrome 
N02 Recurrent and persistent 
haematuria 
N03 Chronic nephritic syndrome 
N04 Nephrotic syndrome 
N05 Unspecified nephritic 
syndrome 
N06 Isolated proteinuria with 
specified morphological lesion 
N07 Hereditary nephropathy, not 
elsewhere classified 
N08 Glomerular disorders in 
diseases classified elsewhere 
N14 Drug- and heavy-metal-
induced tubulo-interstitial and 
tubular conditions 
N15 Other renal tubulo-interstitial 
diseases 
N16 Renal tubulo-interstitial 
disorders in diseases classified 
elsewhere 
N17 Acute renal failure 
N18 Chronic renal failure 
N19 Unspecified renal failure 
N25 Disorders resulting from 
impaired renal tubular function 
N26 Unspecified contracted 
kidney 
N27 Small kidney of unknown 
cause 
 
Cluster 7 
D82 Immunodeficiency 
associated with other major 
defects 
I20 Angina pectoris 
I21 Acute myocardial infarction 
I23 Certain current complications 
following acute myocardial 
infarction 
I25 Chronic ischaemic heart 
disease 
I26 Pulmonary embolism 
I27 Other pulmonary heart 
diseases 
I28 Other diseases of pulmonary 
vessels 
I36 Nonrheumatic tricuspid valve 
disorders 
I37 Pulmonary valve disorders 
I42 Cardiomyopathy 
I44 Atrioventricular and left 
bundle-branch block 
I45 Other conduction disorders 
I46 Cardiac arrest 
I47 Paroxysmal tachycardia 
I48 Atrial fibrillation and flutter 
I49 Other cardiac arrhythmias 
I50 Heart failure 
I51 Complications and ill-defined 
descriptions of heart disease 
I52 Other heart disorders in 
diseases classified elsewhere 
I97 Postprocedural disorders of 
circulatory system, not elsewhere 
classified 
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I99 Other and unspecified 
disorders of circulatory system 
Q20 Congenital malformations of 
cardiac chambers and 
connections 
Q21 Congenital malformations of 
cardiac septa 
Q22 Congenital malformations of 
pulmonary and tricuspid valves 
Q23 Congenital malformations of 
aortic and mitral valves 
Q24 Other congenital 
malformations of heart 
Q25 Congenital malformations of 
great arteries 
Q26 Congenital malformations of 
great veins 
Q33 Congenital malformations of 
lung 
Q34 Other congenital 
malformations of respiratory 
system 
Q96 Turner's syndrome 
 
Cluster 17 
A99 Unspecified viral 
haemorrhagic fever 
B25 Cytomegaloviral disease 
B44 Aspergillosis 
B49 Unspecified mycosis 
B96 Other bacterial agents as 
the cause of diseases classified 
to other chapters 
C91 Lymphoid leukaemia 
C92 Myeloid leukaemia 
C93 Monocytic leukaemia 
C94 Other leukaemias of 
specified cell type 
C95 Leukaemia of unspecified 
cell type 
D46 Myelodysplastic syndromes 
D59 Acquired haemolytic 
anaemia 
D60 Acquired pure red cell 
aplasia [erythroblastopenia] 
D61 Other aplastic anaemias 
D69 Purpura and other 
haemorrhagic conditions 
D70 Agranulocytosis 
D72 Other disorders of white 
blood cells 
D73 Diseases of spleen 
D76 Certain diseases involving 
lymphoreticular tissue and 
reticulohistiocytic system 
D77 Other disorders of blood and 
blood-forming organs in diseases 
classified elsewhere 
 
Cluster 20 
A40 Streptococcal septicaemia 
B95 Streptococcus and 
staphylococcus as the cause of 
diseases classified to other 
chapters 
I01 Rheumatic fever with heart 
involvement 
I05 Rheumatic mitral valve 
diseases 
I06 Rheumatic aortic valve 
diseases 
I07 Rheumatic tricuspid valve 
diseases 
I08 Multiple valve diseases 
I09 Other rheumatic heart 
diseases 
I24 Other acute ischaemic heart 
diseases 
I33 Acute and subacute 
endocarditis 
I34 Nonrheumatic mitral valve 
disorders 
I35 Nonrheumatic aortic valve 
disorders 
I38 Endocarditis, valve 
unspecified 
I39 Endocarditis and heart valve 
disorders in diseases classified 
elsewhere 
I41 Myocarditis in diseases 
classified elsewhere 
 
Cluster 21 
A28 Other zoonotic bacterial 
diseases, not elsewhere 
classified 
A32 Listeriosis 
B59 Pneumocystosis 
B97 Viral agents as the cause of 
diseases classified to other 
chapters 
C81 Hodgkin's disease 
C82 Follicular [nodular] non-
Hodgkin's lymphoma 
C83 Diffuse non-Hodgkin's 
lymphoma 
C84 Peripheral and cutaneous T-
cell lymphomas 
C85 Other and unspecified types 
of non-Hodgkin's lymphoma 
C88 Malignant 
immunoproliferative diseases 
C96 Other and unspecified 
malignant neoplasms of 
lymphoid, haematopoietic and 
related tissue 
D89 Other disorders involving 
the immune mechanism, not 
elsewhere classified 
I88 Nonspecific lymphadenitis 
L04 Acute lymphadenitis 
L41 Parapsoriasis 
 
Cluster 23 
A70 Chlamydia psittaci infection 
J21 Acute bronchiolitis 
J41 Simple and mucopurulent 
chronic bronchitis 
J42 Unspecified chronic 
bronchitis 
J43 Emphysema 
J44 Other chronic obstructive 
pulmonary disease 
J45 Asthma 
J46 Status asthmaticus 
J47 Bronchiectasis 
J63 Pneumoconiosis due to 
other inorganic dusts 
J66 Airway disease due to 
specific organic dust 
J67 Hypersensitivity pneumonitis 
due to organic dust 
J82 Pulmonary eosinophilia, not 
elsewhere classified 
J84 Other interstitial pulmonary 
diseases 
J98 Other respiratory disorders 
 
Cluster 74 
D45 Polycythaemia vera 
D75 Other diseases of blood and 
blood-forming organs 
E45 Retarded development 
following protein-energy 
malnutrition 
 
Cluster 100 
C90 Multiple myeloma and 
malignant plasma cell neoplasms 
D47 Other neoplasms of 
uncertain or unknown behaviour 
of lymphoid, haematopoietic and 
related tissue 
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Meta Cluster 8 
 
Cluster 19 
A01 Typhoid and paratyphoid 
fevers 
A02 Other salmonella infections 
A06 Amoebiasis 
A68 Relapsing fevers 
A79 Other rickettsioses 
A90 Dengue fever [classical 
dengue] 
B50 Plasmodium falciparum 
malaria 
B51 Plasmodium vivax malaria 
B52 Plasmodium malariae 
malaria 
B53 Other parasitologically 
confirmed malaria 
B54 Unspecified malaria 
B65 Schistosomiasis 
[bilharziasis] 
B74 Filariasis 
B76 Hookworm diseases 
B78 Strongyloidiasis 
B83 Other helminthiases 
B89 Unspecified parasitic 
disease 
 
Cluster 63 
H10 Conjunctivitis 
H15 Disorders of sclera 
H20 Iridocyclitis 
H22 Disorders of iris and ciliary 
body in diseases classified 
elsewhere 
 
Cluster 78 
I78 Diseases of capillaries 
L70 Acne 
L71 Rosacea 
 
Cluster 82 
L63 Alopecia areata 
L64 Androgenic alopecia 
L65 Other nonscarring hair loss 
 
Cluster 102 
D86 Sarcoidosis 
L52 Erythema nodosum 
 
Cluster 110 
H00 Hordeolum and chalazion 
H01 Other inflammation of eyelid 
 
Cluster 117 
A75 Typhus fever 
A77 Spotted fever [tick-borne 
rickettsioses] 
 
Meta Cluster 9 
 
Cluster 24 
I71 Aortic aneurysm and 
dissection 
I79 Disorders of arteries, 
arterioles and capillaries in 
diseases classified elsewhere 
J34 Other disorders of nose and 
nasal sinuses 
M95 Other acquired deformities 
of musculoskeletal system and 
connective tissue 
Q30 Congenital malformations of 
nose 
Q35 Cleft palate 
Q36 Cleft lip 
Q37 Cleft palate with cleft lip 
Q38 Other congenital 
malformations of tongue, mouth 
and pharynx 
Q79 Congenital malformations of 
the musculoskeletal system, not 
elsewhere classified 
Q87 Other specified congenital 
malformation syndromes 
affecting multiple systems 
Q89 Other congenital 
malformations, not elsewhere 
classified 
Q91 Edwards' syndrome and 
Patau's syndrome 
 
Cluster 54 
M72 Fibroblastic disorders 
Q71 Reduction defects of upper 
limb 
Q72 Reduction defects of lower 
limb 
Q73 Reduction defects of 
unspecified limb 
Q74 Other congenital 
malformations of limb(s) 
 
Cluster 84 
D16 Benign neoplasm of bone 
and articular cartilage 
Q77 Osteochondrodysplasia with 
defects of growth of tubular 
bones and spine 
Q78 Other 
osteochondrodysplasias 
 
Cluster 103 
Q16 Congenital malformations of 
ear causing impairment of 
hearing 
Q17 Other congenital 
malformations of ear 
 
 
 
Cluster 119 
Q67 Congenital musculoskeletal 
deformities of head, face, spine 
and chest 
 
Cluster 120 
Q68 Other congenital 
musculoskeletal deformities 
 
Cluster 121 
M43 Other deforming 
dorsopathies 
 
Meta Cluster 10 
 
Cluster 33 
A39 Meningococcal infection 
A87 Viral meningitis 
G00 Bacterial meningitis, not 
elsewhere classified 
G02 Meningitis in other infectious 
and parasitic diseases classified 
elsewhere 
G03 Meningitis due to other and 
unspecified causes 
G06 Intracranial and intraspinal 
abscess and granuloma 
G07 Intracranial and intraspinal 
abscess and granuloma in 
diseases classified elsewhere 
G09 Sequelae of inflammatory 
diseases of central nervous 
system 
H75 Other disorders of middle 
ear and mastoid in diseases 
classified elsewhere 
 
Cluster 46 
A85 Other viral encephalitis, not 
elsewhere classified 
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A86 Unspecified viral 
encephalitis 
A89 Unspecified viral infection of 
central nervous system 
B94 Sequelae of other and 
unspecified infectious and 
parasitic diseases 
G04 Encephalitis, myelitis and 
encephalomyelitis 
G05 Encephalitis, myelitis and 
encephalomyelitis in diseases 
classified elsewhere 
 
Cluster 52 
A35 Other tetanus 
G35 Multiple sclerosis 
G36 Other acute disseminated 
demyelination 
G37 Other demyelinating 
diseases of central nervous 
system 
H46 Optic neuritis 
 
Cluster 55 
A26 Erysipeloid 
A69 Other spirochaetal infections 
A84 Tick-borne viral encephalitis 
G01 Meningitis in bacterial 
diseases classified elsewhere 
G51 Facial nerve disorders 
 
Cluster 81 
M45 Ankylosing spondylitis 
M46 Other inflammatory 
spondylopathies 
M49 Spondylopathies in 
diseases classified elsewhere 
 
 
 
 
Meta Cluster 11 
 
Cluster 31 
C70 Malignant neoplasm of 
meninges 
C71 Malignant neoplasm of brain 
C72 Malignant neoplasm of 
spinal cord, cranial nerves and 
other parts of central nervous 
system 
D32 Benign neoplasm of 
meninges 
D33 Benign neoplasm of brain 
and other parts of central 
nervous system 
D42 Neoplasm of uncertain or 
unknown behaviour of meninges 
D43 Neoplasm of uncertain or 
unknown behaviour of brain and 
central nervous system 
G32 Other degenerative 
disorders of nervous system in 
diseases classified elsewhere 
Q85 Phakomatoses, not 
elsewhere classified 
 
Cluster 66 
D22 Melanocytic naevi 
D23 Other benign neoplasms of 
skin 
L81 Other disorders of 
pigmentation 
L82 Seborrhoeic keratosis 
 
Cluster 76 
D18 Haemangioma and 
lymphangioma, any site 
Q27 Other congenital 
malformations of peripheral 
vascular system 
Q82 Other congenital 
malformations of skin 
 
Cluster 118 
Q28 Other congenital 
malformations of circulatory 
system 
 
Meta Cluster 12 
 
Cluster 36 
F81 Specific developmental 
disorders of scholastic skills 
F82 Specific developmental 
disorder of motor function 
F83 Mixed specific 
developmental disorders 
F90 Hyperkinetic disorders 
F91 Conduct disorders 
F93 Emotional disorders with 
onset specific to childhood 
F94 Disorders of social 
functioning with onset specific to 
childhood and adolescence 
F98 Other behavioural and 
emotional disorders with onset 
usually occurring in childhood 
and adolescence 
 
Cluster 38 
B47 Mycetoma 
N47 Redundant prepuce, 
phimosis and paraphimosis 
N48 Other disorders of penis 
Q53 Undescended testicle 
Q54 Hypospadias 
Q55 Other congenital 
malformations of male genital 
organs 
Q56 Indeterminate sex and 
pseudohermaphroditism 
 
Cluster 91 
Q41 Congenital absence, atresia 
and stenosis of small intestine 
Q43 Other congenital 
malformations of intestine 
Q45 Other congenital 
malformations of digestive 
system 
 
Cluster 107 
F42 Obsessive-compulsive 
disorder 
F95 Tic disorders 
 
Meta Cluster 13 
 
Cluster 26 
H21 Other disorders of iris and 
ciliary body 
H25 Senile cataract 
H26 Other cataract 
H27 Other disorders of lens 
H33 Retinal detachments and 
breaks 
H40 Glaucoma 
H42 Glaucoma in diseases 
classified elsewhere 
H44 Disorders of globe 
H59 Postprocedural disorders of 
eye and adnexa, not elsewhere 
classified 
Q11 Anophthalmos, 
microphthalmos and 
macrophthalmos 
Q12 Congenital lens 
malformations 
Q13 Congenital malformations of 
anterior segment of eye 
Q15 Other congenital 
malformations of eye 
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Cluster 62 
B58 Toxoplasmosis 
H30 Chorioretinal inflammation 
H32 Chorioretinal disorders in 
diseases classified elsewhere 
H35 Other retinal disorders 
 
Cluster 80 
H34 Retinal vascular occlusions 
H43 Disorders of vitreous body 
H45 Disorders of vitreous body 
and globe in diseases classified 
elsewhere 
 
Meta Cluster 14 
 
Cluster 30 
E05 Thyrotoxicosis 
[hyperthyroidism] 
E06 Thyroiditis 
E07 Other disorders of thyroid 
E50 Vitamin A deficiency 
E52 Niacin deficiency [pellagra] 
H03 Disorders of eyelid in 
diseases classified elsewhere 
H05 Disorders of orbit 
H06 Disorders of lacrimal system 
and orbit in diseases classified 
elsewhere 
H58 Other disorders of eye and 
adnexa in diseases classified 
elsewhere 
 
Cluster 67 
C73 Malignant neoplasm of 
thyroid gland 
D34 Benign neoplasm of thyroid 
gland 
E01 Iodine-deficiency-related 
thyroid disorders and allied 
conditions 
E04 Other nontoxic goitre 
 
Cluster 92 
E00 Congenital iodine-deficiency 
syndrome 
E02 Subclinical iodine-deficiency 
hypothyroidism 
E03 Other hypothyroidism 
 
Meta Cluster 15 
 
Cluster 15 
A38 Scarlet fever 
E76 Disorders of 
glycosaminoglycan metabolism 
F70 Mild mental retardation 
F71 Moderate mental retardation 
F78 Other mental retardation 
F79 Unspecified mental 
retardation 
F80 Specific developmental 
disorders of speech and 
language 
F84 Pervasive developmental 
disorders 
F88 Other disorders of 
psychological development 
F89 Unspecified disorder of 
psychological development 
H50 Other strabismus 
H51 Other disorders of binocular 
movement 
H52 Disorders of refraction and 
accommodation 
H53 Visual disturbances 
H54 Blindness and low vision 
H55 Nystagmus and other 
irregular eye movements 
H57 Other disorders of eye and 
adnexa 
H61 Other disorders of external 
ear 
Q14 Congenital malformations of 
posterior segment of eye 
Q86 Congenital malformation 
syndromes due to known 
exogenous causes, not 
elsewhere classified 
Q90 Down's syndrome 
Q92 Other trisomies and partial 
trisomies of the autosomes, not 
elsewhere classified 
Q93 Monosomies and deletions 
from the autosomes, not 
elsewhere classified 
Q95 Balanced rearrangements 
and structural markers, not 
elsewhere classified 
Q99 Other chromosome 
abnormalities, not elsewhere 
classified 
 
Cluster 79 
G52 Disorders of other cranial 
nerves 
G53 Cranial nerve disorders in 
diseases classified elsewhere 
H49 Paralytic strabismus 
 
Meta Cluster 16 
 
Cluster 28 
C22 Malignant neoplasm of liver 
and intrahepatic bile ducts 
C23 Malignant neoplasm of 
gallbladder 
C24 Malignant neoplasm of other 
and unspecified parts of biliary 
tract 
C25 Malignant neoplasm of 
pancreas 
C26 Malignant neoplasm of other 
and ill-defined digestive organs 
D13 Benign neoplasm of other 
and ill-defined parts of digestive 
system 
K31 Other diseases of stomach 
and duodenum 
K80 Cholelithiasis 
K81 Cholecystitis 
K82 Other diseases of 
gallbladder 
K83 Other diseases of biliary 
tract 
 
Cluster 83 
K85 Acute pancreatitis 
K86 Other diseases of pancreas 
K87 Disorders of gallbladder, 
biliary tract and pancreas in 
diseases classified elsewhere 
 
Meta Cluster 17 
 
Cluster 99 
E65 Localized adiposity 
E68 Sequelae of 
hyperalimentation 
 
Cluster 106 
L90 Atrophic disorders of skin 
L91 Hypertrophic disorders of 
skin 
 
Meta Cluster 18 
 
Cluster 57 
N44 Torsion of testis 
N45 Orchitis and epididymitis 
Work in progress 1: Supplementary table 1  
 
  107 
N49 Inflammatory disorders of 
male genital organs, not 
elsewhere classified 
N50 Other disorders of male 
genital organs 
N51 Disorders of male genital 
organs in diseases classified 
elsewhere 
 
Meta Cluster 19 
 
Cluster 59 
N31 Neuromuscular dysfunction 
of bladder, not elsewhere 
classified 
Q05 Spina bifida 
Q06 Other congenital 
malformations of spinal cord 
Q76 Congenital malformations of 
spine and bony thorax 
 
 
